




P R O G R A M M E



2006 | October 4 - 7, 2006
Vilamoura, Portugal

www.ever.be

21 CME credits



BE IN A POSITION
TO SUCCEED.

DUOTRAV™ Solution, combining two powerful agents into a single bottle, decreases IOP by up to 38% (12mmHg) from baseline¹. DUOTRAV™ Solution's convenient once-a-day dosing, either morning or evening, enhances patient compliance.
BE IN A POSITION TO SUCCEED in the management of glaucoma.

DUOTRAV™
40 micrograms/ml + 5 mg/ml eye drops solution (travoprost/timolol)

Reference: 1. Barnebey HS, Orente-Nania S, Flowers BE, et al. The safety and efficacy of travoprost 0.004%/timolol 0.5% fixed combination ophthalmic solution. Am J Ophthalmol. 2005;140:1-7. ©2006 Alcon, Inc.

Consult the Summary of Product Characteristics before prescribing, particularly in relation to side-effects, precautions and contraindications.

DuoTrav™ (travoprost and timolol maleate). **Presentation** Plastic bottle containing 2.5ml eye drops. Each 1 ml contains 40 micrograms of travoprost, 5 mg of timolol (as timolol maleate), benzalkonium chloride 0.15 mg, and polyoxyethylene hydrogenated castor oil 40 (HCO-40) 5 mg. **Indication** Decrease of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to topical beta-blockers or prostaglandin analogues. **Dosage/Administration** Adults, including the elderly One drop into affected eye(s) once daily, morning or evening. Administer at same time each day. **Paediatric patients** Not recommended. **Use in hepatic and renal impairment** No studies conducted with DuoTrav. **Contraindications** Hypersensitivity to any component of product. Bronchial asthma, severe chronic obstructive pulmonary disease. Sinus bradycardia, second or third degree atrioventricular block, overt cardiac failure, cardiogenic shock. Severe allergic rhinitis, bronchial hyper reactivity; corneal dystrophies, hypersensitivity to other beta-blockers. **Warnings and precautions** **Systemic effects** Cardiovascular and pulmonary adverse reactions as seen with systemic beta-blockers may occur. Cardiac failure should be adequately controlled before beginning therapy with timolol. Patients with a history of severe cardiac disease should be watched for signs of cardiac failure and have pulse rates checked. Respiratory and cardiac reactions, including death due to bronchospasm in patients with asthma and cardiac failure, have been reported following administration of timolol. Beta-blockers should be administered with caution in patients subject to spontaneous hypoglycaemia or to diabetic patients (especially those with labile diabetes) as beta-blockers may mask the signs and symptoms of acute hypoglycaemia and hyperthyroidism, and cause worsening of Prinzmetal angina, severe peripheral and central circulatory disorders and hypotension. **Anaphylactic reactions** While taking beta-blockers, patients with a history of atopy or

severe anaphylactic reaction to a variety of allergens may be unresponsive to usual doses of adrenaline used to treat anaphylactic reactions. **Concomitant Therapy** Timolol may interact with other products. Effect on IOP or known effects of systemic beta-blockers may be potentiated when DuoTrav is given to patients already taking oral beta-blockers. Use of two local beta-blockers or local prostaglandins is not recommended. **Ocular effects** Travoprost may increase brown pigment within the iris leading to a gradual change in eye colour. Predominantly seen in patients with mixed coloured irides, may be permanent. Unilateral treatment can result in permanent heterochromia. Eyelash changes (length, thickness, pigmentation and/or number of lashes). Long-term consequences unknown. Caution in patients with inflammatory ocular conditions, other types of glaucoma (including neovascular, angle-closure, narrow-angle, congenital, pigmentary or pseudoxfoliative glaucoma), thyroid eye disease, open-angle glaucoma of pseudophakic patients, aphakic patients, pseudophakic patients with a torn posterior lens capsule or anterior chamber lenses, patients with known risk factors for cystoid macular oedema, or in patients with known predisposing risk factors for iritis/uveitis. **Contact lenses** Avoid use of soft contact lenses. Instruct patients to remove contact lenses prior to drop application and wait 15 minutes after instillation before reinsertion. Polyoxyethylene hydrogenated castor oil 40 may cause skin reactions. **Interactions** No interaction studies have been performed. Potential for additive effects resulting in hypotension and/or marked bradycardia when eye drops with timolol are administered concomitantly with oral calcium channel blockers, guanethidine or beta-blockers, antiarrhythmics, digitalis glycosides or parasympathomimetics. Hypertensive reaction to sudden withdrawal of clonidine can be potentiated when taking beta-blockers. **Women of childbearing potential** Do not use unless adequate contraceptive measures are in place. **Pregnancy** Do not use unless clearly necessary. **Lactation** Not recommended. **Driving /use of machines** Eye drop instillation may blur vision. **Undesirable effects** No serious undesirable effects related to DuoTrav were reported. Most frequently reported

treatment-related undesirable effect was ocular hyperaemia (15%). 98% of patients who experienced ocular hyperaemia did not discontinue therapy as a result. **Other very common/common undesirable effects reported in clinical trials with DuoTrav** Nervousness, dizziness, headache, eye irritation, pain, swelling, discomfort, abnormal sensation, dryness, pruritus) punctate keratitis, anterior chamber cells and flare, photophobia, conjunctival haemorrhage, corneal staining, vision (acuity reduced, disturbance, blurred conjunctivitis allergic, lacrimation increased, eyelid (erythema, irritation, dermatitis), asthenopia, growth of eyelashes, heart rate and blood pressure changes, bronchospasm, urticaria, skin hyperpigmentation (periorbital), pain in extremity. **Additional undesirable treatment-related effects have been reported in clinical trials with concomitant therapy (travoprost and timolol) or with monotherapy with travoprost, or postmarketing events reported in the SPC for travoprost or timolol that have not been reported with DuoTrav:** Refer to SPC for additional information and before prescribing. **Overdose** Treat symptomatically. Timolol does not dialyse readily. Incompatibilities Not applicable. **Shelf life** 3 years, discard 4 weeks after first opening. **Special precautions for storage/disposal** None. **PL Holder and Further Information** Alcon Laboratories (UK) Ltd., Boundary Way, Hemel Hempstead, Herts HP2 7UD, United Kingdom. **PL Number** EU/1/06/338/001-003 **Date of Preparation of Prescribing Information** March 2006 **Packaging Quantities and Basic NHS and GMS price(s)** Cartons containing 1 x 2.5ml (£13.20, €19.66), 3 x 2.5ml (£37.62, €56.02), 6 x 2.5ml not marketed. **Legal Category** POM.

Adverse events should be reported to Alcon (UK) Medical Information on 01442 341234. Information about adverse event reporting can also be found on www.yellowcard.gov.uk

Date of preparation: August 2006.

DUO:EVER:0806(HC)

Alcon



a word from the president



Dear Members and Fellow Scientists,

The start of July saw a dedicated and enthusiastic crew of Program secretaries of all EVER Sections gathered together in an old abbey courtyard in Leuven, Belgium, sorting out the multitude of abstracts for oral papers and poster that you had submitted for their evaluation. From this cornucopia of vision and eye research they forged, under the skilful guidance of Amanda Churchill, a perfect program for the next EVER congress - the last one for the time being to be held in the sunny and relaxed, friendly Vilamoura, Portugal.

The forthcoming program builds in structure on the successful programs of previous years, spiced with the advice and guidance that the section meetings provided last year. I would advise you to take notice of the varied keynote lectures and SIS sessions that make up backbone of the program. I especially draw your attention to the increasing number of courses that EVER wishes to provide you, and with an economic price at that. Most importantly, scan carefully the free paper sessions, which provide the possibility to learn of the latest findings in eye research and a good opportunity to express your opinion in scholarly discussions.

The EVER meeting in Vilamoura promises to be the autumn highlight of European ophthalmology and eye research. I am looking forward to meeting you there, and I would like to extend my thanks to everyone who has worked hard for the success of the meeting.

With kind regards,

Tero KIVELÄ
President

Tero KIVELÄ
EVER President 2006

About EVER

EVER is a non-profit organisation. The aims of the Association are to encourage research and the dissemination of knowledge concerning the eye and vision by means of meetings, publications and exchange of information.

EVER is currently the leading ophthalmological research association in Europe which covers all areas of ophthalmology and the visual sciences.

Membership

Membership is open to individuals of any nationality, engaging in or with an interest in ophthalmic and vision research, who meet the requirements established by the EVER Board. To become a member, a candidate should apply on the members module, on www.ever.be and fill in the name of an EVER member who will endorse their application. If candidates do not know a member who can endorse their application, they should write to the EVER office, who will take appropriate action. The candidate becomes a member upon recommendation by the EVER board and upon payment of the dues.

Any group within EVER may organise symposia, workshops or other activities within a meeting. Any proposal should be sent to the Programme Secretary or to the scientific section representative before the end of the preceeding year.

Elections

This year new representatives of the scientific sections **Immunology / Microbiology** and **Physiology / Biochemistry / Pharmacology** will be elected through electronic voting. The result of the elections will be announced at the General Assembly on Saturday, October 7, 2006

The scientific sections will hold their Business Meetings on Friday, October 6, 2006 from 19:00 till 19:30. The place will be announced onsite. The agenda is available see page 35. The sections on **Cornea / Ocular Surface** and on **Glaucoma** will nominate candidates for the succession of their representatives in the Board of EVER.

The statutes and by-laws are available on the website:

www.ever.be » about » statutes



BOARD

Executive Committee

President	T Kivelä, Helsinki
Secretary General	J Jonas, Mannheim
Treasurer	P Aydin, Ankara
Programme Secretary	A Churchill, Bristol
Past president	N Galloway, Nottingham
President Elect	U Pleyer, Berlin
Vice-president	A Safran, Geneva
Vice-president Elect	I Haefliger, Basel
Belgian representative	JJ De Laey, Gent
Co-opted : EVER-ACTA	P Söderberg, Stockholm

Chair of sections

Anatomy / Cell Biology	E Knop, Berlin
Cornea / Ocular Surface	H Dua, Nottingham
Glaucoma	S Orgul, Basel
Immunology / Microbiology	U Pleyer, Berlin
Lens and Cataract	R Michael, Barcelona
Molecular Biology / Genetics / Epidemiology	M Votruba, Cardiff
Neuro-ophthalmology / Strabismology	L Martin, Stockholm
Pathology / Oncology	C All-Ericsson, Stockholm
Physiology / Biochemistry / Pharmacology	I Haefliger, Basel
Retina / Vitreous	Ch Riva, Sion
Vision Sciences / Electrophysiol. / Physiol. Optic	G Holder, London

Regional Representatives

G Maraini, Parma
G Hollo, Budapest

Local Organisers

J Cunha-Vaz, Portugal
R Proenca, Portugal
M Hawlina, Slovenia

EVER Office

Kapucijnenvoer 33
B-3000 Leuven, Belgium
Tel. +32 – 16.233.849
Fax +32 – 16.234.097
marlene.verlaeckt@ever.be
www.ever.be

Information about the meeting of 2006

Location

EVER 2006 will be held in the Marinotel in Vilamoura, Portugal.

The scientific programme will begin on Wednesday, Oct 4 at 14:00 and concludes Saturday, Oct 7 at 19:00.

Registration

Everyone attending the scientific sessions—whether or not an EVER-member, invited speaker, accompanying person or presenter—must register and pay the registration fee.

The early registration deadline is September 1, 2006. At any time, you can register and pay your registration fee on-line at www.ever.be

You can still register on-site from Wednesday Oct 4 at 12:00.

Please note that:

- being or becoming an EVER-member or having an abstract accepted does not imply that you are registered
- if you register as a member in training, you need to prove your traineeship by showing a document signed by the Head of your Department
- if you register as an accompanying person this entitles you to attend the EVER social functions but not the scientific programme
- Refunds—up to 75% of the registration fee—will be granted for cancellation, received in writing, prior to September 20, 2006. Refunds will not be granted for later cancellation or no-shows.



Travel

Vilamoura can be reached in less than 20 minutes from Faro Airport. Algarve is a popular tourist destination, there are many flights to Faro airport, either direct or via Lisbon.

Congress shuttle service

On arrival dates Oct 3 and Oct 4 every 1/2 hour from 7 am till 11 pm.

On departure dates Oct 7 and Oct 8 every hour from 4 am till 8 pm.

Congress shuttle service: no reservation in advance, payment should be done to shuttle driver, 12 EUR per person single trip.

Private transfer: book in advance on the hotel reservation form.

25 EUR per person single trip (max 3 people in a car).

Taxi's are also available at Faro Airport.

Weather

Vilamoura has an exceptional climate and offers sun all year round. Average temperature in October is around 23° Celsius, with about 10 hours of daily sun.

Tourist information

Vilamoura is the name of an area rather than a town. It covers about 2000 hectares of land, partly with vegetation, partly with forests. Thanks to the size of the resort area, it offers every visitor nearly every form of sport and entertainment: four different golf courses, a large marina, a lawn bowling club, a tennis centre, sports club, shooting club, tourist apartments, night clubs, international casino, cinema and riding school. In the center of Vilamoura, there is a preserved Roman site and Museum of Cerro da Vila. In the neighbourhood of Vilamoura, there is the small fishing village called Quarteira and the commercial and administrative town of Loulé.

Liability

The Organisers cannot accept liability for personal accidents, loss of or damage to private property of participants and accompanying persons either during, or directly arising from the Meeting. Participants should make their own arrangements with respect to health and travel insurance.

Registration fees after September 1, 2006

EVER-member or SIS-invited speaker	340 EUR
Member in training	175 EUR
Non-member	550 EUR
Non-member in training	270 EUR
Course	40 EUR
Accompanying person	115 EUR

Website

The EVER website www.ever.be has a central role in the EVER organisation. At this website, you can

- obtain up-to-date information about the scientific programme and the EVER 2006 meeting
- pay on-line and obtain an overview of past payments
- view the status (session, hour, place) of your presentation
- look for other EVER-members
- access general information about EVER
- go to useful links
- express your vote

Information about the meeting of 2006

Social programme

The social programme is open for all participants and registered accompanying persons.

On **Wednesday** 19:00 there is the EVER Welcome Garden Party, in the Marinotel.

On **Saturday** 20:00 the EVER Farewell dinner takes place in the garden of the Marinotel.

Coffee

Coffee and soft drinks are provided, free of charge, during the meeting from 09:30 till 12:30 and from 15:00 till 17:30.

Internet access

There is internet access in the IT room and in the Business Center in the Marinotel.

Scientific programme access

You can visit www.ever.be for the most up-to-date scientific programme. A CD-rom, sponsored by Alcon, is included with the programme.

The abstracts will be published on-line in a special issue of Acta Ophthalmologica Scandinavica.

Poster prizes

A poster prize of 100 EUR will be awarded for the best poster in each section. The winners will be chosen by the moderators and will be announced in the General Assembly meeting on Saturday October 7th, 2006.



Awards 2006

We are pleased to announce that the following 3 researchers have received a travel award from the 'Tear Film and Ocular Surface Society' for the best 3 abstracts submitted to EVER 2006 by young researchers in the cornea section:

Mario Nubile, Chieti, Italy

In vivo confocal microscopy in limbal epithelial damage — (3352)

Felix Bock, Erlangen, Germany


Inhibition of inflammatory corneal lymphangiogenesis by an anti-VEGFR3 antibody (mF4-31C1) — (356)

Rita Barcia, Boston, USA

Gene therapy promotes corneal graft survival — (2131)

Business meetings

- European Academy of Ophthalmology, Thursday Oct 5, 8:30-12:00, GEMINI II
- European Vision Institute EEIG (EVI), Friday Oct 6, 10:00-12:00, GEMINI II
- Ophthalmic Oncology Group (OOG), Friday Oct 6, 11:15-12:45, Vega
- EVER scientific sections business meeting, Friday 6, 19:00-19:30, in different rooms TBA onsite
- European Board of Ophthalmology (EBO), Saturday Oct 7, GEMINI II



Guidelines for speakers and handling presentations

EVER 2006 offers a high-performance network between all the different presentation rooms.

All presenters must read the following instructions:


- In the AV Support room MEDUSA a technician helps the speaker to transfer his or her presentation into the central congress network. When the transfer is complete, the technician performs a quick run of the presentation so the speaker can check whether the presentation runs correctly and all parts of the presentation are copied.
- Inside each presentation room, a technical assistant starts each presentation at the right time using one of our fixed computers connected to the central congress network.
- We do not allow the use of personal laptops for presentations except in rare circumstances (see below). If you bring your laptop to the congress, the technician will copy the files on your hard disk of the laptop into the central congress network, so the laptop will no longer be needed. Of course, the easiest way is to bring your presentation on CD, DVD or memory stick. Slides are no longer allowed. E-mailing or uploading of presentations will not be encouraged but can be used in special circumstances.
- When a speaker wants to modify the presentation after it has been transferred to the central congress network, it can of course be updated to the new version upon request.
- In rare circumstances, the technician will allow the use of personal laptops. For example, when the presentation has been created with Corel, Staroffice software, Apple Keynote or movie creating software.
- At the end of the congress, all presentations will be deleted so no copyright issues will arise.

Posters

The poster exhibition takes place in **Room: Neptuno**. Each poster is exhibited for one day only. You should install your poster in the morning between 08:00 and 09:00 and remove it the same day after 19:00. EVER is not responsible for any poster left behind at the end of the day.

You will find the number of your posterboard in one of the poster sections of this programme book. The size of the posterboards is 195 cm wide x 100 cm high (landscape orientation).

You should ensure that you are standing beside your poster during the poster session. On Thursday and Friday from 16:30 to 17:20, on Saturday from 15:35 to 16:25. During this time moderators will be voting which poster should win the poster prize.




Withdrawals

First authors unable to attend EVER for reasons beyond their control, may request permission of the Programme Secretary to have another author present the paper. Alternatively, they should send a written notice of withdrawal to the EVER Office before September 20, 2006.

Please note that any first author whose paper is not presented without a valid excuse, once it has been accepted, will be prohibited from presenting papers at EVER for the next two years.





ever 2006

Wednesday 4 October



COURSE I

Gemini I	Statistics	14:00 – 17:00
	Tero KIVELÄ, Bertil DAMATO	
1311	Typical pitfalls, seldom addressed during basic courses in statistics, await the unwary scientist who is starting research in ophthalmology. These include proper ways of analysing data that is collected from both eyes of patients, proper ways of summarising and comparing visual acuities, and recognising and properly analysing time-to event type data in follow-up studies. Moreover, senior scientists who regularly review manuscripts are aware of certain problems in presentation of research data that should be trivial to solve, but which are surprisingly persistent. These comprise recognising the often neglected yet common problem of making multiple comparisons, how to differentiate statistical from clinical significance, how to communicate effect size, and how to cope with statistically non-significant results. This course will clarify the problems mentioned, based on examples from real life and from a practical rather than mathematical point of view. It will provide guidelines for clear presentation of key aspects of the results. The course will specifically address principles that help in reporting statistical results in an informative way.	

COURSE II

Gemini III	How to handle Emergency situations in patients with ocular inflammation ?	14:00 – 16:00
	Bahram BODAGHI	
14:00	1321 Acute anterior uveitis and keratouveitis KESTELYN P, DE SCHRYVER I–Gent	
14:20	1322 Secondary Glaucoma BRON A–Dijon	
14:40	1323 Acute non infectious posterior uveitis COCHEREAU I–Angers	
15:00	1324 Ocular toxoplasmosis threatening visual function KODJIKIAN L–Lyon	
15:20	1325 Viral uveitis and retinopathies BODAGHI BAHRAM, LEHOANG P–Paris	
15:40	1326 Retinal detachment in patients with uveitis DE SMET MD–Antwerp	
16:00	END	

Please remember that you need to register separately if you want to participate in a course.

COURSE III

Vega	<i>Electrophysiology in acquired retinal disease and extended ERG</i>		14:00 – 17:00
	Graham HOLDER		
14:00	1331	Basics of Electrophysiological testing HAWLINA M– Ljubljana	
14:40	1332	ERGs in inflammatory disease HOLDER GE–London	
15:20		Break	
15:40	1333	ERGs in acquired retinal disease LEROY BP–Ghent	
16:20	1334	Extended ERG techniques HOLDER GE–London	
17:00		END	

COURSE IV

Pegasus	<i>Visual Fields in Optic Nerve diseases</i>		14:00 – 16:30
	Pinar AYDIN, Volkan DAYANÍR, Lene MARTIN, Rabla OZDEN		
<p>This course will cover general information on 'Basics in Automated Perimetry and special perimetric techniques for pediatric patients during the first part. During the second part a detailed information will be given on the diagnosis and follow-up of glaucoma with the progression analysis and neuro-ophthalmology with various examples.</p> <p>Participants are welcome to bring challenging clinical cases and contribute to the discussion with their questions and experiences.</p>			
14:00	1341	Basics in automated perimetry, the glaucoma progression analysis software and case discussions DAYANÍR V– Aydín	
14:30	1342	Perimetry in children MARTIN L–Stockholm	
15:00		Break	
15:15	1343	New Developments in perimetry: Frequency Doubling Technology and Blue on Yellow SITA OZDEN R– Danville, CA	
15:45	1344	Interactive case discussion AYDIN P– Ankara	
16:00		Discussion	
16:30		END	

Fenix I Joint M.	FRO: Fund for Research in Ophthalmology Luc MISSOTTEN		14:00 – 16:15
14:00	1351	Aquaporins expression in experimental autoimmune uveitis MOTULSKY E–Brussels	
14:15	1352	Development and evaluation of a minitablet and colloidal carrier for the enhancement of topical ocular delivery of cyclosporin VANDERVOORT J–Antwerp	
14:30	1353	Vernal keratoconjunctivitis in Rwanda school children and its association with atopy and parasitic infestation. A pilot study DE SMEDT S–Gitarama, Rwanda	
14:45	1354	Aetiology and prevalence of visually impaired children in Flanders, Belgium CASAER P–Leuven	
15:00		Break	
15:30	1355	Neuroprotection of neuroglobin: a therapeutic perspective on glaucoma LI Z–Leuven	
15:45	1356	The role of vascular endothelial growth factor in glaucoma surgery VAN DE VEIRE S–Leuven	
16:00	1357	The use of the lens capsule in protecting the corneal endothelial cells during phacoemulsification in patients with compromised endothelium SAKELLARIS D–Antwerp	
16:15		END	

COURSE V

IT Room	Web-Based Resources in Ophthalmology: Resources and Strategies		14:00 – 16:30
	Pamela SIEVING		
1361	The Web presents both opportunities and challenges. This course will help you save time and maximize results when you seek information. Topics to be covered:		
<ul style="list-style-type: none"> • PubMed: content; search techniques; how to access resources identified when you search • Other bibliographic databases: Embase, Scopus, Web of Knowledge, LILACS • Best sources for evidence-based medicine • Genetics resources • What is free, and how to get it • New information resources: Google and Google Scholar; institutional repositories; evaluating Web sites 			
<p>The course is lecture, demonstration, and hands-on. If you like, submit questions and problems to the instructor beforehand: PamSieving@nih.gov</p>			

Welcome

17:15 – 17:30
Fenix III

Welcome by the President

Tero KIVELÄ — President EVER 2006



AER Lecture

17:35 – 18:15
Fenix III

Antivirals for viral eye infections

Erik DE CLERCQ, Leuven
Introduction by Anthony BRON




EVER Lecture

18:20 – 19:00
Fenix III

The Evolution of Electrical Responses from the Eye

Nicholas GALLOWAY, Nottingham
Introduction by Tero KIVELÄ



Social

19:00 - 21:00
Marinotel Garden

EVER Welcome Garden Party



ever 2006

Thursday 5 October



Gemini I SIS	Myopia – Eye growth, development and Genetics		08:30 – 10:00
		Seang Mei SAW, Marcela VOTRUBA	
08:30	2111	Genetic and environmental determinants of myopia: investigations in the 1958 British birth cohort RAHI JS, CUMBERLAND PM, BHATTACHARYA SS, HAMMOND CJ, WEBSTER AR, SHAM P, PECKHAM CS–London	
08:48	2112	Myopia and worldwide variations with ethnicity SAW SM–Singapore	
09:06	2113	Imaging the myopic eye GILMARTIN B, SINGH KD, LOGAN NS–Birmingham, Cardiff	
09:24	2114	Familial influences in refractive development GUGGENHEIM JA, SAW SM, PONG-WONG R, HALEY CS–Cardiff, Singapore, Edinburgh	
09:42	2115	The twin eye study HAMMOND C–London	
Gemini III FP	Free papers Immunology / Microbiology : Experimental and clinical uveitis/microbiology		08:30 – 10:00
	Bahram BODAGHI, Philippe KESTELYN		
08:30	2121	Antigen Specific CD4+CD25+ Regulatory T-Cells Modulate Intraocular Inflammation in a Model of Experimental Uveoretinitis Induced by a Neoretinal Antigen BODAGHI B, TERADA C, DE KOZAK Y, FISSON S, LEHOANG P, KLATZMANN D, SALOMON B–Paris	
08:42	2122	Is Polymerase Chain Reaction Useful in Uveitis? PROENCA H, FERREIRA C, MIRANDA M, CASTANHEIRA-DINIS A, MONTEIRO-GRILLO M–Lisbon	
08:54	2123	PCR in the diagnosis of Borrelia burgdorferi in ocular Lyme disease SILVA BELTRÁN B, BASTOS A, FERREIRA C, MIRANDA M, CASTANHEIRA-DINIS A, MONTEIRO-GRILLO M–Lisbon	
09:06	2124	Bacterial Identification Using PCR In A Large Series Of Acute Post-Cataract Endophthalmitis CHIQUET C, CREUZOT-GARCHER C, ROUBEROL F, PALOMBI K, DENIS P, LAFONTAINE PO, BENITO Y, CORNUT PL, THURET G, ROMANET JP, VANDENESCH F–Grenoble, Dijon, Lyon, Saint Etienne	
09:18	2125 <i>rf</i>	Antibiotic Resistances of Bacteria Identified in an Endophthalmitis Prospective Study BRON AM, PASSEMARD M, LAFONTAINE PO, PECHINOT A, CORNUT PL, ROUBEROL F, ROMANET JP, CREUZOT-GARCHER C, CHIQUET C–Dijon, Lyon, Grenoble	
09:24	2126 <i>rf</i>	<i>S. epidermidis</i> : Friend or Foe in Dry Eye- Its Interaction with Goblet Cells GRAHAM JE, MOORE JE, DARLT D, BEST R, ALARBI M, MCGIMPSEY S, DIABOLD Y, DOWNES CS, MOORE CBT, MOORE JE–Coleraine, Belfast, Boston, Valladolid	
Vega FP	Free papers Cornea : Cornea Grafting		08:30 – 10:00
	Christopher LIU, Gilles THURET		
08:30	2131	Gene therapy promotes corneal graft survival BARCIA B, DANA RM, KAZLAUSKAS A–Boston	
08:42	2132	Long term corneal endothelial cell count after Verisyse IOL implantation associated with Penetrating Keratoplasty in the management of pseudophakic bullous keratopathy GICQUEL JJ, DIGHERO PL–Poitiers	
08:54	2133	Development of an experimental model of lamellar and penetrating keratoplasty FABIANI L, BLANCO-MEZQUITA JT, MARTINEZ-GARCIA MC, BARCIA A, FERRARA P, MERAYO-LLOVES JM–Valladolid, Bello Horizonte	
09:06	2134	Compositional dynamics of phospholipids in the tear film CAMPBELL D, GRIFFITHS G, TIGHE BJ–Birmingham	
09:18	2135	Corneal endothelial status twenty years after penetrating keratoplasty BOURNE WM, PATEL SV, HODGE DO–Rochester, Minnesota	
09:30	2136 <i>rf</i>	Expression of CTLA4-Ig and vIL-10 by gene-engineered dendritic cells leads to prolongation of corneal allograft survival SCHLICKER S, RITTER T, LI XQ, APPELT C, VOLK HD, PLEYER U, SAWITZKI B–Berlin, Galway	
09:36	2137 <i>rf</i>	Prolongation of corneal allograft survival by topical application of Everolimus PLEYER U, BÜCH G, OTASEVIC L, SCHLICKER S, BERTELmann E, LI X–Berlin, Wuhan	
09:42	2138 <i>rf</i>	Comparison of the Visual Acuity by Time Index with conventional Survival Curves for the evaluation of osteo-odonto keratoprosthesis functional results MICHAEL R, TEMPRANO J, CHAROENROOK V, DE LA PAZ M, HITZL W, GRABNER G, BARRAQUER RI–Barcelona, Salzburg	
09:48	2139 <i>rf</i>	Swelling and deswelling of human corneas during eye banking: present and future THURET G, ZHAO M, GAIN P–Saint-Etienne	

Pegasus SIS	Diabetes and Cataract Shambhu D. VARMA, Kavita HEGDE	08:30 – 10:00
----------------	--	---------------

08:30	2141	Lens Crystallin glycation and ascorbylation in diabetes and aging MONNIER V, FAN X, RENEKER L, JARVIS S, OBRENOVICH M, CHENG R, ORTWERTH B—Cleveland, Columbia, Canterbury
08:52	2142	Glycation and Cataract HARDING J—Oxford
09:14	2143	Antioxidants in cataract prevention HEGDE K, VARMA S—Baltimore
09:36	2144	Evidence for protection against oxidative stress in the lens SÖDERBERG P G, DONG X, AYALA M, MODY V, LÖFGREN S, MEYER L, KAKAR M, J WANG, ZHANG F—Stockholm, Örebro, Bonn, Dalian

Fenix I SIS	Ocular Biomechanics Konstantin KOTLIAR	08:30 – 10:00
----------------	--	---------------



08:30	2151	Fluidmechanical analysis of microstructural changes in retinal arteries in glaucoma KOTLIAR KE, SCHILLING R, VILSER W, LANZL IM—Munich, Ilmenau
08:42	2152	Biomechanical estimation of the optic nerve head parameters, measured with HRT-II in myopia and in its combination with glaucoma RYABTSEVA AA, CHOMYAKOVA EN, SERGUSHEV SG, SVETLOVA OV—Moscow, St.Petersburg
08:54	2153	Clinical estimation of scleral rigidity for biomechanical modeling of hypotensive non-penetrating sclerotomy ZASEEVA MV, SVETLOVA OV, KRASNITSKAYA S, KOTLIAR KE, KOSHITS IN—St.Petersburg, Munich
09:06	2154	On the mathematical modeling of applanation method for measuring intraocular pressure BAUER SM, LYUBIMOV GA—St. Petersburg, Moscow
09:18	2155	Modeling the human cornea – a stromal tissue constitutive model based on measured collagen architecture CHERNYAK DA, VAN DER HEIDE DT, PINSKY PM—Santa Clara, Palo Alto
09:30	2156	Mechanical properties of certain eye tissues IOMDINA EN—Moscow
09:42	2157	Biomechanical analysis of the hypothesis on “rest of accommodation” KOSHITS IN, SVETLOVA OV, SMOLNIKOV BA, GORBAN AI, KOTLIAR KE—St.Petersburg, Aachen, Munich

Fenix III FP	Free papers Retina : Retinal Imaging Charles RIVA, Frank VERBRAAK	08:30 – 10:00
-----------------	---	---------------

08:30	2161	Quantification of Drusen Deposits using Image Processing Techniques MORA A, FONSECA J, VIEIRA P—Caparica, Lisbon
08:42	2162	Early neuroglial loss in DM type 1 patients, an OCT study VERBRAAK FD, BIALLOSTERSKI C, VAN VELTHOVEN M, SCHLINGEMANN RO, MICHELS BPJ, DE VRIES HH—Amsterdam
08:54	2163	Establishment of a normative database by registration of RTA maps into the RT-Atlas BAPTISTA P, SANTOS T, NUNES S, BERNARDES R, CUNHA-VAZ J—Coimbra
09:06	2164	Increased OCT Mapping Resolution by Merging Line and Circle Scan-Types SANTOS T, BAPTISTA P, BERNARDES R, CUNHA-VAZ J—Coimbra
09:18	2165	May OCT/SLO improve our understanding in pathophysiology of optic disc coloboma- related maculopathy? PICCIRILLO V, RAO V, DI NUZZO A, SAVASTANO S, SAVASTANO MC, FORTE R, MOSCATO B, ROSEN R—Cassino, Maddaloni, Rome, Naples, Benevento, New York
09:30	2166	Development of a Fluorescent Lifetime Image Ophthalmoscope BARBOSA A, MANIVANNAN A, VIEIRA P—Lisbon, Aberdeen
09:42	2167	Establishment of a Retinal Thickness Atlas (RT-Atlas) BERNARDES R, SANTOS T, CUNHA-VAZ J—Coimbra

Keynote Lecture

10:15 – 10:55
Fenix III

Cone and cone rod dystrophies, genotype, phenotype and disease mechanisms

Anthony MOORE, London

Introduction by Amanda CHURCHILL



Gemini I SIS	<i>Myopia and refractive error: epidemiology</i>		11:15 – 12:45
	Seang Mei SAW, Cathy WILLIAMS		
11:15	2211	Risk factors for hypermetropia, strabismus and amblyopia in the ALSPAC Study WILLIAMS C, NORTHSTONE K, HOWARD M, HARRAD RA, SPARROW JM–Bristol	
11:33	2212	Comparisons of refractive error in UK and Singapore children: the ALSPAC and SCORM studies GAZZARD G, WILLIAMS C, SAW S-M, MILLER L, ALSPAC STUDYGROUP–London, Bristol, Singapore	
11:51	2213	Underlying patterns of refractive development in Sydney children: the Sydney Myopia Study MORGAN IG, ROSE KA–Canberra, Sydney	
12:09	2214	Prevalence and risk factors for myopia, hypermetropia, strabismus and amblyopia in Australian children: the Sydney Myopia Study ROSE KA, MORGAN IG–Sydney, Canberra	
12:27	2215	The epidemiology of refractive error in UK children: the Aston Eye Study LOGAN NS, SHAH P, RUDNICKA AR, OWEN CG, GILMARTIN B–Birmingham, London	
Gemini III SIS	<i>Current approaches in Endophthalmitis</i>		11:15 – 12:45
	Marc D DE SMET, Laurent KODJIKIAN		
11:15	2221	What is new in endogenous endophthalmitis ? BODAGHI B–Paris	
11:30	2222	Relationship between bacterial adhesion to intraocular lenses and postoperative endophthalmitis KODJIKIAN L–Lyon	
11:45	2223	Endophthalmitis after cataract surgery, risk factors and prophylaxis : myths and facts GARWEG JG, KODJIKIAN L–Bern, Lyon	
12:00	2224	Endoscopy for the management of severe endophthalmitis DE SMET MD, GHYCZY-CARLBORG EAE, MURA M–Antwerp, Amsterdam	
12:15	2225	New antibiotics in endophthalmitis treatment COCHEREAU I–Angers	
12:30	2226	Complete and Early Vitrectomy for Eyes with Postoperative Endophthalmitis KUHN F, GINI G–Birmingham, USA	
Vega SIS	<i>Anatomy and Immune regulation at the Ocular Surface</i>		11:15 – 12:45
	Erich KNOP, Nadja KNOP, Jean-Jacques GICQUEL		
11:15	2231	Contribution of the Eye-Associated Lymphoid Tissue (EALT) to immune regulation at the ocular surface KNOP E, KNOP N–Berlin, Hannover	
11:30	2232	Role of M-cells in the afferent limb of ocular surface immunity KNOP N, KNOP E–Hannover, Berlin	
11:45	2233	Aspects of innate immunity at the ocular surface DUA HS, ABEDIN A, RAHMAN I, MATHEW M, HOPKINSON A–Nottingham	
12:00	2234	The Role of Surfactant Protein-D (SP-D) at the Ocular Surface BRON AJ, CLARK HW–Oxford	
12:15	2235	Flow cytometry study of Impression Cytology specimens during the long term follow-up of severe ocular burns GICQUEL JJG, NAVARRE RN, GOMBERT JMG, DIGHERO PLD–Poitiers	
12:30	2236	The Implication of TLR's in Sjögren's Syndrome and severe Dry eye LANGMAN ME–Saint Jean d'Angély	

Pegasus SIS	Use of micronutrients Imre LENGYEL, Neville OSBORNE	11:15 – 12:45
----------------	---	---------------



11:15	2241	Mitochondrial dysfunction and cell death: focus on -lipoic acid OSBORNE NN–Oxford
11:33	2242	Reducing the risk of AMD: diet vs supplements KLAVER CCW, VAN LEEUWEN R, DE JONG PTVM–Rotterdam, Amsterdam
11:51	2243	Lutein and zeaxanthin: genetics and supplementation VAN KUIJK E, LIEW M, BEATTY S, MELLERIO J, MARSHALL J, HAMMOND C, GILBERT C–Galveston, TX, London, Waterford, Orpington
12:09	2244	Can the macular pigment be influenced? The LUNA (Lutein nutrition effects measured by autofluorescence) Study TRIESCHMANN MBT, PAULEIKHOFF DP–Münster
12:27	2245	Zinc, Drusen and Complement Factor H LENGYEL I–London

Fenix I FP	Free papers Glaucoma : Microbiology & Bloodflow & IOP Selim ORGUL, Ingeborg STALMANS	11:15 – 12:45
---------------	--	---------------

11:15	2251	Role of Vascular Endothelial Growth Factor and Placental Growth Factor in Glaucoma and Scar Formation after Glaucoma Filtration Surgery LI Z, VAN DE VEL I, ZEYEN T, CARMELIET P, STALMANS I–Leuven
11:27	2252	Colour Doppler Imaging as a diagnostic tool in Normal Tension Glaucoma REMKY A, KAUP M, AREND O, WEBER A, PLANGE N–Aachen
11:39	2253	Ocular pulse amplitude and colour doppler imaging in glaucoma patients versus normal subjects STALMANS I, SIESKY B, VAN BELLINGHEN V, ZEYEN T, HARRIS A–Leuven, Indianapolis, IN, Indiana, IN
11:51	2254	Clinical evaluation of Applanation resonance tonometry – a comparison with Goldmann applanation tonometry HALLBERG P, EKLUND T, BÄCKLUND T, LINDÉN C–Umeå
12:03	2255	Correlation Between Ocular Response Analyzer, Dynamic Contour Tonometry, and Goldmann Applanation Tonometry RENIER C, ZEYEN T, STALMANS I–Leuven
12:15	2256 <i>rf</i>	Inducible NOS synthase in the human trabecular meshwork (TM) from patients with primary open-angle glaucoma (POAG). FERNANDEZ DURANGO R, GARCIA FEIJOO J, CASTILLO A, MARTÍNEZ DE LA CASA JM, GARCIA-BUENO B, FERNANDEZ-CRUZ A, LEZA JC–Madrid
12:21	2257 <i>rf</i>	Intraocular pressure measurement using near infrared spectroscopy KAMPPETER BA, WITZENMANN T, BACKHAUS J, JONAS JB–Mannheim

Fenix III SIS	EPOS : Diagnostic and therapeutic advances in paediatric retinal diseases - Part 1 Birgit LORENZ	11:15 – 12:45
------------------	--	---------------

11:15		Introduction by Birgit Lorenz
11:20	2261	Tips and Tricks in Paediatric Retinal Electrophysiology HOLDER GE–London
12:00	2262	Molecular Genetic Analysis of Early Onset Severe Retinal Dystrophies EOSRD PREISING MN–Regensburg
12:25	2263	Dissecting the Clinical Phenotype of EOSRD LORENZ B–Regensburg

Gemini I SIS	Mechanism of action of neuroprotective factors in retina			14:00 – 15:30
	Joyce TOMBRAN-TINK, Colin BARNSTABLE			
14:00	2311	PEDF in Development, Diseases, and Therapeutics TOMBRAN-TINK J, BARNSTABLE CJ–New Haven, CT		
14:18	2312	Signalling pathways in photoreceptor and ganglion cell responses to neurotrophic factors HICKS D, SIFFROI-FERNANDEZ S, BUGRA K, SWAROOP A, BONNET D–Strasbourg		
14:36	2313	CNTF Cascades in Retinal Development and Disease BARNSTABLE CJ, TOMBRAN-TINK J–New Haven, CT		
14:54	2314	Role of GDNF in the differentiation of photoreceptors in 3D-retinal spheres of the chick embryo LAYER PG, VOLPERT K, ROTHERMEL A–Darmstadt		
Gemini III FP	Free papers Immunology / Microbiology : Clinical uveitis			14:00 – 15:30
	Uwe PLEYER, Narsing RAO, Philippe KESTELYN			
14:00	2321	Acute anterior (kerato)uveitis DE SCHRYVER I, KESTELYN PH–Ghent		
14:12	2322	Long term survival in sarcoid uveitis MISSOTTEN T, VAN DAELE PL, VAN LAAR JAM, VAN DER LOOS T, VAN HAGEN PM, BAARSMA GS–Rotterdam		
14:24	2323	Optimal pulmonary investigations in patients with uveitis of suspected sarcoidosis origin. EBRAERT HE, MICHEL OM, WILLERMAIN FW, CASPERS LC–Brussels		
14:36	2324	Infliximab for the treatment of chronic uveitis SEN HN, LEVY-CLARKE G, NUSSENBLATT RB–Bethesda, MD		
14:48	2325	Intravitreal Bevacizumab (AvastinTM) as a potent treatment for refractory macular oedema in patients with uveitis MACKENSEN F, HEINZ C, HEILIGENHAUS A, BECKER MD–Heidelberg, Münster		
15:00	2326	Use of Ocular Hypotensive Prostaglandin Analogs in Uveitis: Potential Effects on Anterior Uveitis and Cystoid Macular Oedema GURBAXANI A, LIGHTMAN S, CHANG JH, MCCLUSKEY P–London, Sydney		
Vega FP	Free papers Anatomy : Ocular anatomy and cell biology			14:00 – 15:30
	Erich KNOP			
14:00	2331	Alpha 11 integrin in the human cornea – importance in development and disease BYSTRÖM B, GULLBERG D, PEDROSA-DOMELLÖF F–Umeå, Bergen		
14:12	2332	Expression of Neopeptope BKS-1 and distribution of collagen fibrils diameter in normal and keratoconus cornea AKHTAR S, BRON AJ, KERR BC, CATERSON B, HUGHES C, MEEK KM–Cardiff, Oxford		
14:24	2333	Glycogen synthase kinase (GSK-3) inhibitors prolong the life of human lens epithelial cells KARLSSON J-O, PETERSEN A, ZETTERBERG M–Göteborg		
14:36	2334	Studies on nitric oxide generation and Na,K-ATPase inhibition in porcine nonpigmented ciliary epithelium DELAMERE NA, SHAHIDULLAH M–Louisville, KY		
14:48	2335	Age-related changes in the orbital layer of human extraocular muscles (EOMs) BRUENECH JR, KJELLEVOLD HAUGEN IB–Kongsberg		
15:00	2336 <i>rf</i>	Ectasia After LASIK; Case Report ABAHUSSIN M, VELARDE J, MEEK KM, COTERO J–Cardiff		
15:06	2337 <i>rf</i>	Metabolic and Molecular Signalling Pathways of Retinoids on Human Trabecular meshwork SAPIN V, BLANCHON L, MARCEAU G, NEZZAR H, DASTUGUE B, RIGAL D, YUE B, CHIAMBARETTA F–Clermont Ferrand, Chicago		
ACTA Lecture 15:45 – 16:25 Fenix III	The Interplay of Clinical and Basic Knowledge in X-linked Retinoschisis Paul SIEVING, Bethesda Introduction by Einar STEFÁNSSON, Editor-in-Chief, Acta Ophthalmologica			

Pegasus FP	Free papers Lens Shambhu D. VARMA, Per SÖDERBERG	14:00 – 15:30
14:00	2341	Mapping of the age-related EMORY cataract: indication for a complex trait GRAW J, WEBER A, LÖSTER J–Neuherberg
14:12	2342	Removal of retrolental cysticercus cellulosae BARRAQUER J–Barcelona
14:24	2343	Binocular vision and refractive results of the secondary IOL implantation in children with long-term follow-up. AUTRATA R, PYROCHTOVA S, REHUREK J–Brno
14:36	2344 <i>rf</i>	Evolution of Ultraviolet Radiation-B (UVR-B)-Induced Cataract in the Pigmented Guinea Pig MODY VC, KAKAR MK, LÖFGREN S, AYALA M, MEYER L, DONG X, WANG J, BUCHT C, SÖDERBERG PG–Stockholm
14:42	2345 <i>rf</i>	A Phacoemulsification Anticipation of Difficulty (PAD): Anterior chamber depth predicts difficulty of surgery SIDDQUI S, SOLEBO L, HAYWARD JM, KERR-MUIR M, GALE RP–York, Cambridge
14:48	2346 <i>rf</i>	Cataract and inflammation: a new drug delivery system EPERON S, BOSSY-NOBS L, GUEX-CROSIER Y, PETROPOULOS IK, GURNY R–Lausanne, Geneva
14:54	2347 <i>rf</i>	Ocular Anaesthetic Scoring System CEHAJIC J, LIYANAGE SE, WEARNE IM–London, Eastbourne

Fenix I SIS	Dynamic contour tonometry Mona PACHE, Thierry ZEYEN	14:00 – 15:30
----------------	---	---------------



14:00	2351	Dynamic Contour Tonometry – the new „gold standard“ for intraocular pressure measurement? PACHE M–Freiburg
14:18	2352	Technical Principle of Dynamic Contour Tonometry compared with Goldmann Applanation Tonometry LANGENBUCHER A–Erlangen
14:36	2353	Clinical Impact of Dynamic Contour Tonometry - a new state of the art? VIESTENZ A–Magdeburg
14:54	2354	Dynam-Ico - DCT versus intracameral manometry LAUTEBACH S, NEUBURGER M, FUNK J–Freiburg
15:12	2355	Correlation between OPA and CDI in glaucoma patients versus normal subjects STALMANS I, ZEYEN T, HARRIS A–Leuven, Indianapolis

Fenix III SIS	EPOS : Diagnostic and therapeutic advances in paediatric retinal diseases - Part 2 Birgit LORENZ	14:00 – 15:30
------------------	--	---------------

14:00	2361	Gene Therapeutic Prospects in EOSRD ROLLING F–Nantes
14:25	2362	Retinoblastoma Update DESJARDINS L, LUMBROSO-LEROUC L, LEVY-GABRIEL C, DOZ F, DENDALE R, SASTRE X, BOURS S, ASSELAIN B–Paris
15:00	2363	Retinopathy of Prematurity Update LORENZ B–Regensburg

Poster session16:30 – 17:20
Neptuno**Anatomy / Cell Biology, Immunology / Microbiology, Lens and Cataract,
Vision Sciences / Electrophysiolog. / Physiol. Optic, Information technology**

Hannu UUSITALO, Luc MISSOTTEN, Tom MISSOTTEN, Antonio BERGUA, Joaquin BARRAQUER, Kavita HEGDE, Marko HAWLINA, Werner SPIELEERS

Gemini I FP	Free papers Molecular Biology / Genetics / Epidemiology : Phenotyping & Mutations		17:30 – 19:00
	Anthony MOORE, Marcela VOTRUBA		
17:30	2411	Ophthalmological data of 837 patients with FABRY disease: latest analysis from FOS – the Fabry Outcome Survey PITZ S, IOANNIDES A, SODI A, SUNDER-PLASSMANN G–Mainz, London, Florence, Vienna	
17:42	2412	Novel mutations in ABCR gene associated with Stargardt Disease in Italian patients SODI A, PASSERINI I, GIAMBENE B, MENCHINI U, TORRICELLI F–Florence	
17:54	2413	A novel homozygous NR2E3 mutation in a patient with enhanced S-cone syndrome ROCHA DE SOUSA A, HAYASHI T, BRANDÃO E, GOMES N, PENAS S, MARQUES CJ, TAKEUCHI T, FALCÁO-REIS F–Porto, Tokio	
18:06	2414	Screening for Sequence Changes in the OPA1 gene in 21 patients with Optic Atrophy CARTER JG, CHURCHILL AJ–Bristol	
18:18	2415	Is the clinical picture of Leber hereditary optic neuropathy changing? WEFERS BETTINK - REMEIJER M, SPRUIT L–Rotterdam, Maastricht	
18:30 <i>rf</i>	2416 <i>rf</i>	Mutation analysis of RHO gene and novel mutation Arg252Pro (755G→C) in patients with nonsyndromic retinitis pigmentosa from Bashkortostan GRINBERG E, DZHEMILEVA L, KHUSNUTDINOVA E–Ufa	
18:36 <i>rf</i>	2417 <i>rf</i>	Familial high myopia in Polish population RYDZANICZ MA, PODFIGURNA-MUSIALAK M, FRAJDENBERG A, BEJJANI BA, LEAL SM, GAJECKA M–Poznan, Leszno, Spokane, Houston	
Gemini III SIS	ARVO session: Pearls of Research From U.S. Institutions		17:30 – 19:00
	Nicholas DELAMERE		
			
17:30	2421	Opportunities for Research Collaboration and Training at The Wilmer Eye Institute ZACK DJ–Baltimore	
18:00	2422	Research at Rochester MERIGAN W–Rochester	
18:30	2423	Vision research at the Doheny Eye Institute – University of Southern California RAO N–Los Angeles	
Vega SIS	Leukokoria: Differential diagnosis		17:30 – 19:00
	Theodora HADJISTILIANOU		
17:30	2431	Leukocoria: What is hidden behind a white pupil HADJISTILIANOU T, DE FRANCESCO S–Siena	
17:48	2432	Differential diagnosis of retinoblastoma: A review of 205 children seen at Curie Institute DESJARDINS L, LEVY-GABRIEL C, LUMBROSO LEROUC L, DOZ F, DENDALE R, BRISSE H, SASTRE X–Paris	
18:06	2433	Differential diagnosis of leukocoria: Emblematic cases MUNIER F, BALMER A, UFFER S–Lausanne	
18:24	2434	The role of diagnostic imaging (MRI) in children with leucocoria IMHOF S, MOLL A, DE GRAAF P–Amsterdam	
18:42	2435	Leukocoria associated with glaucoma FREZZOTTI P, DE FRANCESCO S, MENICACCI F, HADJISTILIANOU T–Siena	

Pegasus SIS	New IOL technologies Rafael I. BARRAQUER, Per SÖDERBERG	17:30 – 19:00
17:30	2441 Macular protection versus scotopic vision with blue light filtering IOLs SÖDERBERG P G–Stockholm	
17:45	2442 IOLs correcting spherical aberrations: benefit and limitations ARTAL P, TABERNERO J–Murcia	
18:00	2443 Global characterization of optical quality in eyes with various types of monofocal lenses MARCOS S–Madrid	
18:15	2444 The Sarfarazi Elliptical Accommodating Intraocular Lens SARFARAZI M–Boston	
18:30	2445 New accomodative IOL ALIO SANZ J–Alicante	
18:45	2446 Current status of Phaco Ersatz BARRAQUER RI, MICHAEL R–Barcelona	
Fenix I FP	Free papers Glaucoma : Epidemiology & Medical treatment Jost B JONAS, Anne COLEMAN	17:30 – 19:00
17:30	2451 A new approach for mass glaucoma screening HOLLÓ G, TÓTH M, KÓTHY P, VARGHA P–Budapest	
17:42	2452 Eating Fruits and Vegetables May Decrease Risk of Glauoma COLEMAN AL, TOPOUZIS F, BADALA F, YU F–Los Angeles, Thessaloniki, Philadelphia	
17:54	2453 Systemic antihypertensive medication and the risk of incident glaucoma. MUSKENS RPHM, DE VOOGD S, WOLFS RCW, WITTEMAN JC, HOFMAN A, DE JONG PTVM, STRICKER BHC, JANSONIUS NM–Groningen, Rotterdam	
18:06	2454 Frequency of Optic Disc Hemorrhages in Adult Chinese in Rural and Urban China. The Beijing Eye Study JONAS JB, WANG Y, XU L, HU L, WANG Y, YANG H–Mannheim, Beijing	
18:18	2455 The impact of dorzolamide/timolol unfixed combination on visual field in primary open-angle glaucoma patients. MARTÍNEZ-GARCÍA A, SÁNCHEZ-SALORIO M–Santiago de Compostela	
18:30	2456 rf Community optometrist referrals for glaucoma- referral accuracy and outcomes MALIK ANJ, YUEN L, ALTHAUSER S–London	
18:36	2457 rf Development of an Instrument to Assess Behavior and Readiness for Behavior Change in Patients Taking Ocular Hypotensive Therapy SCHWARTZ GF, PLAKE K, MYCHASKIW MA–Baltimore, West Lafayette, New York	
Fenix III FP	Free papers Retina : Antiangiogenic treatments Marc D DE SMET, Francesco BANDELLO	17:30 – 19:00
17:30	2461 Mechanism of Action of Anecortave Acetate DE SMET M–Antwerp	
17:42	2462 Photodynamic therapy associated to peri-bulbar triamcinolone injection in the treatment of subfoveal choroidal neovascularization MAESTRONI L, BARTESELLI G, MIGLIOR S–Monza	
17:54	2463 Pegaptanib Sodium in the Treatment of Patients with Macular Oedema Following Central Retinal Vein Occlusion (CRVO) PATEL S, MACUGEN RETINAL VEIN OCCLUSION STUDY GROUP–New York	
18:06	2464 Benefits of Pegaptanib Sodium in Subjects with Diabetic Macular Oedema CUNHA-VAZ JG, FOR THE MACUGEN DIABETIC RETINOPATHY STUDY GROUP–Coimbra, New York	
18:18	2465 Symmetry of age related maculopathy and macular degeneration in the London AMD Study Cohort PETO T, DANDEKAR SS, RUTISHAUSER-ARNOLD Y, JENKINS S, WEBSTER A, LEUNG I, BIRD AC–London, Zurich	
18:30	2466 Visual Acuity Change after Intravitreal Bevacizumab for Exudative Age-Related Macular Degeneration in Relation to Subfoveal Membrane Type LIBONDI T, IHLOFF AK, HARDER B, KREISSIG I, SCHLICHTERNBREDE F, SPANDAU UHM, JONAS JB–Napoli, Mannheim	
18:42	2467 rf Short term effect of intravitreal Bevacizumab (Avastin) for exudative age-related macular degeneration CHRISTMANN S, CORDES AK, DOHM S, SCHRAGE NF, DEGENRING RF–Cologne	

Poster Session 1 — 16:30-17:20 — Neptuno

- Anatomy / Cell Biology: 201 > 213, moderators: Hannu UUSITALO, Luc MISSOTTEN
- Immunology / Microbiology: 214 > 226, moderators: Tom MISSOTTEN, Antonio BERGUA
- Lens and Cataract: 227 > 236, moderators: Joaquin BARRAQUER, Kavita HEGDE

ANATOMY / CELL BIOLOGY

- 201 Ectasia After LASIK; Case Report
rf ABAHUSIN M, VELARDE J, MEEK KM, COTERO J—Cardiff, Spain
- 202 Metabolic and Molecular Signalling Pathways of Retinoids on Human Trabecular meshwork
rf SAPIN V, BLANCHON L, MARCEAU G, NEZZAR H, DASTUGUE B, RIGAL D, YUE B, CHIAMBARETTA F—Clermont Ferrand, Chicago
- 203 Influence of Toll-like receptor agonists on IL-6 expression in human retinal pigment epithelial cells (ARPE-19).
PAIMELA T, RYHÄNEN T, SALMINEN A, UUSITALO H, KAARNIRANTA K—Kuopio
- 204 Geldanamycin modulates ubiquitin-proteasome pathway mediated protein aggregation in human ARPE-19 cells
RYHÄNEN T, KAARNIRANTA K, KUUSISTO E, MIETTINEN R, SALMINEN A, UUSITALO H—Kuopio
- 205 Methylglyoxal destabilizes HIF-1 by an ubiquitin-proteasome-dependent pathway in retinal pigment epithelial cells
BENTO CA, PEREIRA P—Coimbra
- 206 Cyclooxygenase-2 gene expression and immunolocalization in human epiretinal membranes
SCHUMANN RG, BAUER C, STRAUSS R, YU A, GANDORFER A, KAMPIK A, WELGE-LUESSEN UC—Munich
- 207 Quantitative astroglial changes in an experimental model of hypercholesterolemia; variations after normalization of cholesterol blood values induced by a normal diet
RAMIREZ AI, SALAZAR JJ, DE HOZ R, ROJAS B, RUIZ E, TEJERINA T, TRIVIÑO A, RAMIREZ JM—Madrid
- 208 Preservation of retinal anatomy and synaptic connectivity following preventive subretinal injections of Schwann cells in the RCS rat.
PINILLA I, CUENCA N, SAUVÉ Y, MARTINEZ-NAVARRETE G, BORQUE E, LUND RD—Zaragoza, Alicante, Edmonton, Salt Lake City
- 209 Expression of lumican and keratocan in normal and keratoconus cornea
AKHTAR S, BRON AJ, KERR BC, CATERSON B, HUGHES C, MEEK KM—Cardiff, Oxford
- 210 Corneal sensitivity and corneal nerve morphology in diabetic patients
FRUSCHELLI M, MARTONE G, HAKA G, TRAVERSI C, CAPOROSSI A—Siena
- 211 Where are the deposits in cornea verticillata in Fabry?
LANZL I, KOTLIAR K, MAIER M, FIORE B, MESSMER E—Munich
- 212 DACRIO – TC in the follow up of dacriocistorinostomy ab externo
PESCE GP, MESIANI MAZZACUVA FMM, CATALANO CC, RECHICHI MR, CARNOVALE SCALZO GCS, PARDATSCHER KP, STANA' CS, BOMBARDIERI CB—Catanzaro
- 213 Morgan's Transconjunctival Correction of Age-Related Lower Eyelid Entropion
GANDHI JS, ZIAHOSSEINI K, ODAT T, MANIK KS, MORGAN LH—Manchester, Leeds

IMMUNOLOGY / MICROBIOLOGY

- 214 Antibiotic Resistances of Bacteria Identified in an Endophthalmitis Prospective Study
rf BRON AM, PASSEMARD M, LAFONTAINE PO, PECHINOT A, CORNU PL, ROUBEROL F, ROMANET JP, CREUZOT-GARCHER C, CHIQUET C—Dijon, Lyon, Grenoble
- 215 S. epidermidis: Friend or Foe in Dry Eye- Its Interaction with Goblet Cells
rf GRAHAM JE, MOORE JE, DARTT D, BEST R, ALARBI M, MCGIMPSEY S, DIABOLD Y, DOWNES CS, MOORE CBT, MOORF JE—Coleraine, Belfast, Boston, Valladolid
- 216 Selective innate immunodeficiency in patients with severe herpesvirus retinitis?
BERGUA A, KITTAN N, HAUPP S, DONHAUSER N, KORN K, SCHMIDT B—Erlangen
- 217 Detection of virulence factors in Pseudomonas aeruginosa strains isolated from contact lens-associated corneal ulcers
PINNA A, USAI D, ZANETTI S, BITTI A, PORCU F, ZANETTI F, CARTA A, CARTA F—Sassari, Ozieri, Parma
- 218 Expression of Interleukin-6, Tumour Necrosis Factor-alpha and Nitric Oxides during Episodes of Ocular Toxoplasmosis in an HIV Patient
PRADA J, LIEKFELD A, BERGMANN F, GROBUSCH MP—Berlin, Johannesburg

- 219 Ocular Presentation of Syphilis with Co-incident HIV Infection
WRIDE NK, PANDIT RJ—Newcastle-upon-Tyne

- 220 Humira / Adalimumab therapy in non-infectious posterior segment uveitis
MISSOTTEN T, VAN LAAR JAM, VAN DAELE PL, VAN DER LOOS T, BAARSMA GS, VAN HAGEN PM—Rotterdam

- 221 OCT – SLO findings in a case of toxoplasma chorioretinitis complicated by epimacular membrane: a new diagnostic tool
PICCIRILLO V, RAO V, DI NUZZO A, FORTE R, DE CRECCHIO G, SAVASTANO S, SAVASTANO MC, MOSCATO B, ROSEN R—Cassino - FR, Maddaloni-CE, Maddaloni- CE, Naples, Naples, Rome, Benevento, New York

- 222 Ocular hypothony in Fuchs heterochromic cyclitis: case report
PARISE S, PENDINO V, VARANO L, SCORCIA G. B., SCORCIA V, CARNOVALE SCALZO G, SCORCIA G—Catanzaro

- 223 Secondary open-angle glaucoma caused by sarcoidosis: a rare case
CATALANO CC, PESCE GP, RECHICHI MR, FRATTO MF, MESIANI MAZZACUVA FMM, SCORCIA GS—Catanzaro, Catanzaro

- 224 Case Series on Scleritis in Newcastle
VELUSAMI P, SANDHU S S, PANDIT R—Siccup, Newcastle upon Tyne

- 225 Agitation of contact lenses by the use of the Complete Rapid Care Cleaning Device
NTAMPOS K, NATSIS K, KARAMPATAKIS V, GOULIA O, ANTONIADIS M, SAMANIDOU E, AMIRIDIS I—Thessaloniki

- 226 Silencing of nitric oxide production by siRNA, application for corneal transplantation
NEUWIRTH A, FRIC J, JIRSOVA K, FILIPEC M, HOLAN V—Prague

LENS AND CATARACT

- 227 Evolution of Ultraviolet Radiation-B (UVR-B)-Induced Cataract in the Pigmented Guinea Pig
rf MODY VC, KAKAR MK, LÖFGREN S, AYALA M, MEYER L, DONG X, WANG J, BUCHT C, SÖDERBERG PG—Stockholm

- 228 A Phacoemulsification Anticipation of Difficulty (PAD): Anterior chamber depth predicts difficulty of surgery
rf SIDDIQUI S, SOLEBO L, HAYWARD JM, KERR-MUIR M, GALE RP—York, Cambridge

- 229 Cataract and inflammation: a new drug delivery system
rf EPERON S, BOSSY-NOBS L, GUEX-CROSIER Y, PETROPOULOS IK, GURNY R—Lausanne, Geneva

- 230 Ocular Anaesthetic Scoring System
rf CEHAJIC J, LIYANAGE SE, WEARNE IM—Bromley Hospitals NHS Trust, London, Eastbourne

- 231 Quality of life and visual outcomes following cataract surgery in patients with early cataract
GILMOUR DF, CACKETT P, DHILLON B—Leeds, Edinburgh

- 232 Long term visual outcome after surgery of cataract with hyperplastic primary vitreous- Fifteen year-experiences.
AUTRATA R, HELMANOVÁ I, REHUREK J—Brno

- 233 Rationale for the development of a viscoelastic fitting all steps of cataract surgery: Rhexel®
RIGAL SASTOURNE JC, LEBRETOM P—Paris, Pringy

- 234 Comparison of higher order aberrations and contrast sensitivity after Verisyse phakic IOL, and Icare IOL
DIGHIERO PL, BRIAT B, AGUSSAN J, GICQUEL JJ—Poitiers, La Rochelle

- 235 Bilateral Congenital Cataracts in Western Sweden: A Longitudinal Follow-up
SJÖSTRAND JB, NYSTRÖM A, MAGNUSSON GCB—Göteborg

- 236 Phakic refractive lens implantation to correct moderate to high hyperopia:
1 year follow-up
GIL-CAZORLA R, FUENTES I, HERNÁNDEZ-VERDEJO JL, SANCHEZ JM, TEUS MA—Madrid

Poster Session 1 — 16:30-17:20 — Neptuno

- Vision Sciences / Electrophysiolog. / Physiol. Optic: 237 > 256, moderators: Marko HAWLINA, Werner SPIELEERS
- Information technology: 257 > 258

VISION SCIENCES / ELECTROPHYSIOL. / PHYSIOL. OPTIC

- 237 Clinical usefulness of visual evoked potentials in mild to moderate traumatic brain injury
MCKERRAL M, LACHAPELLE J—Québec
- 238 VEPs results in children with meningitis
PILECKI W, SOBIESZCZANSKA M, SALOMON E, JANOWA A, KOLEDŁA P—Wroclaw
- 239 The MVEP - problems and benefits of the method
GRZYBOWSKI AE, HULEWICZ A—Poznań
- 240 Oscillatory potentials under the thyroid-associated eye's disease
SEIDOVÁ SF, PANTELEEVA OG, SHAMSHINOVÁ AM—Moscow
- 241 Photopic negative responses to long duration stimuli in the mfERG of primary open-angle glaucoma patients
TODOROVA MG, PALMOWSKI-WOLFE AM, FLAMMER J, ORGUEL S—Basel
- 242 Selective ERG b-wave reduction in mice deficient for anion exchanger 3
SAUVÉ Y, ALVAREZ BV, PINILLA I, MACDONALD IM, CASEY JR—Edmonton, Zaragoza
- 243 Best Macular Dystrophy: Comparison of psychophysical performance with multifocal ERG responses in different stages of the disease
MAIA-LOPES S, SILVA E, SILVA MF, REIS A, CAMPOS S, CASTELO-BRANCO M—Coimbra
- 244 The effect of cataract on the Rarebit visual field
NILSSON M, ANDERSSON AM, MARTIN L—Stockholm
- 245 Published clinical studies: Acuity through the ages
MOUTRAY TN, WILLIAMS M, JACKSON AJ—Belfast
- 246 Visual Acuity measures across the specialties
WILLIAMS MA, MOUTRAY TN, JACKSON J—Belfast
- 247 Refractive errors in diabetic patients from DR Congo
KAIMBO WA KAIMBO D, MISSOTTEN L—Kinshasa, Leuven
- 248 Peripheral refraction in myopes and emmetropes
GONCALVES ROSADO JL, NASCIMENTO SMC—BRAGA
- 249 Uncorrected ametropias and visual symptoms
SORO MARTÍNEZ MI, VIDAL LÓPEZ J, SOBRADO CALVO P, SÁNCHEZ-MIGALLÓN MC—Murcia
- 250 Evolution of the ametropias in different educational levels
JAVALOYES MORENO B, VIDAL LÓPEZ J, SOBRADO CALVO P, GONZALEZ MARTINEZ M, SÁNCHEZ-MIGALLÓN CARRERAS MC, SORO MARTÍNEZ MI—Murcia
- 251 The effect of ocular aberrations with two different contact lenses
LINDSKOOG PETTERSSON A, JARKÖ C, BRAUTASET RL—Stockholm
- 252 Ultrasonic estimating of accommodation changes after the treatment of myopic eyes
KRIAUCIUNIENE L, PAUNKSNIS A—Kaunas
- 253 Assessment of real-time changes in wavefront aberrations with accommodation using the irx3 aberrometer
CHATEAU N, NGUYEN KHOA JL, LOPEZ GIL N, GICQUEL JJ—Orsay, Suresnes, Murcia, Poitiers
- 254 VCD/CR or AL/CR which is the best predictor for refractive changes in young adults
JORGE J, BORGES DE ALMEIDA J, PARAFITA M—Braga, Santiago de Compostela
- 255 Reliability of the measurements taken by the students of the Murcia University School of Optometry (Spain)
SOBRADO-CALVO P, JAVALOYES-MORENO B, VIDAL-LÓPEZ J, GONZÁLEZ-MARTÍNEZ M—Murcia
- 256 An Experimental Validation for a New Method of Sclera Reinforcement and Metabolic Therapy of Progressive Myopia
LAZUK AV, IOMDINA EN, ANDREEVA LD—Moscow

INFORMATION TECHNOLOGY

- 257 The Association of Vision Science Librarians: Providing Information and Information Resources for Vision Care, Research and Education Worldwide
SIEVING P, SCHAEFFER-YOUNG J, ASSOCIATION OF VISION SCIENCE LIBRARIANS Bethesda, Philadelphia, Berkeley
- 258 The Impact of Open Access on the Vision Literature
SIEVING P, ANTON B, ASSOCIATION OF VISION SCIENCE LIBRARIANS—Bethesda, Berkeley



ever 2006

Friday 6 October



Gemini I SIS	<i>Retinal Pigment Epithelium</i>			08:30 – 10:00
	Hannu UUSITALO, Kai KAARNIRANTA			
08:30	3111	The Role RPE in Aging Eye	UUSITALO H–Kuopio	
08:48	3112	Lipofuscin Accumulation and Lysosomal Dysfunction in RPE Cells	KOPITZ J, KROHNE T, BERGMANN M, KAEMMERER E, SCHUTT F, HOLZ FG–Heidelberg	
09:06	3113	Proteasomes and Heat shock Proteins in Protein aggregation of RPE cells	KAARNIRANTA K–Kuopio	
09:24	3114	Macular and peripheral gene expression differences in human eyes: significance for macular degenerations	MULLINS RF–Iowa City	
09:42	3115	The complement cascade and age-related macular degeneration, a review	IMMONEN I–Turku	

Gemini III FP	<i>Free papers Neuro-ophthalmology</i>			08:30 – 10:00
	Gordon PLANT, Aki KAWASAKI			
08:30	3121	VEGF-A Forms Part of the Adaptive Response to Ischemia Responsible for Retinal Neuroprotection	SHIMA DT, NISHIJIMA K, NG Y-S, JO N, AKITA J, NAKAZAWA T, ROBINSON GS, ADAMIS AP–Lexington, New York	
08:42	3122	Automated perimetry and laser polarimetry in the assessment of nerve fibers involvement in pituitary adenoma	MILANO G, MACERI C, BORDIN M, SERRA U, TISO C–Pavia	
08:54	3123	Variability of control in intermittent exotropia	HOLMES JM, MOHNEY BG, LESKE DA–Rochester	
09:06	3124	VFA-K test: A new pediatric eye test for the general pediatric population	KOZEIS N–Thessaloniki	
09:18	3125	Complementary Medicine for blepharospasm, in patients without effect of Botulinum toxin A	NEPP J, RICHTER-MÜKSCH S–Vienna	
09:30	3126	Edmonde Mariotte (1620-1684), pioneer of neurophysiology and neuro-ophthalmology	GRZYBOWSKI AE, AYDIN P–Poznań, Ankara	
09:42	3127 <i>rf</i>	Early diagnosis of ocular motility alterations in thyroid autoimmune ophthalmopathy (TAO)	VARANO L, CARNOVALE SCALZO G, CAMPAGNA F, SCORCIA GB, ROTONDO E, PENDINO V, PARISE S, BRUZZICHESI D, PAOLA A, SCORCIA G–Catanzaro	

Vega SIS	<i>Ocular complications of radiotherapy</i>			08:30 – 10:00
	Bertil DAMATO, Martine J JAGER			

Radiotherapy is the main form of treatment for several ocular and adnexal tumours and is also used as adjunctive therapy. The different methods include: iodine, ruthenium or strontium brachytherapy; proton beam radiotherapy; external beam photon therapy and stereotactic radiotherapy. High rates of local tumour control are achievable. Many eyes lose vision, however, as a result of cataract, optic neuropathy, neovascular glaucoma and various forms of 'radiation retinopathy'. The concept of the 'toxic tumour syndrome' is gaining acceptance and this is leading to new treatments such as transpupillary thermotherapy or local resection of the irradiated tumour and intra-vitreal triamcinolone injection. There is scope for further studies evaluating intraocular and systemic anti-angiogenic agents. This symposium overviews current knowledge of the pathology and biology of the ocular complications of radiotherapy and of the current approach to this morbidity in different centres.

08:30	3131	Pathology of radiation-induced complications	KIVELÄ T–Helsinki	
08:45	3132	Biology of radiation-induced complications	DENDALE R, BOLLET M, COSSET JM–Paris	
09:00	3133	Liverpool approach to complications of radiotherapy of uveal melanoma	DAMATO B–Liverpool	
09:15	3134	Leiden approach to long-term complications of brachytherapy of uveal melanoma	JOURNÉE DE KORVER H–Leiden	
09:30	3135	Paris approach to radiation-induced intraocular complications	DESJARDINS L, LEVY-GABRIEL C, LUMBROSO-LEROUC L, DENDALE R, DELACROIX S, PLANCHER C, ASSELAIN B–Paris, Orsay	
09:45	3136	Ocular complications after radiotherapy of extraocular tumour	MIDENA E–Padova	

Keynote Lecture

10:15 – 10:55

Fenix III

Advance of Ophthalmology in China and the Way to International Ophthalmology

Jiali Zhao, Beijing

Introduction by Jost JONAS



Pegasus FP	Free papers Anatomy : Cell biology of retina and optic nerve head		08:30 – 10:00
	Karin LOEFFLER		
08:30	3141	Hypoxia/Reoxygenation and TGF-beta2 Increase Hsp27 Expression in Human Optic Nerve Head Astrocytes YU AL, KAMPIK A, WELGE-LUSSEN U–Munich	
08:42	3142	Correct gene dosage of Pax2 is important for normal retinal astrocyte differentiation and normal vascular development in the retina . SCOTT A, BISCOE MP, WOLFF J, MOSS S, GREENWOOD J, FRUTTIGER M–London	
08:54	3143	The avascular area in the OIR mouse model: Pathogenesis and kinetics LANGE CAK, MARTIN G, EHLKEN C, HANSEN LL, AGOSTINI HT–Freiburg	
09:06	3144	Melanocyte Stimulating Hormone Induces Pigmentation of Human Mesenchymal Stem Cells VOSSMERBAEUMER U, KUEHL S, KERN S, KLUETER H, JONAS JB, BIEBACK K–Mannheim	
09:18	3145	Integrin $\alpha 5\beta 1$ ($\alpha 5\beta 1$) in Choroidal Neovascularization (CNV) associated with Age-Related Macular Degeneration (AMD) LOEFFLER KU, VOGEL A, ZAHN G, HOLZ FG–Bonn, Berlin	
Fenix I FP	Free papers Cornea : Ocular surface, inflammation and dry eye		08:30 – 10:00
	Harminder S DUA, Catherine GARCHER CREUZOT		
08:30	3151	Schirmer test and thyroid disease CHATZIBALIS T, SKRIAPA-MANTA A, KARAMPATAKIS V, RAPTOU E, KALATHAS T, SIABANOPOLOU M, KARAMITSOS A–Thessaloniki	
08:42	3152	Ocular Surface Bacterial Flora Identification- A Conundrum GRAHAM JE, MOORE JE, XU J, DOOLEY JSG, HAYES V, DENG W, MOORE CBT, MOORE JE–Coleraine, Belfast	
08:54	3153	Efficacy of an Antibody Based Assay for the Detection of Herpes Simplex Keratitis ANWAR ST, MOORE JE, YEUNG I, GARDINER T, SHARMA A, FRAZER DG, JACKSON AJ, SHAH S, MOORE CBT–Coleraine, Belfast, Birmingham	
09:06	3154	Nodular Degeneration WOOD TO, WILLIAMS EE, HAMILTON DL–Germantown	
09:18	3155 <i>rf</i>	Improvement of dry eye symptoms with polyunsaturated fatty acids GARCHER CREUZOT C, PASSEMARD M, LAFONTAINE P-O, VIAU S, JOFFRE C, ELENA P-P, POULIQUEN P, BAUDOUIN C, BRON AM–Dijon, Nice, Clermont-Ferrand, Paris	
09:24	3156 <i>rf</i>	Ultrastructural Conjunctival Surface Changes in Patients with Sjögren's Syndrome: Long term Results KOUKAKIS DI, KARABATSAS CH, SAKKAS LI, ALVANOU A, MANTHOS AK, CHATZOULIS DZ–Larissa, Thessaloniki	
09:30	3157 <i>rf</i>	Addition of ganciclovir to the cornea preservation medium : kinetics and toxicity ROBERT PY, SAUVAGE FL, THURET G, RANGER-ROGEZ S, ADENIS JP, ROUSSANE MC, GAIN P, MARQUET P–Limoges, Saint-Etienne	
09:36	3158 <i>rf</i>	Bevacizumab (Avastin) inhibits inflammatory hem- and lymphangiogenesis in the cornea BOCK FB, ONDERKA J, DIETRICH T, BACKMANN B, KRUSE FE, CURSIEFEN C–Erlangen	
09:42	3159 <i>rf</i>	Use of Platelet-Rich Plasma In The Treatment of Ocular Surface Syndrome Following Laser In Situ Keratomileusis (LASIK) PASTOR S, RUIZ-COLECHÁ J, RODRÍGUEZ A, ARTOLA A, ALIÓ JL–Alicante	
09:48	31510 <i>rf</i>	Correlation between impression cytology and Labial salivary gland biopsy in Sjögren's syndrome LANGMAN ME, GICQUEL JJ, ROBLOT P, GOMBERT JM, DIGHIERO PL–Saint Jean d'Angély, Poitiers	
Fenix III SIS	Genoret - An integrated project funded by the European Union: Functional Genomics of the Retina in Health and Disease		08:30 – 10:00
	Jose SAHEL, Jose CUNHA-VAZ		
08:30		Introduction by Jose-Alain SAHEL	
08:40	3161	The European EVI-Genoret database POCH O–Strasbourg	
08:50	3162	Phenotyping retinal degenerations ZRENNER E–Tübingen	
09:00	3163	Bringing large scale genotyping into the agenda BHATTACHARYA S–London	
09:10	3164	Stem cell differentiation : the importance of functional genomics MARIGO V, FIOCCO R, GUILLONEAU X, VETRINI F, GOUREAU O–Naples, Milan, Paris	
09:20	3165	Molecular interactions of rhodopsin - from the proteome inventory of the outer segment towards analysis of functional protein networks UEFFING M, SWIATEK-DE LANGE M, CHATR-ARYAMONTRI A, BEER M, CESAREN G–Munich-Neuherberg, Rome	
09:30	3166	Gene therapy: from bench to benchside ALI RR–London	
09:40	3167	Towards European Clinical Trials CUNHA-VAZ J–Coimbra	

Gemini I	Free papers Molecular Biology / Genetics / Epidemiology : Gene expression, Animal models & Eye development			11:15 – 12:45
FP	Donald ZACK, Jochen GRAW			
11:15	3211	Bioinformatic Approaches to Retinal Gene Expression ZACK DJ, YU X, QIAN J–Baltimore		
11:27	3212	Two novel mouse models with retinal degeneration DALKE C, PUK O, HRABÉ DE ANGELIS M, GRAW J–Neuherberg		
11:39	3213	Screening for new mouse mutants affected in eye development using the OLCI technique PUK O, DALKE C, GRAW J–Neuherberg		
11:51	3214	Phenotypic assessment of a novel murine ENU-induced mutant line expressing a nonsense mutation in the opa1 gene DAVIES VJ, PIECHOTA MJ, HOLLINS AJ, VOTRUBA M–Cardiff		
12:03	3215	Polymorphism in PITX2 is associated with Open Angle Glaucoma VAIDEAU D, SOWDEN J, FRASER S–Sunderland, London		
12:15	3216 <i>rf</i>	Delayed development of Retinal Vessel Network in Alpha 2B Adrenergic Receptor Knock-out Mice HUA J, MUTHIG V, GROSS N, LANGE C, MARTIN G, HANSEN LL, HEIN L, AGOSTINI H–Freiburg		
12:21	3217 <i>rf</i>	Temporal expression profile of murine cornea: a possible role for Vsx1 in corneal development? SHEPPARD JPB, MEEK K, VOTRUBA M–Cardiff		

Gemini III	Botulinum usage in ophthalmology practice			11:15 – 12:45
SIS	Pinar AYDIN			
11:15	3221	Role of Botulinum toxin A in non-paralytic strabismus OZKAN SB–Aydin		
11:37	3222	Botulinum toxin usage in extraocular muscle paralysis YGGE J–Stockholm		
11:59	3223	The treatment for hemifacial and other essential spasms with botulinum toxin PLANT G–London		
12:21	3224	Other rare and useful indications of botulinum toxin AYDIN P–Ankara		

Vega	OOG Business meeting			11:15 – 12:45
Joint M.	Edoardo MIDENA			

Pegasus	MAP Kinase Functions in the Ocular Lens and beyond			11:15 – 12:45
SIS	David W LI			
11:15	3241	Life and death decisions: the role of the IKK-JNK interplay KARIN M–La Jolla, CA		
11:45	3242	Promotion of lens epithelial to fiber differentiation by connexin 45.6, a role independent of gap junction communication JIANG JX, BANKS EA, YU SX–San Antonio, TX		
12:05	3243	G-proteins and their signaling pathways in eye development LIU M, WENG J–Houston, TX		
12:25	3244	Signaling transduction pathways mediating apoptosis in the ocular lens: the role of MAP kinases LI DW, LIU J–Omaha, Nebraska		

Fenix I SIS	Wavefront Aberrometry Jean-Jacques GICQUEL, Paul Louis DIGHIERO	11:15 – 12:45
11:15	3251 The Basics of Shack-Hartmann Aberrometry GICQUEL JJ, DIGHIERO PL–Poitiers	
11:25	3252 Custom Wavefront Soft Contact Lenses LOPEZ-GIL N–Murcia	
11:35	3253 Wavefront-based evaluation of functional optical zone after LASIK NGUYEN KHOA JL, CHATEAU N, ASSOULINE M, LEBUISSON DA–Suresnes, Orsay	
11:45	3254 Clinical Applications of Aberrometry RADHAKRISHNAN H, O'DONNELL C–Manchester	
11:55	3255 Optical quality of the eye after retropupillary fixation of the Artisan IOL DIGHIERO PL, GICQUEL JJ–Poitiers	
12:05	3256 New developments in Aberrometry MARCOS S–Madrid	
12:15	3257 Our experience on aberrometry in refractive surgery MONTES MICO R–Alicante	
12:25	3258 An adaptive optics device for the simulation of visual outcomes CHATEAU N, VABRE L, NGUYEN KHOA JL–Orsay, Meudon, Suresnes	
Fenix III FP	Free papers Retina : Vitreoretinal surgery: Experimental / Clinical Constantin POURNARAS, Bernd KIRCHHOF	11:15 – 12:45
11:15	3261 Femtosecond laser (FSL) surgery and scanning microscopy in branch retinal vein occlusion (BRVO): experimental pilot study TOROPYGIN SG, KRAUSE MHJ, RIEMANN I, HILD M, KHURIEVA EL, LOEW U, MESTRES P, SEITZ B, RUPRECHT KW, KOENIG K–Tver, Homburg, St. Ingbert	
11:27	3262 Multiphoton Imaging and Disruption of the Retina HEISTERKAMP A, BAUMGART J, KRUEGER RR, LUBATSCHOWSKI H–Hannover, Cleveland	
11:39	3263 Local RPE cells migrate on the uneven surface of two potential Bruch's membrane substitutes after subretinal implantation MOLNAR FE, YELLACHICH D, LENG T, HUIE P, DALAL R, MARMOR MF, FISHMAN HA, BLUMENKRANZ MS–Stanford	
11:51	3264 Prospective randomized clinical trial comparing face down position and semi seated position after surgery for idiopathic full-thickness macular hole: preliminary results. GARCHER CREUZOT C, GUILLAUBEY A, LAFONTAINE PO, MALVITTE L, HUBERT I, BRON AM, BERROD JP–Dijon, Nancy	
12:03	3265 VEGF and PEDF in early PVR; analysis using the IntraOcular Fluid Bank Maastricht DIEUDONNE SC, LA HEIJ EC, DIEDEREN R, KESSELS A, LIEM A, KIJLSTRA A, HENDRIKSE F–Maastricht	
12:15	3266 rf Internal limiting membrane peeling during macular hole surgery: a comparison of outcomes with and without indocyanine green and trypan blue assistance LAMBLEY RG, BATRA R, EWINGS P, GRAY R–Taunton	
12:21	3267 rf TEM of epiretinal tissue in diabetic macular oedema SYNEK S, Páč L, SYNKOVÁ M–Brno	
Fenix III SIS	THEA Lunchtime session : A new approach in topical treatment of ocular infections	12:50 – 13:50
	 Théa	
12:50	Introduction by Philippe KESTELYN	
12:55	Antibiotics and Superficial Ocular Infections. Where do we stand in 2006 ? BRON A–Dijon	
13:05	A 3-day anti-infective treatment : from oral to topical AZM(T1225), an ocular pharmacokinetic study in animals LUYCKX J–Clermont-Ferrand	
13:15	A 3-day treatment with T1225: clinical validation in trachoma GOLDSCHMIDT P–Paris	
13:25	A 3-day treatment with T1225: clinical validation in purulent bacterial conjunctivitis COCHEREAU I–Angers	
13:35	Efficacy of AZM eyedrops (T1225) in non tuberculosis mycobacteria keratitis BOURCIER T–Paris	
13:45	Conclusions by Henri CHIBRET	
13:50	END	

Gemini I SIS	Mitochondria in Eye disease – pathophysiology and mechanisms/cell biology		14:00 – 15:30
	Marcela VOTRUBA, Pinar AYDIN		

14:00	3311	Pathophysiology of mitochondrial optic neuropathies: are LHON and DOA a variation on the same theme? CARELLI V–Bologna	
14:18	3312	Genetic dissection of OPA1 functions in mitochondrial fusion and apoptosis SCORRANO L–Padova	
14:36	3313	Mitochondrial division proteins in <i>C. elegans</i> and mammals VAN DER BLIEK A–Los Angeles	
14:54	3314	A model of OPA1 optic atrophy: protein-truncating nonsense mutation in mouse opa1 GTPase VOTRUBA M, PIECHOTA MJ, HOLLINS AJ, DAVIES VJ–Cardiff	
15:12	3315	OPA1, from functions in mitochondria to dysfunctions in optic neuropathies LENAERS G, DELETTRE C, CORNILLE K, SOUKKARIEH C, CHEN-KUO-CHANG M, ELACHOURY G, DEPEYRE C, ARNDT C, PAYET O, MULLER A, BONNEAU D, AMATI-BONNEAU P, REYNIER P, OLICHON A, BELENGUER P, HAMEL CP–Montpellier, Angers, Heidelberg, Toulouse	

Gemini III SIS	Novel Ophthalmic Technologies IV : imaging techniques	14:00 – 15:30
	Tom MISSOTTEN	

14:00	3321	Autofluorescence Lifetime Imaging of the Human Fundus SCHWEITZER D, SCHWEITZER F, HAMMER M–Jena	
14:25	3322	Clinical applications of autofluorescence imaging: review of pathology and indications PETO T, DANDEKAR SS, JENKINS S, BIRD AC–London	
14:35	3323	Non-Invasive In Vivo Measurement of Retinal Physiology using High-Speed, Ultrahigh Resolution Optical Coherence Tomography SRINIVASAN VJ, WOJTKOWSKI MD, LIU JJ, DUKER JS, CLERMONT A, BURSELL SE, FUJIMOTO JG–Cambridge, MA, Boston, MA	
14:50	3324	Using Nanoshells to achieve molecular contrast in OCT : study results and review of other contrast agents for OCT FABER DJ, DE BRUIN DM, VAN VELTHOVEN MEJ, NOISSER T, GRAF C, ECKART R, VERBRAAK FD, VAN LEEUWEN TG–Amsterdam, Wurzburg	
15:05	3325	Progress in the flying spot dual imaging en-face OCT/confocal channel instrument PODOLEANU A, CUCU R, BRADU A, DOBRE GM, ROSEN RB, GARCIA P, ROGERS JA, HATHAWAY M, PEDRO J, WEISS R, VAN VELTHOVEN ME, DE SMET M, ROSA CC, MERINO D, DAINTY C–Canterbury, New York, Toronto, Amsterdam, Porto, Galway	
15:20	3326	Proteomics in Eye Diseases MISSOTTEN GSOA–Leiden	

Vega FP	Free papers Pathology / Oncology 1	14:00 – 15:30
	Edoardo MIDENA, Laurence DESJARDINS	

14:00	3331	Uveal melanoma: Epidemiologic profile and treatment in an Ocular Oncology unit of the Hospital Clinico Universitario de Valladolid SAORNIL ALVAREZ MA, GARCIA-ALVAREZ C, ALMARAZ A, MUÑOZ MF, LOPEZ-LARA F, DE FRUTOS-BARAJA JM, MUÑOS Y–Valladolid	
14:12	3332	Choroidal perfusion in eyes with untreated choroidal melanoma RESCH H, GARHOFER G, SCHMETTERER L, ZEHETMAYER M, DORNER GT–Vienna	
14:24	3333	Transpupillary thermotherapy of choroidal melanoma: a prospective analysis PARROZZANI R, MIDENA E, BOCCASSINI B, VUJOSEVIC S–Padova, Roma	
14:36	3334	Uveal metastasis and ocular hypertony POURNARAS JAC, SCHALENBORG A, ZOGRAFOS L–Lausanne	
14:48	3335	Potential Blood Markers for the Detection of Metastatic Uveal Melanoma BARAK V, FRENKEL S, FOLBERG R, MAJUMDAR D, KALICKMAN I, PE'ER J–Jerusalem, Chicago, IL	
15:00	3336	Trends in treatment and prognostic factors for conjunctival melanoma in a tertiary referral ocular oncology service over the last 50 years MALIK ANJ, HUNGERFORD JL–London	

Ophthalmic Research Lecture


15:45 – 16:25

Fenix III

Photoreceptor Mitochondrial Oxidative Stress in Experimental Uveitis

Narsing RAO, Los Angeles

Introduction by Uwe PLEYER



Pegasus SIS	Capsular tension Rings Christopher LIU		14:00 – 15:30
14:00	3341	Rationale for use of capsular tension rings - a review of forces acting on the lens capsular bag LIU C–Brighton	
14:22	3342	The pros and cons of a one-piece ring-IOL GALAND AJ–Rotheux-Rimière, Liège	
14:44	3343	Spring constants and foldable equator rings KURZ S, DICK HB–Mainz, Bochum-Langendreer	
15:06	3344	Surgical technique and complications of CTRs LITTLE BC–London	
Fenix I FP	Free papers Cornea : Corneal wound healing Jean-Jacques GICQUEL, Philippe KESTELYN		14:00 – 15:30
14:00	3351	Amniotic membrane-covered bioonlays for treatment of ocular surface disease CURSIEFEN C, KRUSE F–Erlangen	
14:12	3352	In vivo confocal microscopy in limbal epithelial damage NUBILE M, LANZINI M, LIBERALI T, CALIENNO R, MASTROPASQUA L–Chieti	
14:24	3353	Neurotrophic regeneration during the corneal wound healing after refractive surgery BLANCO-MEZQUITA JT, MERAYO-LLOVES JM, MARTINEZ-GARCIA MC, BONINI S, LAMBIASE A, PROENÇA R–Valladolid, Rome, Coimbra	
14:36	3354	Accelerated corneal wound healing in Cx43+- mice GICQUEL JJ, MILIN S, LEVILLAIN PM, MESNIL M, DIGHIERO P–Poitiers	
14:48	3355 <i>rf</i>	NGF promotes the healing of bilateral recurrent corneal erosion in dogs DODI PL, COSTA N, ALOE L–PARMA, Catanzaro, Rome	
14:54	3356 <i>rf</i>	Towards the Development of Purpose-designed Ocular Bandage Lenses BATEMAN S, MANN AM, TIGHE BJ–Birmingham	
15:00	3357 <i>rf</i>	Early limbal stem cell deficiency in KID Syndrome LANGMAN ME, GICQUEL JJ, MILIN S, LEVILLAIN P, MESNIL M, DIGHIERO PL–St Jean d'Angély, Poitiers	
Fenix III FP	Free papers Retina : Medical Retina Jose CUNHA-VAZ, Paula SUMMANEN		14:00 – 15:30
14:00	3361	Autofluorescence findings in Acute Exudative Polymorphous Vitelliform Maculopathy VACLAVIK V, BIRD AC, ROBSON AG, OOI KGJ, HOLDER GE, WEBSTER AR–London	
14:12	3362	Age dependence of macular changes in congenital achromatopsia VARSANYI B, LESCH B, SOMFAI GM, FARKAS A–Budapest	
14:24	3363	Laser phototherapy for von Hippel disease - two case studies VIDE ESCADA EICKMANN A, HENRIQUES J, NASCIMENTO J, CASTANHEIRA-DINIS A–Lisbon	
14:36	3364	Bothnia Dystrophy, a genetical, clinical and electrophysiological study BURSTEDT MSI, SANDGREN O–Umeå	
14:48	3365	Retinal vascular changes in patients with impaired glucose tolerance and early diabetes SUMMANEN PA, VON WENDT G, LINDSTRÖM J, PELTONEN M, UUSITUPA M, TUOMILEHTO J–Helsinki, Stockholm, Kuopio	
15:00	3366	Identification of different phenotypes of nonproliferative retinopathy of diabetes type 2 using cluster and discriminant analysis NUNES S, BERNARDES R, DUARTE L, CUNHA-VAZ J–Coimbra	

Poster session16:30 – 17:20
Neptuno**Retina / Vitreous, Cornea / Ocular Surface, Molecular Biology / Genetics / Epidemiology**

Jean-Jacques DE LAEY, Charles RIVA, Jean-Jacques GICQUEL, Cathy WILLIAMS, Mike WRIDE

Gemini I SIS	Mitochondria in Eye disease – clinical studies and steps towards therapy		17:30 – 19:00
	Marcela VOTRUBA, Pinar AYDIN		
17:30	3411	Genotype-phenotype correlations in mitochondrial optic neuropathies AMATI-BONNEAU P, FERRE M, VERNY C, MALTHIER Y, BONNEAU D, REYNIER P–Angers	
17:48	3412	Biochemical & molecular analysis of skin fibroblasts from patients with mitochondrial optic neuropathy REYNIER P, CHEVROLLIER A, VERNY C, LOISEAU D, POU MA, GUILLET V, MALTHIER Y, AMATI-BONNEAU P, BONNEAU D–Angers	
18:06	3413	Mitochondrial function in LHON and OPA1 studied in vivo using MR Spectroscopy LODI R–Bologna	
18:24	3414	Neuroprotection in inherited optic neuropathy HOLLINS AJ, DAVIES VJ, PIECHOTA MJ, VOTRUBA M–Cardiff	
18:42	3415	The eye muscles and mitochondrial disorders PLANT G–London	
Gemini III FP	Free papers Physiology / Biochemistry / Pharmacology : Blood Flow I		17:30 – 19:00
	Charles RIVA, Claudia ZAWINKA		
17:30	3421	Effects of high dose prednisolone on optic nerve head blood flow in patients with acute optic neuritis WEIGERT G, RESCH H, GARHOFER G, KIRCHER K, DORNER GT, REITNER A, SCHMETTERER L–Vienna	
17:42	3422	Involvement of the dopamine-1 receptor in choroidal blood flow changes during light/dark transitions FUCHSJÄGER-MAYRL G, HUEMER K-H, KARL K, RESCH H, WEIGERT G, POLSKA E, GARHOFER G, SCHMETTERER L–Vienna	
17:54	3423	Effects of yohimbine on dynamic autoregulation. POLSKA E, KOLODJASCHNA J, BERISHA F, SCHMETTERER L–Vienna	
18:06	3424	Nitric Oxide and Choroidal Blood Flow in Healthy Subjects GARHOFER G, BERISHA F, FUCHSJÄGER-MAYRL G, WOLZT M, SCHMETTERER L–Vienna	
18:18	3425 <i>rf</i>	Choroidal blood flow of patients undergoing an hemodilution for retinal vein occlusion CHIQUET C, ROMANET JP, SAVY O, KUCHLER F, DRILLAT P, VINH V, TONINI M, GEISER MH–Grenoble, Sion	
18:24	3426 <i>rf</i>	The effects of intravenous histamine and histamine-receptor blockade on ocular blood flow KARL K, RESCH H, WEIGERT G, ZAWINKA C, GARHOFER G, SCHMETTERER L–Vienna, Basel	
18:30	3427 <i>rf</i>	Effects of Indomethacin on Retinal and Choroidal Blood Flow in Healthy Volunteers BERISHA F, WEIGERT G, FUCHSJÄGER-MAYRL G, SCHMETTERER L, GARHOFER G–Vienna	
Vega FP	Free papers Pathology / Oncology 2		17:30 – 19:00
	Charlotta ALL-ERICSSON, Steffen HEEGAARD		
17:30	3431	Ocular sebaceous carcinomas: differential diagnosis in clinical and pathological presentation DE KEIZER RJW, DE WOLFF ROUENDAAL D–Leiden	
17:42	3432	Sebaceous carcinoma in a spanish series of eyelid tumors. MENDEZ MC, SARASA JL, SAORNIL MA, BLANCO G–Valladolid, Madrid	
17:54	3433	Caruncular lesions in Denmark 1978-2002. A histopathological study with correlation to clinical referral diagnosis HEEGAARD S, ØSTERGAARD J, PRAUSE JU–Copenhagen	
18:06	3434	Screening for Optic Pathway Gliomas in Children with Type 1 Neurofibromatosis VELUSAMI P, SANDHU S, CLARKE M–Sidcup, Newcastle	
18:18	3435	A young man with progressive visual loss and an optic disc tumour ALIAMAL R, KIVELÄ T–Helsinki	
18:30	3436	Progesterone receptor and c-kit expression in orbital cavernous hemangiomas BRISCOE D, ROSEN E, NESHER R, KIDRON D–Kfar Saba	
18:42	3437 <i>rf</i>	Merkel cell carcinoma of the eyelid with two cases of spontaneous regression MISSOTTEN GS, DE WOLFF-ROUENDAAL D, DE KEIZER RJW–Leiden	
18:48	3438 <i>rf</i>	Vascular features of mushroom-shaped uveal melanomas AMIRYAN AG, SAAKYAN SV, LEJUK VG–Moscow	

Pegasus FP	Free papers Vision Sciences, Electrophysiology, Physiol. Optics			17:30 – 19:00
	Graham HOLDER, Werner SPIELEERS			
17:30	3441	Attention effects in visual texture segregation HEINRICH SP, ANDRES M, BACH M–Freiburg		
17:42	3442	Local motion discrimination deficits in ocular hypertension FARIA P, SILVA MF, CASTELO-BRANCO M–Coimbra		
17:54	3443	Assessment of chromatic sensitivity loss in subjects with unusual congenital deficiencies - a study of the factors that affect anomaloscope matches BARBUR JL, RODRIGUEZ-CARMONA ML, HARLOW JA–London		
18:06	3444	Subretinal Chronic Multi-Electrode Arrays Implanted in Blind Patients ZRENNER E, BESCH D, BARTZ-SCHMIDT KU, GEKELER F, GABEL VP, KUTTENKEULER C, SACHS H, SAILER H, WILHELM B, WILKE R–Tuebingen, Regensburg, Reutlingen, Ofterdingen		
18:18	3445	Differences in ametropia prevalence obtained different methods of refraction JORGE J, GONZALEZ-MEIJOME J, QUEIRÓS A, BORGES DE ALMEIDA J, PARAFITA M–Braga, Santiago de Compostela		
18:30	3446	Accommodative changes as measured by optical biometry LANZL I, NURISPAPHIC A, KOTLIAR K–Munich		
18:42	3447	Functional visual performance assessed with and without correction of ocular aberrations DALIMIER E, DAINTY J C, BARBUR J–Galway, London		

Fenix I FP	Free papers Cornea : Contact lenses and Refractive surgery “The best of both worlds”			17:30 – 19:00
	Jean-Jacques GICQUEL, Norberto LOPEZ-GIL			
17:30	3451	Comparative study of two silicone hydrogel contact lenses used as bandage after LASEK GIL-CAZORLA R, TORRES J, HERNÁNDEZ-VERDEJO JL, ARRANZ E, TEUS MA–Madrid		
17:42	3452	Biometric changes in the anterior eye with orthokeratology OWENS H, WONG E, LO JP–Auckland		
17:54	3453	Effect of intraoperative Mitomycin C (MMC) in LASEK refractive surgery on corneal endothelium cells PIZZAMIGLIO-MARTIN C, ORTEGA M, DE BENITO L, SÁNCHEZ-PINA J, TEUS-GUEZALA MA–Madrid		
18:06	3454 <i>rf</i>	In vivo interferometric measurements of the tear film stability on soft contact lenses SZCZESNA DH, STENEVI U, KASPRZAK H–Wroclaw, Mönldal		
18:12	3455 <i>rf</i>	Oxygen Transmission Characteristics of a Silicone Hydrogel Lens in Custom Parameters GILES TG–Duluth		
18:18	3456 <i>rf</i>	Solutions, Contact Lenses & Wear: Then & Now FRANKLIN VJ, TIGHE BJ–Birmingham		
18:24	3457 <i>rf</i>	Microfluidic Technology for Routine Tear Analysis MANN A, TIGHE B–Birmingham		
18:30	3458 <i>rf</i>	Measurement of Frictional Characteristics of Contact Lenses ROSS G, TIGHE BJ–Birmingham		

Fenix III SIS	New Options in the treatment of diabetic macular oedema	17:30 – 19:00
	Jose CUNHA-VAZ, Francesco BANDELLO	

ALLERGAN

17:30	Welcome and Introduction, Francesco BANDELLO	
17:35	3461	Role of inflammatory mediators in macula oedema, BURKE J–Milwaukee
17:50	3462	Alternatives for Drug Delivery in DME, KUPPERMANN BD–Irvine
18:05	3463	Clinical Characterization of DME, CUNHA-VAZ J–Coimbra
18:20	3464	Clinical experience of different treatment modalities in DME, BANDELLO F–Udine
18:35		Treatment Algorithms – Decision Trees - Panel
18:55		Conclusions, Jose CUNHA-VAZ

19:00 – 19:30 Business Meetings of the scientific sections:	- Anatomy / Cell Biology	- Neuro-ophthalmology / Strabismology
Agenda	- Cornea / Ocular Surface	- Pathology / Oncology
1. Report of the scientific officer	- Glaucoma	- Physiology / Biochemistry / Pharmacology
2. Report of the Programme Secretary	- Immunology / Microbiology	- Retina / Vitreous
3. Next year's meeting:	- Lens and Cataract	- Vision Sciences / Electrophysiology / Physiol.
• nomination of a section programme secretary	- Molecular Biology / Genetics / Epidemiology	Optics
• proposals of Special Interest Symposia		
4. Comment on the EVER activities		
5. Other business		
	In addition to the agenda, the sections Cornea / Ocular Surface and Glaucoma will nominate candidates for scientific officer.	

Poster Session 2 — 16:30-17:20 — Neptuno

- Retina / Vitreous: 301 > 329, moderators: Jean-Jacques DE LAEY, Charles RIVA
- Cornea / Ocular Surface: 330 > 373, moderator: Jean-Jacques GICQUEL

RETINA / VITREOUS

- 301 Short term effect of intravitreal Bevacizumab (Avastin) for exudative age-related macular degeneration
rf
CHRISTMANN S, CORDES AK, DOHM S, SCHRAGE NF, DEGENRING RF—Cologne
- 302 Internal limiting membrane peeling during macular hole surgery: a comparison of outcomes with and without indocyanine green and trypan blue assistance
rf
LAMBLEY RG, BATRA R, EWINGS P, GRAY R—Taunton
- 303 TEM of epiretinal tissue in diabetic macular oedema
rf
SYNEK S, PÁČ L, SYNKOVÁ M—Brno
- 304 Sedoanalgesia in laser photocoagulation of retinopathy of prematurity
AKKUYUN I, KARAASLAN P, YILMAZ G, DÖNMEZ A, ESEN A, AKOVA YA—Ankara
- 305 Biennial Screening for Mild Nonproliferative Diabetic Retinopathy
GORDON-BENNETT PSC, NEWSOM W, FLANAGAN DW—Huntingdon
- 306 Improving attendance at the diabetic retinopathy screening at East London
PETO T, SCHMERMER C, POWLING A, DIABETIC RETINOPATHY SCREENING TEAM THE—London
- 307 Retinal vessel signs and early retinopathy in type 1 diabetes
KYÖ JP, ROSENGÅRD-BÄRLUND M, FORSLÖM C, HIETALA K, FAGERUDD J, LINDSTRÖM-KARJALAINEN M, GROOP P-H, SUMMANEN PA—Helsinki
- 308 Diabetic retinopathy progression in patients submitted to pancreatic and renal transplant
MIGUEL L, DORES J, MEIRELES A—Porto
- 309 Photodynamic Therapy (PDT) and Periocular Triamcinolone for Retinal Angiomatus Proliferation
HIGGINS GT, SCARMOUSOS F, RILEY A, HARDING SP—Liverpool
- 310 Stabilization of visual acuity after intravitreous pegaptanib injections in patients with neovascular AMD
BREUER B, JOCHMANN C, WIEDEMANN P—Leipzig
- 311 Impairment of the ubiquitin-proteasome pathway by 7-ketosterol on ARPE-19 cells: contributions to AMD
OLIVEIRA FERREIRA JV, GIRÃO H, PEREIRA P—Coimbra
- 312 Autologous choroid-RPE-sheet translocation in exudative AMD
DEGENRING RF, CORDES AK, DOHM S, SCHRAGE NF—Cologne
- 313 The leucine (7)-to-proline (7) polymorphism in the signal peptide of neuropeptide Y is not a risk factor for exudative age-related macular degeneration
KAARNIRANTA K, HOLOPAINEN J, KARVONEN M, KOULU M, KALLIO J, PESONEN U, TERÄSVIRTA M, UUSITALO H, IMMONEN I—Kuopio, Helsinki, Turku
- 314 Associated Factors for Age-Related Maculopathy in the Adult Population in China. The Beijing Eye Study
JONAS JB, XU L, LI Y, ZHENG Y—Mannheim, Beijing
- 315 Transpupillary thermotherapy (TTT) for the treatment of idiopathic choroidal neovascular membranes: A prospective study in the South Indian population
RAJA V, CHANDRAMOHAN K, SHUKLA D, MANOJ S, KIM R, KOSHAL RAM B, NAMPERUMALSAMY P—Liverpool, Madurai
- 316 The association between exposure to blue light and the incidence of age-related maculopathy: an epidemiologic review
SMITH AF, MINASSIAN DC—Hemel Hempstead, London
- 317 Intraocular Pressure Following Intravitreal Injection of Triamcinolone Acetonide
ANSARI EA, ALI N—Maidstone
- 318 Quality Assurance in the UK Macular Degeneration Reading Centre Network
MULDREW KA, PATTON WP, HARDING S, PETO T, REEVES B, CHAKRAVARTHY U—Belfast, Liverpool, London
- 319 Photodynamic therapy combined with intravitreal triamcinolone in exudative AMD, carrying out early retreatment: comparative study
HERNANDEZ VERDEJO JL, ALVAREZ M, FERRER B, MARINA C, TEUS MA—Madrid
- 320 Calculation of the Magnification in Optical Coherence Tomography (STRATUS OCT 3000) to measure Optic Nerve Head (ONH) size
PABLO LE, BARAIBAR B, SÁNCHEZ-CANO A, EGEA MC, GUERRI N—Zaragoza
- 321 Foveal thickness after phacoemulsification. A one year optical coherence tomography evaluation
BARTESELLI G, MAESTRONI L, MIGLIOR S—Monza

- 322 Optical Coherence Tomography (OCT) In Serous Maculopathy Associated With Optic Disk Pit Managed With Vitrectomy-Laser-Gas. Case Report
PENDINO V, SPINELLI A, PARISE S, VARANO L, CARNOVALE SCALZO G, SCORCIA GB, SCORCIA V, SCORCIA G—Catanzaro, Reggio Calabria

- 323 X-linked juvenile retinoschisis - age related macular changes by optical coherence tomography
LESCH B, SZABÓ V, PAMER Z, KNEZY K, SALACZ G, PAPP A, SOMFAI G, VARSANYI B, VAMOS R, HARGITAI J, FARKAS A—Budapest, Pécs

- 324 Profile of Retinal Detachment Management at Public Hospitals of National Health Service (NHS)
SANCHEZ CHICHARRO D, PASTOR JIMENO JC, ROJAS J, FERNANDEZ I, GOMEZ-ULLA F, PIÑERO A—Valladolid, Santiago de Compostela, Sevilla

- 325 Acute Visual Loss and Asteroid Hyalosis Associated With Posterior Vitreous Detachment
BARRY J-S, JAZAYERI F, BOOTH A—Plymouth

- 326 Postsurgical cystoid macular oedema in patients in treatment with prostaglandins. Our experience
CASTEJÓN MA, BOLÍVAR G, TEUS MA—Alcalá de Henares

- 327 Management of rhegmatogenous retinal detachment with 25-g vitrectomy
RUIZ MORENO JM, MONTERO J, DE LA VEGA C—Alicante

- 328 Massive suprachoroidal haemorrhage
VIDE ESCADA EICKMANN A, NASCIMENTO J, HENRIQUES J, QUINTÃO T, CASTANHEIRA-DINIS A—Lisbon

- 329 An audit of clinical indications for day-case binocular indirect laser Panretinal Photocoagulation for Diabetic eye disease
SOMANATHAN S, MUSHTAQ B, TSALOUMAS MD—Birmingham

CORNEA / OCULAR SURFACE

- 330 Expression of CTLA4-Ig and vIL-10 by gene-engineered dendritic cells leads to prolongation of corneal allograft survival
rf
SCHLICKEISER S, RITTER T, LI XQ, APPELT C, VOLK HD, PLEYER U, SAWITZKI B—Berlin, Galway

- 331 Prolongation of corneal allograft survival by topical application of Everolimus
rf
PLEYER U, BÜCH G, OTASEVIC L, SCHLICKEISER S, BERTELmann E, LI X—Berlin, Wuhan

- 332 Comparison of the Visual Acuity by Time Index with conventional Survival Curves for the evaluation of osteo-odontokeratoprosthesis functional results
rf
MICHAEL R, TEMPRAÑO J, CHAROENROOK V, DE LA PAZ M, HITZL W, GRABNER G, BARRAQUER RI—Barcelona, Salzburg

- 333 Swelling and deswelling of human corneas during eye banking: present and future
rf
THURET G, ZHAO M, GAIN P—Saint-Etienne

- 334 Correlation between impression cytology and Labial salivary gland biopsy in Sjögren's syndrome
rf
LANGMAN ME, GICQUEL JJ, ROBLOT P, GOMBERT JM, DIGIER PL—Saint Jean d'Angély, Poitiers

- 335 Improvement of dry eye symptoms with polyunsaturated fatty acids
rf
GARCHER CREUZOT C, PASSEMARD M, LAFONTAINE P-O, VIAU S, JOFFRE C, ELENA P-P, POUILQUEN P, BAUDOUIN C, BRON AM—Dijon, Nice, Clermont-Ferrand, Paris

- 336 Ultrastructural Conjunctival Surface Changes in Patients with Sjögren's Syndrome: Long term Results
rf
KOUFAKIS DI, KARABATSAS CH, SAKKAS LI, ALVANOU A, MANTHOS AK, CHATZOULIS DZ—Larissa, Thessaloniki, Thessaloniki

- 337 Addition of ganciclovir to the cornea preservation medium : kinetics and toxicity
rf
ROBERT PY, SAUVAGE F, THURET G, RANGER-ROGEZ S, ADENIS JP, ROUSSANE MC, GAIN P, MARQUET P—Limoges, Saint-Etienne

- 338 Bevacizumab (Avastin) inhibits inflammatory hem- and lymphangiogenesis in the cornea
BOCK FB, ONDERKA J, DIETRICH T, BACKMANN B, KRUSE FE, CURSIEFEN C—Erlangen

- 339 Use of Platelet-Rich Plasma In The Treatment of Ocular Surface Syndrome Following Laser In Situ Keratomileusis (LASIK)
rf
PASTOR S, RUIZ-COLECHÁ J, RODRIGUEZ A, ARTOLA A, ALIÓ JL—Alicante

- 340 NGF promotes the healing of bilateral recurrent corneal erosion in dogs
rf
DODI PL, COSTA N, ALOE L—Parma, Catanzaro, Rome

Poster Session 2 — 16:30-17:20 — Neptuno

- Molecular Biology / Genetics / Epidemiology: 374 > 386, moderators: Cathy WILLIAMS, Mike WRIDE

341	Towards the Development of Purpose-designed Ocular Bandage Lenses <i>r/f</i> BATEMAN S, MANN AM, TIGHE BJ—Birmingham	364	Gene therapy promotes corneal graft survival BARCIA RN, DANA RM, KAZLAUSKAS A—Boston
342	Early limbal stem cell deficiency in KID Syndrome <i>r/f</i> LANGMAN ME, GICQUEL JJ, MILIN S, LEVILLAIN P, MESNIL M, DIGHIERO PL—St Jean d'Angély, Poitiers	365	Influence of corneal factors on tear film in postlaser patients NIETO A, PALOMO-ALVAREZ C, CARBALLO-ALVAREZ J, PUELL MC—Madrid
343	In vivo interferometric measurements of the tear film stability on soft contact lenses <i>r/f</i> SZCZESNA DH, STENEVI U, KASPRZAK H—Wroclaw, Möln达尔	366	A new system for grading staining at the surface of the eye BRON AJ, LANG C, FOULKS GN, SMITH JA, TIFFANY JM—Oxford, Louisville, Bethesda
344	Oxygen Transmission Characteristics of a Silicone Hydrogel Lens in Custom Parameters <i>r/f</i> GILES TG—Duluth	367	Experimental model of corneal wound healing after implantation of intracorneal rings and segments (ferrara) BLANCO-MEZQUITA JT, MERAYO-LLOVES JM, FABIANI L, BARCIA A, FERRARA P—Valladolid, Bello Horizonte
345	Solutions, Contact Lenses & Wear: Then & Now <i>r/f</i> FRANKLIN VJ, TIGHE BJ—Birmingham	368	Design of a new keratoprosthesis: evaluation of the colonization of polymeric biocompatible scaffolds. PASTOR S, ALIÓ JL, RUIZ-MORENO JM, CAMPILLO-FERNÁNDEZ A, GÓMEZ-RIBELLES JL, MESEGUER-DUEÑAS JM—Alicante, Valencia
346	Microfluidic Technology for Routine Tear Analysis <i>r/f</i> MANN A, TIGHE B—Birmingham	369	Safety of Mitomycin c (MMC) in reepithelialization after LASEK PIZZAMIGLIO-MARTIN C, DE BENITO L, FUENTES I, ALVAREZ MT, TEUS-GUEZALA MA—Madrid
347	Measurement of Frictional Characteristics of Contact Lenses <i>r/f</i> ROSS G, TIGHE BJ—Birmingham	370	The Persistent Enemy - recurrence of herpes simplex in three consecutive corneal graft buttons HUNTBACH JA, WORSTMANN T—Nottingham, Burton-on-Trent
348	Corneal morphology, topography and sensitivity in a family with inherited recurrent corneal erosions – Dystrophia Helsingiensis. NEIRA W, LINDBOHM N, TUISKU I, HAMMAR B, DELLBY A, KONTTINEN L, TERVO T, FAGERHOLM P—Helsinki, Linköping	371	Which is more difficult: The test to use or the diagnosis of Dry Eye? MOORE JE, GRAHAM JE, DARTH D, GOODALL E, MOORE CBT—Belfast, Coleraine, Boston
349	Regulation of limbal stem cell growth and differentiation by factors produced by the wounded cornea HOLAN V, KRULOVA M, TAVANDI Z, POKORNA K, ZAJICOVA A, FILIPEK M—Prague	372	Anti-BP180 antibodies in Ocular Pemphigoid ROBERT PY, AL YOUSSEF A, BEDANE C, COGNE M, ADENIS JP, DROUET M—Limoges
350	Soluble Fas in tear fluid of patients with cystic fibrosis MRUGACZ M, ZELAZOWSKA-RUTKOWSKA BEATA, BAKUNOWICZ-LAZARCZYK A, WYSOCKA J—Bialystok	373	Automatic estimation of corneal endothelial cell density in images from swollen organ cultured donor corneas RUGGERI A, GRISAN E, SCHROETER J—Padova, Berlin
351	Mitosis in the endothelium of donor corneas SLETTEDAL JK, BERAKI K, RAMSTAD H, NICOLAISSEN B—Oslo	MOLECULAR BIOLOGY / GENETICS / EPIDEMIOLOGY	
352	PDT of corneal neovessels using a new hydrosoluble photosensitizer (WST11) BOURGES J-L, BENEZRA D, BEJJANI RA, SAVOLDELLI M, JEANNY JC, BLANC D, BEHAR-COHEN F—Paris, Jerusalem, Toussus le Noble	374	Mutation analysis of RHO gene and novel mutation Arg252Pro (755G→C) in patients with nonsyndromic retinitis pigmentosa from Bashkortostan GRINBERG E, DZHEMILEVA L, KHUSNUTDINOVA E—Ufa
353	Increased expression of matrix metalloproteinases 1, 2 and 9 in human corneal grafts during corneal melting JUKLOVA K, FILIPEK M, JIRSOVA K—Prague	375	Familial high myopia in Polish population <i>r/f</i> RYDZANICZ MA, PODFIGURNA-MUSIALAK M, FRAJDENBERG A, BEJJANI BA, LEAL SM, GAJECKA M—Poznan, Leszno, Spokane, Houston
354	Refractive changes after LASIK corneal flap formation in corneas after penetrating keratoplasty PODKOCHY A, FAGERHOLM P—Linköping	376	Delayed development of Retinal Vessel Network in Alpha 2B Adrenergic Receptor Knock-out Mice HUA J, MUTHIG V, GROSS N, LANGE C, MARTIN G, HANSEN LL, HEIN L, AGOSTINI H—Freiburg
355	Biglycan protects keratocytes from apoptosis KOULIKOVSKA M, FAGERHOLM P—Linköping	377	Temporal expression profile of murine cornea: a possible role for Vsx1 in corneal development? SHEPPARD JPB, MEEK K, VOTRUBA M—Cardiff
356	Inhibition of inflammatory corneal lymphangiogenesis by an anti-VEGFR3 antibody (mF4-31C1) BOCK FB, ONDERKA J, DIETRICH T, BACHMANN B, KRUSE FE, CURSIEFEN C—Erlangen	378	Ocular manifestations of Nail Patella Syndrome RAJA V, SANDANSHIV P, NEUGEBAUER M, SWEENEY E, MCINTOSH I—Liverpool, Crewe, Baltimore
357	Clinical Practice of Consultant Ophthalmologists in Treating Herpetic Eye Disease in the United Kingdom ZIAHOSSEINI K, MORGAN LH, IKRAM K—Stockport	379	Management and visual outcome in children with Lowe syndrome PINELLO L, MAIMONE PE, MAZZAROLO M, CALDIRONI P—Padua
358	Traumatic wound dehiscence following penetrating keratoplasty: clinical outcomes and in vivo confocal microscopy MALANDRINI A, BALESTRUZZI A, FRUSCHELLI M, TOSI GM, CAPOROSSI A—Siena	380	VMD2 mutations in Italian patients with Best maculopathy SODI A, PASSERINI I, BINI A, MENCHINI U, TORRICELLI F—Florence
359	Novel Ocular Lubricants Based On Polymer-Phospholipid Recombinants & Hyaluronic Acid RASUL N, TIGHE BJ—Birmingham	381	Clinical and genetic study of myopia in St. Peter island (Sardinia) ZUCCA I, GALANTUOMO MS, MALLOCI C, STAMBOLIAN D, FOSSARELLO M—Cagliari, Philadelphia
360	Comparison between different test used to evaluate the quality and the quantity of the tear film GONZÁLEZ MARTÍNEZ M, VIDAL LÓPEZ J, SOBRADO CALVO P, JAVALOYES MORENO B—Murcia	382	Follow-up of young patients with retinitis pigmentosa by multifocal ERG VA'MOS R, LESCH B, SOMFAI GM, FARKAS A—Budapest
361	Cross – Infection and Contact Ophthalmic Devices: Clinical Trials of a Disposable Ophthalmic Barrier System TIGHE BJ, FRANKLIN VJ, HENLEY CE, KERR J, GEE H, WOLFFSOHN J, FLANAGAN J—Birmingham, Croydon, Ramsbury, Waterloo, Canada	383	Visual and ocular motor functions in Russian orphanage children with fetal alcohol syndrome (FAS) GUMMEL KK, YGGE J, BRZHESKY VV—St-Petersburg, Stockholm
362	Age-related changes in the corneal thickness profile assessed with Orbscan JONUSCHEIT S, DOUGHTY MJ, BUTTON NF—Glasgow	384	Palpebral fissure size of aged people in Korea JEON SL, PARK CY, WOO KI, CHANG HR—Seoul
363	Short-term Effects of Contact Lens Corneal Refractive Therapy on Corneal Topography QUEIROS A, GONZALEZ-MEJOME JM, VILLA-COLLAR C, JORGE J, ALMEIDA JB, PARAFITA MA—Braga, Madrid, Santiago de Compostela	385	Golf-related ocular injuries: injury pattern, visual outcome and prevention GAWLEY SD, WILLIAMS MA, RANKIN SJA, WILLOUGHBY CE, FRAZER DG—Belfast
		386	Spontaneous iris bleed and management options SKINNER KC, KHETTERPAL S, CHRONI FC, MURRAY C—Reading, St-Leonards-on-Sea



ever 2006

Saturday 7 October



Gemini I SIS	Keratoprosthesis and Corneal Bioengineering 1			08:30 – 10:00
	Christopher LIU, Jean-Jacques GICQUEL			
08:30	4111	When is the right time to perform limbal grafting after severe ocular alkali burns GICQUEL JJ, NAVARRE R, DIGHIERO P–Poitiers		
08:50	4112	Strengths and Weaknesses of the OOKP LIU C–Brighton		
09:10	4113	AlphaCor: An overview of current outcome data HICKS C–Nedlands		
09:30	4114	The future of corneal bioengineering in the prevention or treatment of graft rejection BOURGES J-L–Paris		
09:50		Discussion		
Gemini III Workshop	Neuro-ophthalmology in the Emergency Room			08:30 – 10:00
	Aki KAWASAKI			
08:30	4121	Acute visual loss: Evaluation and differential diagnosis PURVIN V–Indianapolis		
08:48	4122	A dilated pupil: Neurologic or pharmacologic? BOSCHI A–Brussels		
09:06	4123	Sixth nerve palsy: When is it a sign of danger? MILEA D–Copenhagen		
09:24	4124	Visual loss from papilledema: Management and prognosis KAWASAKI A–Lausanne		
09:42	4125	Radiation optic neuropathy: Can hyperbaric oxygen help? BORRUAT FX–Lausanne		
Vega SIS	Eyelid tumours I			08:30 – 10:00
	Frédéric MOURIAUX, Mordechai ROSNER			
08:30	4131	Clinical and pathological review of eyelids tumours LASUDRY J–Brussels		
08:55		Discussion		
09:00	4132	Basal cell carcinoma of the eyelid in Finland during 1953-97 SAARI KM, PAAVILAINEN V–Turku		
09:20		Discussion		
09:30	4133	Clinical and histopathological characteristics of recurrent BCC of the eyelids ROSNER M–Tel Hashomer		
09:50		Discussion		

Pegasus Workshop	How to get your work published ? Uwe PLEYER, Pinar AYDIN, Andrew DICK, Jochen GRAW, Shambhu VARMA	08:30 – 10:00
Junior researchers often face the challenge of getting their interesting work published. The goal of this course will be to provide some keys to write a high quality paper that will help to transform innovative ideas into a research article.		
The panellists will discuss major aspects of the editorial process including basic decisions: where to submit your work, how to organize and prepare a manuscript, lengths of the review process, the revision process for re submission.		
The panellists will raise the discussion on issues like:		
<ul style="list-style-type: none"> • How to choose a journal ? • How to organize your paper ? • What are the characteristics of a good manuscript ? • Delayed response: When is it appropriate to ask for the status of your manuscript ? • How to interpret the letter from the editor ? • How to write a good reply to the reviewers? • What to do when your paper is rejected ? • When can it be appropriate to request a re-evaluation of a rejected paper ? 		

Fenix I FP	Free papers Glaucoma : Psychophysics & Optic disc Stefano MIGLIOR, Gabor HOLLÓ	08:30 – 10:00
08:30	4151 Perimetric Performance of Artificial Neural Networks based on Pattern Deviation for Glaucoma Diagnosis BIZIOS D, BENGTSSON B, HEIJL A–Malmö	
08:42	4152 Search for an optimal combination of structural and functional methods for the diagnosis and follow-up of glaucoma SKORKOVSKA S, MICHALEK J–Brno	
08:54	4153 Reproducibility of optic disc examination by HRT III MIGLIOR S, GUARESCHI M, BERTUZZI F, DI MATTEO F, RULLI E–Monza, Milano	
09:06	4154 Can new version 3 software improve diagnostic ability of Heidelberg Retina Tomograph parameters? FERRERAS A, PAJARIN AB, BORQUE E, PUEYO V, POLO V, LARROSA JM, PABLO LE, HONRUBIA FM–Zaragoza	
09:18	4155 rf Influence of Central Corneal Thickness in pre-perimetric glaucoma subjects defined by means of HRT II, OCT and GDx VCC BORQUE E, LARROSA JM, POLO V, FERRERAS A, MAYORAL F, HONRUBIA FM–Zaragoza	
09:24	4156 rf Impact of Neuroretinal Rim Measurements as Predictive Factor for the Development of Glaucoma in Patients with Ocular Hypertension LAEMMER R, MARTUS P, MARDIN CY–Erlangen, Berlin	
09:30	4157 rf Inadequate anterior segment compensation is not a major cause of false-negative GDx Nerve Fiber Analyzer test results MUSKENS RPHM, HEEG GP, JANSONIUS NM–Groningen	

Fenix III SIS	VEGF from Basic Pharmacology to Clinical Use Leopold SCHMETTERER, Ingeborg STALMANS	08:30 – 10:00
		
08:30	4161 VEGF Pharmacology and Role in Ocular Angiogenesis SCHLINGEMANN R–Amsterdam	
08:48	4162 Triggers of VEGF in the eye KVANTA A–Stockholm	
09:06	4163 Mouse models for diabetic retinopathy and age-related macular BOSCH F–Barcelona	
09:24	4164 Role of VEGF isoforms in the eye STALMANS I, CARMELIET P–Leuven	
09:42	4165 Anti-VEGF from laboratory to clinics SCHMIDT – ERFURTH U–Lubeck	

Keynote Lecture

10:15 – 10:55

Fenix III

**Light damage and retinal degenerations:
a model that sometimes tells the truth**

Charlotte REME, Zürich

Introduction by Constantin POURNARAS



Gemini I SIS	Keratoprosthesis and Corneal Bioengineering 2		11:15 – 12:45
	Jean-Jacques GICQUEL, Christopher LIU		
11:15	4211	Implantation studies of cross-linked collagen tissue substitutes into pig corneas - An update FAGERHOLM P, LIU W, GAN L, GRIFFITH M–Linköping, Ottawa, Ontario	
11:35	4212	Results from the Multi-Center Boston KPro Study Group BELIN MWB, ZERBE BZ–Albany, NY	
11:55	4213	Towards a synthetic OOKP support frame VIITALA R, FRANKLIN VJ, TIGHE BJ, LIU C, LLOYD AW–Birmingham, Brighton	
12:15	4214	State of the art of human corneal endothelial cell proliferation THURET G, ZHAO M, GAIN P–Saint-Etienne	
12:35		Discussion	

Gemini III SIS	Cellular and molecular mechanisms of angiogenesis and lymphangiogenesis	11:15 – 12:45
	Hansjürgen T. AGOSTINI	



11:15	4221	VEGF isoforms in ocular neovascularisation BATES D–Bristol
11:33	4222	Angiopoietins in the retina: physiological and pathological functions HAMMES HP–Mannheim
11:51	4223	Is the Ephrin/Eph system essential for physiological and pathological retinal vascularization? AGOSTINI HT–Freiburg
12:09	4224	Mechanisms underlying the angio-fibrotic switch in CNV and proliferative retinopathies SCHLINGEMANN R–Amsterdam
12:27	4225	The dual role of macrophages in inflammatory lymphangiogenesis CURSIEFEN C–Erlangen

Vega SIS	Eyelid tumours II	11:15 – 12:45
	Frédéric MOURIAUX, Mordechai ROSNER	

11:15	4231	Measurement of depth of basal cell carcinomas using pulsed ultrasound and its possible use in the diagnosis and treatment of tumors of the eyelids ALLAN E, LONCASTER J, SHERIDAN L, LEACH C–Manchester
11:35		Discussion
11:45	4232	Sebaceous gland carcinoma of the eyelids - clinically and pathologically challenging cases MUQIT MMK–Leeds
12:05		Discussion
12:15	4233	Argon laser for the treatment of benign eyelids tumors MOURIAUX F–Caen
12:35		Discussion

Pegasus FP	Free papers Physiology / Biochemistry / Pharmacology : Pharmacology		11:15 – 12:45
	Gerhard GARHOFER, Kivanc GUNGOR		
11:15	4241	Effects of ET-1 and NO in an experimental model of rabbit eye DELGADO E, MARQUES-NEVES C, ROCHA I, SALES-LUIS J, SILVA-CARVALHO L–Lisbon	
11:27	4242	Effects of high dose Triamcinolone Acetonide on proliferation of retinal endothelial cells in a rop-mouse-model AKKUYUN I, YILMAZ G, OTO S, HABERAL N, BACANLI D, TUFAN H, AKOVA YA–Ankara	
11:39	4243	Retinal toxicity of intravitreal triamcinolone acetonide at high doses in the rabbit MONTERO-MORENO JA, RUIZ-MORENO JM, BAYON A, RUEDA J, VIDAL M–Alicante, Murcia	
11:51	4244	Bevacizumab (Avastin) has no toxicity on cultured cell from the anterior and posterior segment of the human eye WELGE-LÜBEN U, KERNT M, YU AL, KAMPIK A, NEUBAUER AS–Munich	
12:03	4245 <i>rf</i>	Adrenergic receptors in retinal arterioles GISLADOTTIR S, EYSTEINSSON T, SIGURDSSON SB–Reykjavik	
12:09	4246 <i>rf</i>	Retrobulbar Use of Poloxamer for Ocular Drug Delivery VEHANEN K, HORNOF M, URTTI A, UUSITALO H–Kuopio, Helsinki	
12:15	4247 <i>rf</i>	Structural Aspects of the Design of Ocular Drug Delivery Systems MAHOMED A, TIGHE BJ–Birmingham	

Fenix I SIS	Ocular Blood Flow in Glaucoma Practice	11:15 – 12:45
	Ingeborg STALMANS	



11:15	4251	Techniques to evaluate OBF SCHMETTERER L–Vienna
11:30	4252	Retinal oxymetry STEFANSSON E, HARDARSON SH, HALLDORSSON GH, KARLSSON RA, BENEDIKTSSON JA, EYSTEINSSON T, BEACH JM, HARRIS A–Reykjavik, Indiana
11:45	4253	Correlation between Colour doppler and Ocular Pulse Amplitude in glaucoma STALMANS I, ZEYEN T, HARRIS A–Leuven, Indianapolis
11:53	4254	Prostaglandin analogues' effect on ocular blood flow ORGUL S, ZAWINKA C, KATAMAY R, REINHARD G, FLAMMER J–Basel
12:08	4255	Carbonic Anhydrase Inhibitor's effects on ocular blood flow HARRIS A, SIESKY B, MARQUES C, YUNG CW, SINES D–Indianapolis
12:23	4256	Additive effect of topical CAIs to prostaglandins on IOP lowering HOLLÓ G–Budapest
12:38	4257	Additive effect of topical CAIs to prostaglandins on ocular blood flow STALMANS I–Leuven

Fenix III SIS	The patient can't see but the doctor can't see why	11:15 – 12:45
	Graham HOLDER	
11:15	4261	When to decide on non-organic visual loss? SPILEERS W–Leuven
11:45	4262	Conditions that may mimic non-organic visual loss LEROY BP–Ghent
12:15	4263	The role of electrophysiology in medically unexplained visual loss HOLDER GE–London

Gemini I SIS	Confocal Imaging of the Ocular Surface		14:00 – 15:30
	Leonardo MASTROPASQUA		

14:00	4311	Advanced imaging and quantitative evaluation techniques of the ocular surface using confocal microscopy STACHS O, ZHIVOV A, GUTHOFF RF–Rostock	
14:18	4312	Microscopic imaging of limbus and conjunctiva MASTROPASQUA L–Chieti Pescara	
14:36	4313	The pro's and con's of imaging corneal and limbal nerves with in vivo confocal microscopy MÜLLER LJ, TERVO T, KRUSE F–Amsterdam, Helsinki, Erlangen	
14:54	4314	Confocal microscopy in immune and inflammatory responses of the ocular surface NUBILE M–Chieti	
15:12	4315	In vivo confocal microscopy of the conjunctiva and lid margin MESSMER EM–Munich	

Gemini III SIS	Biochemical and Genetic Markers in Diabetic Retinopathy		14:00 – 15:30
	Paulo DE SOUZA RAMALHO, Manuel P BICHO		

14:00	4321	Oxidative stress markers in diabetic retinopathy BICHO MP–Lisbon	
14:15	4322	Inflammatory markers and blood changes DE SOUZA RAMALHO P, PEREIRA DA SILVA A–Lisbon	
14:30	4323	Growth factors and pro-angiogenic molecules-survival pathways PEREIRA DA SILVA A, DE SOUZA-RAMALHO P–Lisbon	
14:45	4324	Genetic factors in diabetic retinopathy PEGO P, BICHO MP–Lisbon	
15:00	4325	VEGF and PEDF, the main regulators of angiogenesis in the retina MARTINEZ A–Madrid	
15:15		Discussion	

Vega FP	Free papers Pathology / Oncology 3		14:00 – 15:30
	Jacob PE'ER, Maria Antonia SAORNIL ALVAREZ		

14:00	4331	The use of hydroxyapatite implant in enucleations : retrospective review of 689 cases DESJARDINS L, LUMBROSO-LEROUC L, LEVY GABRIEL C, PLANCHER C, ASSELAIN B–Paris	
14:12	4332	Intravitreal methotrexate for managing vitreoretinal involvement of primary central nervous system lymphoma: Nine years of experience. FRENKEL S, SIEGAL T, PE'ER J–Jerusalem	
14:24	4333	Orbital involvement of retinoblastoma HADJISTILIANOU T, DE FRANCESCO S, ACQUAVIVA A, MENICACCI F, GALLUZZI P–Siena	
14:36	4334	Punch biopsy for iris lesions: a novel technique for obtaining histology samples PE'ER J, BLUMENTHAL EZ, FRENKEL S–Jerusalem	
14:48	4335	Utility of Biopsy in cases of Pigmented Iris Tumour SCHALENBOURG A, UFFER S, ZOGRAFOS L–Lausanne	
15:00	4336	Intraocular biopsy forceps - A new promising approach AKGUEL H, JURKLIES B, BORNFELD N–Essen	
15:12	4337 <i>rf</i>	Optico-reconstructive operations in block excision of iridociliary tumours SAAKYAN SV, CHENTSOVA EV–Moscow	

Poster session

15:35 – 16:25
Neptuno

***Neuro-ophthalmology / Strabismology, Glaucoma,
Physiology / Biochemistry / Pharmacology, Pathology / Oncology***

Jan YGGE, Lene MARTIN, Volkan DAYANIR, Fotis TOPOUZIS, Andreas REMKY, Thor EYSTEINSSON, Gerhard GARHOFER, Jan PRAUSE

Pegasus FP	Free papers Physiology / Biochemistry / Pharmacology : Blood Flow II			14:00 – 15:30
	Leopold SCHMETTERER, Guenther WEIGERT			
14:00	4341	Software for the semi-automatic determination of the retinal vessels diameter MONTEIRO-GRILLO M, LOPES D, MORA A, FERREIRA A, FONSECA J, VIEIRA P–Lisbon		
14:12	4342	Age-dependence of dynamic retinal arterial reaction to monochromatic flickering light in a representative sample of normal volunteers KOTLIAR KE, BOCK A, SCHMIDT-TRUCKSÄB A, HALLE M, VILSER W, LANZL IM–Munich, Ilmenau		
14:24	4343	Response of retinal vessel diameters to flicker-light in vasospastics ZAWINKA C, RICKENBACHER I, REINHARD G, FLAMMER J, ORGUEL S–Basel		
14:36	4344	Retinal Blood Flow and Nerve Fiber Layer Measurements in Normal Tension Glaucoma BERISHA F, FEKE GT, PASQUALE LR, HIROSE T, MCMEEL JW–Boston		
14:48	4345 <i>rf</i>	Spatial properties and shortterm vasomotion of retinal vessels in vasospastic subjects KOCHKOROV A, GUGLETA K, ZAWINKA C, KATAMAY R, FLAMMER J, ORGUL S–Basel		
14:54	4346 <i>rf</i>	The effects of voluntary fasting on retinal and peripheral vessel reactivity – a case study HEITMAR R, GHERGHEL D–Birmingham		
15:00	4347 <i>rf</i>	Optic Nerve Blood Flow and Retinal Diameter Responses to Flicker Stimulation are Described by a 2nd Order Linear System Model RIVA CE, BONAIUTI M, ROVATI L–Bologna, Modena		
15:06	4348	Apoptosis and neurite retraction explain the structural and functional loss in the rat model of postnatal hyperoxia LACHAPELLE P, DORFMAN A, PINILLA I, CUENCA N, DEMBINSKA O, JOLY S, CHEMTOB S, CASANOVA C–Montréal, Québec, Zaragoza, Alicante		
Fenix I SIS	Compliance in the management of Glaucoma			14:00 – 15:30
	Alan ROBIN			
Alcon®				
14:00	4351	The importance of circadian IOP variation, endurance of glaucoma medications, and compliance in the successful treatment of glaucoma and ocular hypertension ROBIN AL–Baltimore		
14:30	4352	Fixed Combination clinical results TOPOUZIS F–Thessaloniki		
15:00	4353	Associated compliance benefits with fixed combinations DENIS P–Lyon		
Fenix III SIS	Doctor I cannot see well, but can I still drive?			14:00 – 15:30
	John BARBUR, Graham HOLDER			
14:00	4361	Driver's vision and in-Vehicle information systems: a review GALE A–Loughborough		
14:15	4362	Training, biopic telescopes and practical fitness to drive with reduced visual acuity KOOIJMAN AC, MELIS-DANKERS BJM, BUSSCHER RB, BREDEWOUD RA, VAN DELDEN, BROUWER WH, WITVLIET J–Groningen, Huizen		
14:30	4363	Usefulness and shortcomings of standard perimetry for assessment of driving abilities PETZOLD A, RAUSCHER FG, BARBUR JL, PLANT GT–London		
14:45	4364	UFOV test performance in patients with central scotomata DUNNE MCM, DAVIES LN, RAUSCHER FG, EDGAR DF, CHISHOLM CM, BARBUR JL–Birmingham, London		
15:00	4365	Loss of visual field sensitivity in relation to driving performance as assessed by HPT and UFOV RAUSCHER FG, BARBUR JL, EDGAR DF, CHISHOLM CM, PETZOLD A, PLANT GT, DUNNE MCM, UNDERWOOD GJ–London, Birmingham, Nottingham		
15:15	4366	Driving and vision: working towards a policy based on evidence PLANT G–London		

General Assembly16:30 – 17:25
Fenix III**EVER General Assembly and Prize Giving****Agenda**

1. President's address
2. Minutes of the General Assembly 2005
3. Report of the General Secretary
4. Report of the Programme Secretary
5. Report of the Treasurer, approval of the accounts 2005, budget for 2007
6. Newsletters ; EVER Journal
7. Results of the elections
8. Presentation of the BOARD 2006-2007
9. President Elect, Vice President Elect, Programme Secretary
10. Honorary Members
11. Presentation and Report of the Scientific Sections meetings
12. Future congresses
13. Prize giving
14. Miscellanea

Gemini I SIS	Ocular Surface and New developments in Dry eye		17:30 – 19:00
	Maurizio ROLANDO		



17:30	4411	Lacrimal film stability GOES F Jr–Antwerp
17:50	4412	Lacrimal punctal plugs: new concepts, indications, when and how? BREMOND GIGNAC D–Paris
18:10	4413	Protecting the Ocular Surface and improving the quality of life of dry eye patients. A comparative study of the efficacy of two tear substitutes in a population of dry eyes ROLANDO M, AUTORI S, BADINO M–Genoa
18:30	4414	Outcome Analysis of HP Guar PEG 400 and PG based lubricant eye drops in lasik Patients MERAYO-LLOVES J–Valladolid

Vega SIS	Immunotherapeutic options in uveal melanoma	17:30 – 19:00
	Uwe PLEYER, Martine J JAGER	

17:30	4431	Tumour cell vaccines to prevent growth of uveal melanoma KSANDER BR, BOSCH JJ, THOMPSON JA, OSTRAND-ROSENBERG S–Boston, Baltimore
17:45	4432	Using FasL to inhibit tumour growth GREGORY M, SAFF R, MARSHAK-ROTHSTEIN A, KSANDER BR–Boston
18:00	4433	Immunomodulation of intraocular tumours JAGER MJ, BOONMAN ZFHM, VAN MIERLO GJD, FRANSEN MF, MELIEF CJM, TOES REM–Leiden
18:15	4434	Presence and phenotype of dendritic cells in uveal melanomas. POLAK M E, BORTHWICK NJ, JAGER MJ, CREE IA–Portsmouth, London, Leiden
18:30	4435	IFNg and uveal melanoma resistance to CTL HALLERMALM K, SEKI K, DEGEER A, ZUBER B, MOTYKA B, BLEACKLEY RC, JAGER M, FROELICH CJ, KISSLING R, LEVITSKY V, LEVITSKAYA J–Stockholm, Edmonton, Alberta, Leiden, Evanston
18:45	4436	Adjuvant therapy for uveal melanoma ECONOMOU M–Stockholm

Pegasus FP	Free papers Physiology / Biochemistry / Pharmacology : Oxygen & Animal Models	17:30 – 19:00
	Ulrich-Christoph WELGE-LÜBEN, Ivan O HAEFLIGER	

17:30	4441	Dietary Superoxide Dismutase Protects Against Light-Induced Retinal Oxidative Stress in Young Senescence Accelerated Mice (SAM) BRON AM, SICARD P, ACAR N, JOFFRE C, VERGELY C, CREUZOT-GARCHER C, BRETILLON L, ROCHELLE L–Dijon
17:42	4442	PARP inhibition counteracts diabetes-induced retinal oxidative stress and apoptosis OBROSOVA IG, SHIN J, DREL VR, XU W, ZHANG J, ALI TK, JULIUS U, EL-REMEZZY A–Baton Rouge, LA, Baltimore, MD, Augusta, GA, Dresden
17:54	4443	Stokes-Einstein equation and the physiological effects of vitreous surgery STEFANSSON E, LOFTSSON T–Reykjavik
18:06	4444 <i>rf</i>	Oximetry in retinal vascular occlusions HARDARSON SH, KARLSSON RA, HALLDORSSON GH, JOELSSON SR, EYSTEINSSON T, BENEDIKTSSON JA, BEACH JM, STEFANSSON E–Reykjavik
18:12	4445 <i>rf</i>	Diabetes-induced cataract amplified in mice lacking CuZn-superoxide dismutase OLOFSSON EM, MARKLUND SL, BEHNDIG A–Umeå
18:18	4446 <i>rf</i>	Transient Hypertonic Saline (ths)-induced Intraocular Pressure (IOP) as a rabbit model to assess potential new antiglaucoma drugs BASTIA E, IMPAGNATIELLO F, BORGHI V, BIONDI S–Bresso, Milan
18:24	4447 <i>rf</i>	Invasive Real Intraocular Pressure (IOP) Measurement. How to do it correctly HERNANDEZ VERDEJO JL, ROMAN JM, BOLÍVAR G, FERRER B, TEUS MA–Madrid

Fenix I	Free papers Glaucoma : Surgery		17:30 – 19:00
FP	Thierry ZEYEN, Alan ROBIN		
17:30	4451	Long-term result of trabeculectomy with mitomycin C (MMC) using modern advanced techniques CHIANG MY, SII F, WILLIAMS TA, LOCKWOOD A, LEE GA, SHAH P–Birmingham	
17:42	4452	ReGAE 3 (Research into Glaucoma and Ethnicity) Trabeculectomy with Mitomycin C (MMC) – a two year follow up LOCKWOOD A, SII F, CHIANG M, WILLIAMS TA, SHAH P–Birmingham	
17:54	4453	Morphological evaluation of blebs after filtering glaucoma surgery by means of in vivo confocal microscopy and optical coherence tomography LANZINI M, NUBILE M, FASANELLA V, COSTANTINO O, MASTROPASQUA L–Chieti	
18:06	4454	On table gonioscopy with intraocular viscoelastic in the operating theatre for accurate identification of cyclodialysis cleft in occult hypotony WILLIAMS TA, CHAING YM, LOCKWOOD AJ, SII F, SHAH P–Birmingham	
18:18	4455	The comparison of outcome results of using diode laser for neovascular glaucoma after diseases of retina BUNIATYAN IY–Yerevan	
18:30	4456	Effect of non penetrating glaucoma filtering surgery on visual acuity. A one year follow up study TEUS MA, ARRANZ-MARQUEZ E, GIL R, PIZZAMIGLIO C, MARINA C–Madrid	
18:42	4457 <i>rf</i>	The safety and efficacy of trabeculectomy with mitomycin C (MMC) in juvenile open angle glaucoma CHIANG MY, LOCKWOOD A, WILLIAMS TA, JAYAPRAKASAM A, SII F, SHAH P–Birmingham	
18:48	4458 <i>rf</i>	Excimer laser trabeculotomy (ELT) - an alternative laser treatment to reduce intraocular pressure WILMSMEYER S, PACHE M, FUNK J–Freiburg, Stuttgart	
Fenix III	ISCEV session		17:30 – 19:00
Joint M.	Pierre LACHAPELLE		
17:30	4461	Use of Electrophysiologic Testing in Everyday Practice LAM BL–Miami	
17:45	4462	Functional imaging of the retina HAWLINA M–Ljubljana	
18:00	4463	Using the EOG as a detective tool LEROY BP, YARDLEY J, HART-HOLDEN N, LAFAUT BA, PUECH B, DE LAEY JJ, MOORE AT, KESTELYN P, BLACK GCM–Ghent, Manchester, Bruges, Lille, London	
18:15	4464	The value of Visual Evoked Potentials (VEP) in the monitoring and prognosis of pituitary tumours. GRZYBOWSKI AE, LIEBERT W, ADAMCZAK N, DRUŻDŻ A., MIŚKOWIAK B– Poznań	
18:30	4465	Diagnostic value of electroretinography in retinitis pigmentosa associated syndromes FARKAS A–Budapest	
18:45	4466	Cone dystrophy with supernormal rod ERG HOLDER GE, MICHAELIDES M, WU H, ROBSON AG, JENKINS S, MOORE AT, HUNT DM, WEBSTER AR–London	
Social	EVER Farewell Dinner		
20:00 – 23:00 Marinotel garden			

Poster Session 3 — 15:35-16:25 — Neptuno

- Neuro-ophthalmology / Strabismology: 401 > 410, moderators: Jan YGGE, Lene MARTIN
- Glaucoma: 411 > 444, moderators: Volkan DAYANIR, Fotis TOPOUZIS, Andreas REMKY

NEURO-OPTHALMOLOGY / STRABISMOLOGY

- 401 Early diagnosis of ocular motility alterations in thyroid autoimmune ophthalmopathy (TAO)
r/f
VARANO L, CARNOVALE SCALZO G, CAMPAGNA F, SCORCIA GB, ROTONDO E, PENDINO V, PARISE S, BRUZZICHESI D, PAOLA A, SCORCIA G–Catanzaro
- 402 Variation of fusional vergences with age and their relation to type of horizontal heterophoria
VIDAL LÓPEZ J, SORO MARTÍNEZ MI, SOBRADO CALVO P, SÁNCHEZ-MIGALLÓN MC–Murcia
- 403 Variation of the binocular function based on the age
SÁNCHEZ-MIGALLÓN CARRERAS MC, VIDAL LÓPEZ J, SOBRADO CALVO P, SORO MARTÍNEZ MI–Murcia
- 404 Atypical blepharospasm
VILLAFLUERA I, SAAVEDRA J–Madrid
- 405 Particularities of pupillograms in children and adults with hypermetropic amblyopia
BUSHUYEVA NN, BOYCHUK IM, SHAKER M.H.DUHAIR MH–Odessa
- 406 Results of optical coherent tomography of retina and optical nerve in children with unilateral amblyopia of high degree
BOYCHUK IM, IVANITSKAYA EV–Odessa
- 407 Visual evoked potentials (VEPs) in early diagnosis of myelomeningocele in infants
SOBIESZCZANSKA M, PILECKI W, JANOWSKA A, SALOMON E, GUTH C–Wroclaw
- 408 Time dynamic of visual field progression in patients with drusen of the optic disc compared to patients with normal tension glaucoma and frequency of visual field progression in patients with drusen of the optic disc
SCHARGUS M, GRAMER G, GRAMER E–Wuerzburg
- 409 Early diagnosis of compressive optic neuropathy (NOC) in patients with Thyroid Autoimmune Ophthalmopathy (TAO)
CARNOVALE SCALZO G, LABONIA AF, PAOLA A, SCORCIA V, SCORCIA GB, BRUZZICHESI D, COSTANTE G, SCORCIA G–Catanzaro
- 410 Severe maculopathy and leukoencephalopathy in a young patient
WILLERMAIN F, DIELMAN C, BRADSTREET C, HOUA N, KAMPOURIDIS S, CASPERS L–Bruxelles

GLAUCOMA

- 411 Microhaemodynamics in patients with primary open angle glaucoma
SHAMSHINOVA A, BAKHINSKI P–Moscow, Vidnoe
- 412 Community optometrist referrals for glaucoma- referral accuracy and outcomes
r/f
MALIK ANJ, YUEN L, ALTHAUSER S–London
- 413 Development of an Instrument to Assess Behavior and Readiness for Behavior Change in Patients Taking Ocular Hypotensive Therapy
r/f
SCHWARTZ GF, PLAKE K, MYCHASKIW MA–Baltimore, West Lafayette, New York
- 414 Effect of Nerve Growth Factor on Retinal Ganglion Cell Loss in Ocular Hypertension Model of Rats
YEOM HY, KIM SG, MA KT, KIM CY, SEONG GJ–Seoul
- 415 Cellular Response of Astrocytes to Increased Intraocular Pressure in Rat Glaucoma Model
NIITYKOSKI M, KALESNYKAS G, RANTALA J, MIETTINEN R, SALMINEN A, KAARNIRANTA K, UUSITALO H–Kuopio
- 416 Comparison of simultaneous readings of intraocular pressure in rabbits using Perkins' hand-held, Tono-Pen XL and TonoVet tonometers
KALESNYKAS G, KÄSNÄNEN H, TERÄSVIRTA M, UUSITALO H–Kuopio
- 417 Inducible NOS synthase in the human trabecular meshwork (TM) from patients with primary open-angle glaucoma (POAG).
r/f
FERNANDEZ DURANGO R, GARCIA FEIJOO J, CASTILLO A, MARTINEZ DE LA CASA JM, GARCIA-BUENO B, FERNANDEZ-CRUZ A, LEZA JC–Madrid
- 418 Selective laser trabeculoplasty in pseudoexfoliation secondary glaucoma
CELLINI M, LEONETTI P, ZAMPARINI E, CAMPOS EC–Bologna
- 419 Efficacy and safety of selective laser trabeculoplasty (SLT) in a busy clinic setting
BYARD S, ANSI S–Maidstone
- 420 Topical plus subconjunctival versus retrobulbar anesthesia in non perforant sclerectomy supplemented with 5-FU
GUTIERREZ C, TEUS MA, BOLIVAR G–Alcalá de Henares, Madrid
- 421 The safety and efficacy of trabeculectomy with mitomycin C (MMC) in juvenile open angle glaucoma
r/f
CHIANG MY, LOCKWOOD A, WILLIAMS TA, JAYAPRAKASAM A, SII F, SHAH P–Birmingham
- 422 Trabeculectomy with Mitomycin C – Safety and Efficacy for patients with Normal Tension Glaucoma
LOCKWOOD A, CHIANG M, SII F, WILLIAMS TA, SHAH P–Birmingham

- 423 Excimer laser trabeculotomy (ELT) - an alternative laser treatment to reduce intraocular pressure
r/f
WILMSMEYER S, PACHE M, FUNK J–Freiburg, Stuttgart

- 424 The Macula in Glaucoma
CILLIERS H, FRANZCO GB, FRANZCO DM, FRANZCO MC, LAMOUREUX E–Melbourne, Gloucestershire, Rotorua

- 425 Correlation between perimetric indices of conventional automated perimetry and structural papillary parameters obtained by means of OCT
LÓPEZ PEÑA MJ, FERRERAS AMEZ A, LARROSA POVES JM, POLO LLORENS V, BORQUE RODRIGUEZ E, HONRUBIA LÓPEZ FM–Zaragoza

- 426 Diagnostic ability of the optic head measurements performed with the OCT in pre-perimetric glaucomas
MAYORAL F, POLO V, LARROSA JM, FERRERAS A, PUEYO V, HONRUBIA FM–Zaragoza

- 427 Evaluation of structural parameters for the diagnosis of preperimetric glaucoma
GUERRI MONCLAS N, EGEA MC, PEREZ O S, PABLO LE, BARAIBAR B, HONRUBIA FM–Zaragoza

- 428 Effectiveness of long term follow-up by means of structural and functional test in early glaucoma diagnosis
EGEA MC, GUERRI N, PABLO LE, PEREZ S, SANCHEZ A, HONRUBIA FM–Zaragoza

- 429 Diagnostic ability of the automated classification of the HRT3 versus the Moorfields regression analysis
FERRERAS A, PAJARIN AB, LARROSA JM, POLO V, MAYORAL F, PUEYO V, HONRUBIA FM–Zaragoza

- 430 Impact of Neuroretinal Rim Measurements as Predictive Factor for the Development of Glaucoma in Patients with Ocular Hypertension
r/f
LAEMMER R, MARTUS P, MARDIN CY–Erlangen, Berlin

- 431 Inadequate anterior segment compensation is not a major cause of false-negative GDx Nerve Fiber Analyzer test results
r/f
MUSKENS RPHM, HEEG GP, JANSONIUS NM–Groningen

- 432 Agreement among Optical coherence tomography (OCT), Scanning laser tomography (HRT-II) and Scanning laser polarimetry (GDx) in open-angle glaucoma
PUEYO V, POLO V, LARROSA JM, FERRERAS A, ALIAS E, HONRUBIA FM–Zaragoza

- 433 Influence of the corneal thickness on the measures of the no contact tonometry MUÑOZ MA, GONZÁLEZ F, PUELL MC, SANZ JC–Madrid

- 434 Importance of the central corneal thickness in the study of ocular hypertensive and pre-perimetric glaucomas.
ALIAS EG, FERRERAS A, POLO V, LARROSA JM, PUEYO V, HONRUBIA FM–Zaragoza

- 435 Influence of Central Corneal Thickness in pre-perimetric glaucoma subjects defined by means of HRT II, OCT and GDx VCC
r/f
BORQUE E, LARROSA JM, POLO V, FERRERAS A, MAYORAL F, HONRUBIA FM–Zaragoza

- 436 Clinical comparison between rebound tonometry and Goldmann Applanation tonometry in patient with glaucoma's diagnosis.
RECHICHI MR, PESCE GP, FRATTO MF, CATALANO CC, MESIANI MAZZACUVA FMM–Catanzaro

- 437 Intraocular pressure measurement using near infrared spectroscopy
r/f
KAMPPETER BA, WITZENMANN T, BACKHAUS J, JONAS JB–Mannheim

- 438 Finite element model of the cornea for applanation tonometry
LJUBIMOVA DY–Stockholm

- 439 Effects of physical exercise on intraocular pressure after the instillation of latanoprost eye drops
CHATZIBALIS T, NTAMPOS K, KARAMPATAKIS V, ECONOMIDES P, GARYFALLOS A, NATSIS K–Thessaloniki

- 440 Differences in Central and Peripheral Tonometry with ICare® Rebound Tonometry as a Function of Age
FERNANDES P, GONZÁLEZ-MÉJOME JM, JORGE J, QUEIRÓS A, ALMEIDA JB, PARAFITA MA–Braga, Santiago de Compostela

- 441 Analysis of Optineurin gene in Italian Normal Tension Glaucoma
FREZZOTTI P, LONGO I, CAPOROSSI A, MITTICA V, MELONI I, HADJISTILIANOU T, LOMURNO L, MOTOLESE P, RENIERI A–Siena

- 442 Bimatoprost, Latanoprost and Travoprost for the treatment of glaucoma: a cost-effectiveness analysis in Scandinavia
STEWART JA, STEWART WC, MYCHASKIW MA–Charleston, New York

- 443 Latanoprost versus Timolol monotherapy for the treatment of glaucoma: a cost-effectiveness analysis in scandinavia and the united kingdom using a decision-analytic health economic model
MYCHASKIW MA, STEWART WC, STEWART JA–New York, Charleston

- 444 When is it cost-effective to treat ocular hypertension?
Results of a decision-analytic health economic model
STEWART WC, STEWART JA, MYCHASKIW MA–Charleston, New York

Poster Session 3 — 15:35-16:25 — Neptuno

- Physiology / Biochemistry / Pharmacology: 445 > 476, moderators: Thor EYSTEINSSON, Gerhard GARHOFER
- Pathology / Oncology: 477 > 486, moderator: Jan PRAUSE

PHYSIOLOGY / BIOCHEMISTRY / PHARMACOLOGY

- 445 Choroidal blood flow of patients undergoing an hemodilution for retinal vein occlusion
rf CHIQUET C, ROMANET JP, SAVY O, KUCHLER F, DRILLAT P, VINH V, TONINI M, GEISER MH—Grenoble, Sion
- 446 The effects of intravenous histamine and histamine-receptor blockade on ocular blood flow
rf KARL K, RESCH H, WEIGERT G, ZAWINKA C, GARHOFER G, SCHMETTERER L—Vienna, Basel
- 447 Effects of Indomethacin on Retinal and Choroidal Blood Flow in Healthy Volunteers
rf BERISHA F, WEIGERT G, FUCHSJAEGER-MAYRL G, SCHMETTERER L, GARHOFER G—Vienna
- 448 Adrenergic receptors in retinal arterioles
rf GISLADOTTIR S, EYSTEINSSON T, SIGURDSSON SB—Reykjavik
- 449 Retrobulbar Use of Poloxamer for Ocular Drug Delivery
rf VEHANEN K, HORNOF M, URTIA A, UUSITALO H—Kuopio, Helsinki
- 450 Structural Aspects of the Design of Ocular Drug Delivery Systems
rf MAHOMED A, TIGHE BJ—Birmingham
- 451 Spatial properties and shortterm vasomotion of retinal vessels in vasospastic subjects
rf KOCHKOROV A, GUGLETA K, ZAWINKA C, KATAMAY R, FLAMMER J, ORGUL S—Basel
- 452 The effects of voluntary fasting on retinal and peripheral vessel reactivity – a case study
rf HEITMAR R, GHERGHEL D—Birmingham
- 453 Optic Nerve Blood Flow and Retinal Diameter Responses to Flicker Stimulation are Described by a 2nd Order Linear System Model
rf RIVA CE, BONAIUTI M, ROVATI L—Bologna, Modena
- 454 Oximetry in retinal vascular occlusions
rf HARDARSON SH, KARLSSON RA, HALLDORSSON GH, JOELSSON SR, EYSTEINSSON T, BENEDIKTSSON JA, BEACH JM, STEFANSSON E—Reykjavik
- 455 Diabetes-induced cataract amplified in mice lacking CuZn-superoxide dismutase
rf OLOFSSON EM, MARKLUND SL, BEHNDIG A—Umeå
- 456 Transient Hypertonic Saline (ths)-induced Intraocular Pressure (IOP) as a rabbit model to assess potential new antiglaucoma drugs
rf BASTIA E, IMPAGNATELLO F, BORGHI V, BIONDI S—Bresso, Milan
- 457 Invasive Real Intraocular Pressure (IOP) Measurement. How to do it correctly
rf HERNANDEZ VERDEJO JL, ROMAN JM, BOLÍVAR G, FERRER B, TEUS MA—Madrid
- 458 Lipofuscin accumulation in the retina due to Zinc deficiency
KOZEIS N, KOKINOU D, FELEKIDIS A, SCHRAERMAYER U—Thessaloniki, Tuebingen
- 459 Activities and concentrations of matrix metalloproteinase 9 and 2 (MMP-9 and MMP-2) in human diabetic aqueous humor.
LEWANDOWSKA AB, KOMOROWSKI J, HRABEC E, GOŚ R, NOWAK MS—Tódz
- 460 Aqueous Humor Concentrations of Moxifloxacin, Gatifloxacin and Levofloxacin Following Topical Ocular Administration of VIGAMOX®, GATIFLO® or CRAVIT® Ophthalmic Solutions to Rabbits
IPINAZAR UNDURRAGA M, ROY A, SANDERS M, TRAWICK D, CURRY S, JASHEYAW D, COCKRUM P, DAHLIN D—Barcelona, Fort Worth, Tx
- 461 Long-term effect of dorzolamide/timolol unfixed combination on ocular blood flow
MARTÍNEZ-GARCÍA A, SÁNCHEZ-SALORIO M—Santiago de Compostela
- 462 Protective effects of ocular hypotensive drugs against the neuronal damage occurred by oxygen-induced retinopathy in the newborn rat
GUNGOR K, TUGLU IH, CEZAYIRLI E, VAROL T, OZBILGIN K, BEKIR NA—Gaziantep, Manisa
- 463 Effects of prostaglandins on Anterior Chamber Depth in Patients with Glaucoma or Ocular Hypertension. A control-matchet study
GUTIERREZ C, TEUS MA, BOLIVAR G—Alcalá de Henares
- 464 Effects of acute increases of the intraocular pressure on the corneal pachymetry en eyes treated with travatoprost. An animal study
BOLIVAR G, CASTEJÓN MA, TEUS MA—Alcalá de Henares
- 465 Effects of physical aerobic exercise on intraocular pressure after instillation of timolol maleate eye drops
KARAMPATAKIS V, NATSIS K, ECONOMIDES P, CHATZIBALIS T, NTAMPOS K, STANGOS N, MERMOUD A—Thessaloniki, Lausanne
- 466 Diurnal variability of the ocular pulse amplitude (OPA) measured with Dynamic Contour Tonometry (DCT- Pascal Tonometry) in normal subjects
POURJAVAN S, DETRY-MOREL M—Brussels
- 467 Redox regulation of the 20S proteasome in human lens epithelial cells and intact mouse lens
PETERSEN A, CARLSSON T, KARLSSON J-O, ZETTERBERG M—Göteborg, Mölndal
- 468 Triamcinolone acetonide induces non apoptotic cell death of retinal pigment epithelial cells in vitro and in vivo
VALAMANESH F, TORRIGLIA A, SAVOLDELLI M, GANDOLPE C, BEHAR-COHEN F—Paris
- 469 Safety of high doses intravitreal triamcinolone: two years outcome.
RUIZ MORENO JM, MONTERO J, LUGO F, AMAT P—Alicante
- 470 Obestatin potentiates the carbachol-elicited contraction of the iris sphincter muscle
ROCHA DE SOUSA A, ALVES-FARIA P, SARAIVA J, FALCÃO-REIS F, LEITE-MOREIRA AF—Porto
- 471 In vitro potency and stability of vancomycin eye drops
KARAMPATAKIS V, PAPANIKOLAOU T, GIANNOUSIS M, KILBASANI M, GOULAS A, MANDRAVELI K, ALEXIOU-DANIEL S, MIRTOSU V—Thessaloniki
- 472 A New In Vivo Rabbit Model that Simulates Human Dosing to Determine the Distribution of Antibiotics in Ocular Tissues
MICHAUD JE, ROBERTSON SM, BROOKS AC, JAMES O, OWEN GR—Hemel Hempstead, Fort Worth, Tx
- 473 Comparative intraocular penetration of a new ofloxacin formulation versus ofloxacin solution in rabbits
RAMOS P, FERNANDES AP, BAPTISTA A, PROENÇA R—Coimbra, Linda-a-Velha
- 474 Expression of fibronectins in response to poly(lactide) (PLA) and poly(lactide-co-glycolide) (PLGA) polymer implants in the rat eye
OKSÁL E, KAARNIRANTA K, RÖNKÖ S, HUHTALA A, UUSITALO H—Kuopio, Tampere
- 475 Assessment of poloxamers as new deswelling macromolecules for corneal organ culture
THURET G, ZHAO M, MANISSOLLE C, DUMOLLARD J-M, PEOC'H M, ACQUART S, GARRAUD O, PRADES JM, ROBERT PY, GAIN P—Saint-Etienne, Limoges
- 476 N-Vinyl Amides: A Versatile Family of Monomers For Ophthalmic Biomaterials
HENLEY CE, TIGHE BJ—Birmingham

PATHOLOGY / ONCOLOGY

- 477 Merkel cell carcinoma of the eyelid with two cases of spontaneous regression
rf MISSOTEN GS, DE WOLFF-ROUENDAAL D, DE KEIZER RJW—Leiden
- 478 Vascular features of mushroom-shaped uveal melanomas
rf AMIRYAN AG, SAAKYAN SV, LELJUK VG—Moscow
- 479 Optico-reconstructive operations in block excision of iridociliary tumours
rf SAAKYAN SV, CHENTSOVA EV—Moscow
- 480 Uveal lymphoma with extraocular involvement
GARCIA-ALVAREZ C, SAORNIL MA, MENDEZ MC, VALLE ML, LÓPEZ LARA F, BLANCO G—Valladolid
- 481 Bilateral ocular leukemic infiltrate
BOGDANICI C, MIRON I, DUMITRAS S, SARBU L, MOTOC I—Iasi
- 482 Choroidal biopsy and ultrasound: importance in diagnosis of indeterminate intraocular melanoma. Case report
SANCHEZ CHICHARRO D, SAORNIL M. A.—Valladolid
- 483 Ethmoidal melanoma with orbital invasion
GARCIA-ALVAREZ C, BLANCO G, SAORNIL MA, MENDEZ MC, VALLE ML, SANTOS J—Valladolid
- 484 Recurrent primary conjunctival melanoma with nasolacrimal extension
DE KEIZER RJW, DE WOLFF ROUENDAAL D—Leiden
- 485 Comparison of Diagnostic Imaging Techniques in the evaluation of uveal melanoma
DE FRUTOS-BARAJA JM, SAORNIL-ALVAREZ MA, ALMARAZ A, GARCIA-ALVAREZ C, BLANCO-MATEOS G, LOPEZ-LARA-MARTIN F—Valladolid
- 486 Malignant transformation of retinocytoma: successful conservative treatment
DE FRANCESCO S, CERASE A, MENICACCI F, FRUSCHELLI M, HADJISTILIANOU T—Siena

MACUGEN® (pegaptanib sodium injection)
Prescription only medicine.
Brief Summary of Product Characteristics

1. NAME OF THE MEDICINAL PRODUCT

Macugen 0.3 mg solution for injection

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

A single dose pre-filled syringe delivers 1.65 mg pegaptanib sodium, corresponding to 0.3 mg of the free acid form of the oligonucleotide, in a nominal volume of 90 microlitres.

3. PHARMACEUTICAL FORM

Solution for injection.

The solution is clear and colourless.

4. CLINICAL PARTICULARS

4.1 Therapeutic indications

Macugen is indicated for the treatment of neovascular (wet) age-related macular degeneration (AMD).

4.2 Posology and method of administration

FOR INTRAVITREAL USE ONLY.

Treatment with Macugen is for intravitreal injection only and should be administered by ophthalmologists experienced in intravitreal injections.

Macugen 0.3 mg should be administered once every six weeks (9 injections per year) by intravitreal injection into the affected eye.

Macugen should be inspected visually for particulate matter and discolouration prior to administration.

The injection procedure should be carried out under aseptic conditions, which includes the use of surgical hand disinfection, sterile gloves, a sterile drape and a sterile eyelid speculum (or equivalent) and the availability of sterile paracentesis (if required). The patient's medical history for hypersensitivity reactions should be carefully evaluated prior to performing the intravitreal procedure (see section 4.4). Adequate anaesthesia and a broad-spectrum topical microbicide should be administered prior to the injection.

Following the injection, transient increases in intraocular pressure were seen in Macugen treated patients. Therefore, the perfusion of the optic nerve head and intraocular pressure should be monitored. Moreover patients should be closely monitored for endophthalmitis in the two weeks following the injection. Patients should be instructed to report any symptoms suggestive of endophthalmitis without delay (see section 4.4).

Specific patient groups:

Renal insufficiency:

Macugen has not been adequately studied in patients with creatinine clearance < 20 ml/min. No special considerations are needed in patients with creatinine clearance above 20 ml/min (see section 5.2 of the full SPC).

4.3 Contraindications

Active or suspected ocular or periocular infection. Known hypersensitivity to the active substance or to any of the excipients.

4.4 Special warnings and precautions for use

As expected with intravitreal injections, transient increases in intraocular pressure may be seen. Therefore, the perfusion of the optic nerve head should be verified and elevation of intraocular pressure should be managed appropriately post injection.

Immediate (on the day of injection) and delayed intravitreous haemorrhages may occur following pegaptanib injections.

Intravitreal injection procedures are associated with a risk of endophthalmitis; in Macugen clinical trials, the incidence of endophthalmitis was 0.1% per injection.

Cases of anaphylaxis/anaphylactoid reactions, including angioedema, have been observed within several hours after the pegaptanib intravitreal administration procedure in the post-marketing experience. A direct relationship to Macugen or any of the various medications administered as part of the injection preparation procedure, or to other factors has not been established in these cases.

4.5 Interaction with other medicinal products and other forms of interaction

Drug interaction studies have not been conducted with Macugen. Pegaptanib is metabolised by nucleases and therefore cytochrome P450 mediated drug interactions are unlikely.

Two early clinical studies conducted in patients who received Macugen alone and in combination with PDT (photodynamic therapy) revealed no apparent difference in the plasma pharmacokinetics of pegaptanib.

4.6 Pregnancy and lactation

Pegaptanib has not been studied in pregnant women. Animal studies are insufficient, but have shown reproductive toxicity at high systemic exposure levels (see section 5.3 of the full SPC). The potential risk to humans is unknown. The systemic exposure to pegaptanib is expected to be very low after ocular administration. Nevertheless, Macugen should be used during pregnancy only if the potential benefit to the mother justifies the potential risk to the foetus.

It is not known whether Macugen is excreted in human milk. Macugen is not recommended during breast-feeding.

4.8 Undesirable effects

In postmarketing experience, rare cases of anaphylaxis/anaphylactoid reactions, including angioedema, have been observed within several hours after the intravitreal administration procedure, although a direct relationship to Macugen or other factors has not been established.

Three percent of patients experienced a serious adverse event potentially related to the injection procedure. Serious ocular adverse events reported in patients treated with Macugen included endophthalmitis (1%), retinal hemorrhage (<1%), vitreous hemorrhage (<1%), and retinal detachment (<1%).

Following the injection, patients should be closely monitored for endophthalmitis in the 2 weeks following the injection. Patients should be instructed to report any symptoms suggestive of endophthalmitis without delay.

Very commonly ($\geq 10\%$) reported ocular adverse events were anterior chamber inflammation, eye pain, increased intraocular pressure (IOP), punctate keratitis, vitreous floaters, and vitreous opacities.

Following the injection, transient increases in IOP were seen in patients treated with Macugen. Therefore, the perfusion of the optic nerve head and IOP should be monitored, and elevation of IOP should be managed appropriately postinjection.

6.3 Shelf life

18 months

6.4 Special precautions for storage

Store in a refrigerator (2 °C -8°C). Do not freeze.

Important information regarding how to use Macugen is in section 6.5 (Nature and contents of container) and 6.6 (Special precautions for disposal) of the full SPC.

7. MARKETING AUTHORISATION HOLDER

Pfizer Limited
Ramsgate Road
Sandwich, Kent
CT13 9NJ
United Kingdom

8. MARKETING AUTHORISATION NUMBER(S)

EU/1/05/325/001


9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
31st January 2006

Before prescribing, please review full product information available from Pfizer.

MUP0001801DD



NOW, ONE THERAPY CAN TREAT ALL NEOVASCULAR AMD* AT ITS SOURCE



MACUGEN—the first selective VEGF₁₆₅[†] inhibitor with clinical efficacy in all neovascular AMD

- ▶ Early and sustained efficacy to preserve[‡] visual acuity across a broad patient population^{1,5}
- ▶ Emerging data suggest enhanced efficacy when used early in the disease^{3,4}
- ▶ Excellent ocular and systemic safety profile through 2 years^{1,6}

MACUGEN is indicated for the treatment of neovascular (wet) age-related macular degeneration.

MACUGEN is contraindicated in patients with active or suspected ocular or periocular infection or with known hypersensitivity to the active substance or to any of the excipients.

Safety and efficacy of MACUGEN beyond 2 years have not been demonstrated.

Serious ocular adverse events reported in patients treated with MACUGEN included endophthalmitis (1%), retinal hemorrhage (<1%), vitreous hemorrhage (<1%), and retinal detachment (<1%).

In postmarketing experience, rare cases of anaphylaxis/anaphylactoid reactions, including angioedema, have been observed within several hours after the intravitreal administration procedure, although a direct relationship to MACUGEN or other factors has not been established.

*Age-related macular degeneration.
†Vascular endothelial growth factor.

[‡]Defined as <3 lines lost over 1 year.
[§]Verispan medical claims data, 2006.

www.macugen.com

Please see brief summary of prescribing information published in this journal.

References: 1. MACUGEN Summary of Product Characteristics. 2. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR, for the VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. *N Engl J Med.* 2004;351:2805-2816. 3. The VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group. Enhanced efficacy associated with early treatment of neovascular age-related macular degeneration with pegaptanib sodium: an exploratory analysis. *Retina.* 2005;25:815-827. 4. Lupovitch J, Quiram PA, Hassan TS, Williams GA. MACUGEN as primary therapy for AMD lesions of all angiographic subtypes. Poster presented at Annual Meeting of ARVO, April 30-May 4, 2006, Fort Lauderdale, Fla. Poster B632. 5. The VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group. Year 2 efficacy results of two randomized, controlled clinical trials of pegaptanib, an anti-VEGF aptamer, for neovascular age-related macular degeneration. *Ophthalmology.* In press. 6. VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group. Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials. *Ophthalmology.* 2006;113:992-1001.

>70,000 PATIENTS TREATED[§]

MACUGEN®
PEGAPTANIB SODIUM INJECTION
*Changing Perspectives*TM

For patients who need Xtra IOP control...



You'll Never Look at XALACOM the Same Way Again

- XALACOM dosed in the evening—now proven comparable to the unfixed combination of XALATAN® and twice-daily timolol¹
- XALACOM achieved a 12.4 mm Hg maximal mean reduction of IOP from baseline^{2*}



*A randomised, double-masked, parallel-group, placebo-controlled trial including patients with OH who were treatment naïve. Twenty patients with OH received XALACOM; 10 received placebo eye drops. IOP was measured during 12 hours on baseline day and at different time intervals after administration of XALACOM as a single dose. The primary objective was to measure the effect on IOP following a single-dose administration of XALACOM or placebo.

XALACOM is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) and ocular hypertension (OH) who are insufficiently responsive to topical beta-blockers.

XALACOM is contraindicated in patients with reactive airway disease, including bronchial asthma, a history of bronchial asthma, or severe chronic obstructive pulmonary disease; sinus bradycardia; second- or third-degree atrioventricular block; overt cardiac failure; cardiogenic shock; or hypersensitivity to any component of this product. XALACOM and XALATAN (latanoprost) have been reported to cause changes to pigmented tissues. The most frequently reported changes have been increased pigmentation and growth of eyelashes. The iris pigmentation changes may be permanent. In the 6-month registration trials, the most frequent adverse events were eye irritation, including stinging, burning, and itching (12.0%); eye hyperaemia (7.4%); corneal disorders (3.0%); conjunctivitis (3.0%); blepharitis (2.5%); eye pain (2.3%); headache (2.3%); and skin rash (1.3%).

References: 1. Diestelhorst M, Larsson L-I, for the European–Canadian Latanoprost Fixed Combination Study Group. A 12-week, randomized, double-masked, multicenter study of the fixed combination of latanoprost and timolol in the evening versus the individual components. *Ophthalmology*. 2006;113:70–76. 2. Larsson L-I. The effect on diurnal intraocular pressure of the fixed combination of latanoprost 0.005% and timolol 0.5% in patients with ocular hypertension. *Acta Ophthalmol Scand*. 2001;79:125–128.

Xalacom® (latanoprost and timolol maleate) **Presentation** Plastic bottle containing 2.5ml eye drops. Each 1ml contains latanoprost 50 micrograms (0.005% w/v), timolol maleate 6.8mg equivalent to timolol 5mg (0.5% w/v) and benzalkonium chloride 0.20mg. **Indication** Reduction of intraocular pressure (IOP) in patients with open angle glaucoma and ocular hypertension who are insufficiently responsive to topical beta-blockers. **Dosage and Administration** Adults including the Elderly: One eye drop into the affected eye(s) once daily in the morning. Children and Adolescents: Not recommended. **Contra-indications** Hypersensitivity to any component of this product. Reactive airway disease including bronchial asthma, severe chronic obstructive pulmonary disease. Sinus bradycardia, second or third degree atrioventricular block, overt cardiac failure, cardiogenic shock. **Warnings and Precautions** Due to the beta-adrenergic component, timolol, the same types of cardiovascular and pulmonary adverse reactions as seen with systemic beta-blockers may occur. Cardiac failure should be adequately controlled before beginning therapy with timolol. Patients with a history of severe cardiac disease should be watched for signs of cardiac failure and have their pulse rates checked. Respiratory reactions and cardiac reactions, including death due to bronchospasm in patients with asthma and, rarely, death in association with cardiac failure, have been reported following administration of timolol maleate. Beta-blockers should be administered with caution in patients subject to spontaneous hypoglycaemia or to diabetic patients (especially those with labile diabetes) as beta-blockers may mask the signs and symptoms of acute hypoglycaemia. Beta-blockers may also mask the signs of hyperthyroidism and cause worsening of Prinzmetal angina, severe peripheral and central circulatory disorders and hypotension. While taking beta-blockers, patients with a history of atopy or a history of severe anaphylactic reaction to a variety of allergens may be unresponsive to the usual doses of adrenaline used to treat anaphylactic reactions. The effect on intraocular pressure or the known effects of systemic beta-blockade may be potentiated when Xalacom is given to patients already receiving an oral beta-blocking agent. The use of two local beta-blockers or two local prostaglandins is not recommended. Latanoprost may increase brown pigment within the iris leading to a gradual change in eye colour. This has predominantly been seen in patients with mixed coloured irides and may be permanent. Patients should be examined regularly and treatment discontinued if appropriate. Unilateral treatment can result in permanent heterochromia. Exercise caution in patients with other types of glaucoma, including OAG of pseudophakic patients. Caution in aphakic patients, pseudophakic patients with torn posterior lens capsule and other patients with known risk factors for cystoid macular oedema. **Adverse Effects** These have been limited to those earlier reported for latanoprost and timolol. None specific for Xalacom have been observed in clinical studies. The most frequent adverse reactions reported in clinical trials were: increased iris pigmentation, eyelash changes, eye irritation, hyperaemia, corneal disorders, conjunctivitis, blepharitis, eye pain, headache and skin rash. Adverse effects that have been seen with one of the components may potentially occur also with Xalacom: *Latanoprost*: punctate epithelial erosions, periorbital oedema, corneal oedema and erosions, macular oedema, iritis/uveitis, asthma, asthma exacerbation and dyspnoea, darkening of palpebral skin. *Timolol*: *Special senses*: signs and symptoms of ocular irritation including blepharitis, keratitis, decreased corneal sensitivity, and dry eyes, visual disturbances, diplopia, ptosis, choroidal detachment, tinnitus. *Cardiovascular*: bradycardia, arrhythmia, hypotension, syncope, heart block, cerebrovascular accident, cerebral ischaemia, congestive heart failure, palpitation, cardiac arrest, oedema, claudication, Raynaud's phenomenon, cold hands and feet. *Respiratory*: bronchospasm, dyspnoea, cough. *Body as a whole*: headache, asthenia, fatigue, chest pain. *Integumentary*: alopecia, psoriasis form rash or exacerbation of psoriasis. *Hypersensitivity*: signs and symptoms of allergic reactions. *Nervous system/psychiatric*: dizziness, depression, insomnia, nightmares, memory loss, increase in signs and symptoms of myasthenia gravis, paraesthesia. *Digestive*: nausea, diarrhoea, dyspepsia, dry mouth. *Urogenital*: decreased libido, Peyronie's disease. *Immunologic*: systemic lupus erythematosus. **Interactions** No specific studies have been performed with Xalacom. There is a potential for additive effects resulting in hypotension and/or marked bradycardia when eye drops with timolol are administered concomitantly with oral calcium channel blockers, guanethidine or beta-blocking agents, antiarrhythmics, digitalis glycosides or parasympathomimetics. Interactions similar to those commonly seen with beta-blockers may be expected. **Pregnancy** Do not use. **Lactation** Stop breast feeding or do not use. **Driving** Vision may be blurred following eye drop instillation. **Overdosage** Symptomatic treatment. **Pharmaceutical Precautions** Store at +2°C - +8°C. Once opened, do not store above 25°C and discard after 4 weeks. Keep bottle in the outer carton. **Legal category** POM. **Packaging Quantities and Basic NHS price** 1 x 2.5ml £15.07 PL Number 0032/0288. PL Holder Pharmacia Limited, Davy Avenue, Knowhill, Milton Keynes, MK5 8PH, UK. **Date of Preparation of PI**: August 2003. Further information is available on request from: Pfizer Limited, Walton Oaks, Dorking Road, Tadworth, Surrey, KT20 7NS, UK.



Keynote Lectures

DE CLERCQ, E: Wednesday, 17:35
 GALLOWAY, N: Wednesday, 18:20
 MOORE, A: Thursday, 10:15
 SIEVING, P: Thursday, 15:45
 ZHAO, J: Friday, 10:15
 RAO, N: Friday, 15:45
 REME, C: Saturday, 10:15

- BRON AJ: 366, 2234
 BRON AM: 214, 1322, 2125, 4441
 BRUENECH JR: 2335
 BUNIATYAN IY: 4455
 BURKE J: 3461
 BURSTEDT MSI: 3364
 BUSHUYEVA NN: 405
 BYARD S: 419
 BYSTRÖM B: 2331
 CAMPBELL D: 2134
 CARELLI V: 3311
 CARNOVALE SCALZO G: 409
 AKGUEL H: 4336
 AKHTAR S: 209, 2332
 AKKOVUN I: 304, 4242
 ALI RR: 3166
 ALIAS EG: 434
 ALIO SANZ J: 2445
 ALJAMAL R: 3435
 ALLAN E: 4231
 AMATI-BONNEAU P: 3411
 AMIRYAN AG: 478, 3438
 ANSARI EA: 317
 ANWAR ST: 3153
 ARTAL P: 2442
 AUTRATA R: 232, 2343
 AYDIN P: 1344, 3224
 BANDELLO F: 3464
 BAPTISTA P: 2163
 BARAK V: 3335
 BARBOSA A: 2166
 BARBUR J: 3443
 BARCIA RN: 364, 2131
 BARNSTABLE CJ: 2313
 BARRAQUER J: 2342
 BARRAQUER RI: 2446
 BARRY J-S: 325
 BARTESELLI G: 321
 BASTIA E: 456, 4446
 BATEMAN S: 341, 3356
 BATES D: 4221
 BAUER SM: 2154
 BELIN MWB: 4212
 BENTO CA: 205
 BERGUA A: 216
 BERISHA F: 447, 3427, 4344
 BERNARDES R: 2167
 BHATTACHARYA S: 3163
 BICHO MP: 4321
 BIZIOS D: 4151
 BLANCO-MEZQUITA JT: 367, 3353
 BOCK FB: 338, 356, 3158
 BODAGHI B: 1325, 2121, 2221
 BOGDANICI C: 481
 BOLÍVAR G: 464
 BORQUE E: 435, 4155
 BORRUAT FX: 4125
 BOSCH F: 4163
 BOSCHI A: 4122
 BOURGES J-L: 352, 4114
 BOURNE WM: 2135
 BOYCHUK IM: 406
 BREMOND GIGNAC D: 4412
 BREUER B: 310
 BRISCOE D: 3436
- FRENKEL S: 4332
 FREZZOTTI P: 441, 2435
 FRUSCHELLI M: 210
 FUCHSJÄGER-MAYRL G: 3422
 GALAND AJ: 3342
 GALE A: 4361
 GANDHI JS: 213
 GARCHER CREUZOT C: 335, 3155, 3264
 GARCIA-ALVAREZ C: 480, 483
 GARHOFER G: 3424
 GARWEG JG: 2223
 GAWLEY SD: 385
 GAZZARD G: 2212
 GICQUEL JJ: 2132, 2235, 3251, 3354, 4111
 GIL-CAZORLA R: 236, 3451
 GILES TG: 344, 3455
 GILMARTIN B: 2113
 GILMOUR DF: 231
 GISLADOTTIR S: 448, 4245
 GOES F Jr: 4411
 GONCALVES ROSADO JL: 248
 GONZÁLEZ MARTÍNEZ M: 360
 GORDON-BENNETT PSC: 305
 GRAHAM JE: 215, 2126, 3152
 GRAW J: 2341
 GREGORY M: 4432
 GRINBERG E: 374, 2416
 GRZYBOWSKI AE: 239, 3126, 4464
 GUERRI MONCLUS N: 427
 GUGGENHEIM JA: 2114
 GUMMEL KK: 383
 GUNGOR K: 462
 GURBAXANI A: 2326
 GUTIERREZ C: 420, 463
 HADJISTILIANOU T: 2431, 4333
 HALLBERG P: 2254
 HALLERMALM K: 4435
 HAMMES HP: 4222
 HAMMOND C: 2115
 HARDARSON SH: 454, 4444
 HARDING J: 2142
 HARRIS A: 4255
 HAWLINA M: 1331, 4462
 HEEGAARD S: 3433
 HEGDE K: 2143
 HEINRICH SP: 3441
 HEISTERKAMP A: 3262
 HEITMAR R: 452, 4346
 HENLEY CE: 476
 HERNANDEZ VERDEJO JL: 319, 457, 4447
 HICKS C: 4113
 HICKS D: 2312
 HIGGINS GT: 309
 HOLAN V: 349
 HOLDER GE: 1332, 1334, 2261, 4263, 4466
 HOLLINS AJ: 3414
 HOLLÓ G: 2451, 4256
 HOLMES JM: 3123
 HUA J: 376, 3216
 HUNTBACH JA: 370
 IMHOF S: 2434
 IMMONEN I: 3115
 IOMDINA EN: 2156
 IPINAZAR UNDURRAGA M: 460
 JAGER M: 4433
- JAVALOYES MORENO B: 250
 JEON SL: 384
 JIANG JX: 3242
 JONAS JB: 314, 2454
 JONUSCHEIT S: 362
 JORGE J: 254, 3445
 JOURNÉE-DE KORVER H: 3134
 JUKLOVA K: 353
 KAARNIRANTA K: 313, 3113
 KAIMBO WA KAIMBO D: 247
 KALESNYKAS G: 416
 KAMPPETER BA: 437, 2257
 KARAMPATAKIS V: 465, 471
 KARIN M: 3241
 KARL K: 446, 3426
 KARLSSON J-O: 2333
 KAWASAKI A: 4124
 KESTELYN P: 1321
 KIVELÄ T: 1311, 3131
 KLAVER CCW: 2242
 KNOP E: 2231
 KNOP N: 2232
 KOCHKOROV A: 451, 4345
 KODJIKIAN L: 1324, 2222
 KOUIJMAN AC: 4362
 KOPITZ J: 3112
 KOSHITZ IN: 2157
 KOTLIAR K: 2151, 4342
 KOUFAKIS DI: 336, 3156
 KOULIKOVSKA M: 355
 KOZEIS N: 458, 3124
 KRIAUCIUNIENE L: 252
 KSANDER BR: 4431
 KUHN F: 2226
 KUPPERMANN BD: 3462
 KURZ S: 3343
 KVANTA A: 4162
 KYTÖ JP: 307
 LACHAPELLE P: 4348
 LAEMMER R: 430, 4156
 LAM BL: 4461
 LAMBLEY RG: 302, 3266
 LANGE C: 3143
 LANGENBUCHER A: 2352
 LANGMAN ME: 334, 342, 2236, 31510, 3357
 LANZINI M: 4453
 LANZL I: 211, 3446
 LASUDRY J: 4131
 LAUTEBACH S: 2354
 LAYER PG: 2314
 LAZUK AV: 256
 LENAERS G: 3315
 LENGYEL I: 2245
 LEROY BP: 1333, 4262, 4463
 LESCH B: 323
 LEWANDOWSKA AB: 459
 LI DW: 3244
 LI Z: 1355, 2251
 LIBONDI T: 2466
 LINDSKOOG PETTERSSON A: 251
 LITTLE BC: 3344
 LIU C: 3341, 4112
 LIU M: 3243
 LJUBIMOVA DY: 438
 LOCKWOOD A: 422, 4452

LODI R: 3413	OBREROVA IG: 4442	ROLANDO M: 4413	TOMBRAN-TINK J: 2311
LOEFFLER KU: 3145	OKSÁLA E: 474	ROLLING F: 2361	TOPOUZIS F: 4352
LOGAN NS: 2215	OLIVEIRA FERREIRA JV: 311	ROSE KA: 2214	TOROPYGIN SG: 3261
LOPEZ GIL N: 3252	OLOFSSON EM: 455, 4445	ROSNER M: 4133	TRIESCHMANN MBT: 2244
LÓPEZ PEÑA MJ: 425	ORGUL S: 4254	ROSS G: 347, 3458	UEFFING M: 3165
LORENZ B: 2263, 2363	OSBORNE NN: 2241	RUGGERI A: 373	UUSITALO H: 3111
MACKENSEN F: 2325	OWENS H: 3452	RUIZ MORENO JM: 327, 469	VACLAVIK V: 3361
MAESTRONI L: 2462	OZDEN R: 1343	RYABTSEVA AA: 2152	VAIDEAU D: 3215
MAHOMED A: 450, 4247	ÖZKAN SB: 3221	RYDZANICZ MA: 375, 2417	VALAMANESH F: 468
MAIA-LOPES S: 243	PABLO LE: 320	RYHÄNEN T: 204	VA'MOS R: 382
MALANDRINI A: 358	PACHE M: 2351	SAAKYAN SV: 479, 4337	VAN DER BLIEK A: 3313
MALIK ANJ: 412, 2456, 3336	PAIMELA T: 203	SAARI KM: 4132	VANDEROORT J: 1352
MANN A: 346, 3457	PARISE S: 222	SAKELLARIS D: 1357	VAN DE VEIRE S: 1356
MARCOS S: 2443, 3256	PARROZZANI R: 3333	SANCHEZ CHICHARRO D: 324, 482	VAN KUIJK E: 2243
MARIGO V: 3164	PASTOR S: 339, 368, 3159	SANCHEZ-MIGALLON CARRERAS MC: 403	VARANO L: 401, 3127
MARTIN L: 1342	PATEL S: 2463	SANTOS T: 2164	VARSANYI B: 3362
MARTINEZ A: 4325	PE'ER J: 4334	SAORNIL-ALVAREZ MA: 3331	VEHANEN K: 449, 4246
MARTÍNEZ-GARCÍA A: 461, 2455	PEGO P: 4324	SAPIN V: 202, 2337	VELUSAMI P: 224, 3434
MASTROPASQUA L: 4312	PENDINO V: 322	SARFARAZI M: 2444	VERBRAAK FD: 2162
MAYORAL F: 426	PEREIRA DA SILVA A: 4323	SAUVÉ Y: 242	VIDAL LÓPEZ J: 402
MCKERRAL M: 237	PESCE GP: 212	SAW SM: 2112	VIDE ESCADA EICKMANN A: 328, 3363
MENDEZ MC: 3432	PETERSEN A: 467	SCHALENBOURG A: 4335	VIESTENZ A: 2353
MERAYO-LLOVES J: 4414	PETO T: 306, 2465, 3322	SCHARGUS M: 408	VIITALA R: 4213
MERIGAN W: 2422	PETZOLD A: 4363	SCHLICKEISER S: 330, 2136	VILLAFRUELA I: 404
MESSMER E: 4315	PICCIRILLO V: 221, 2165	SCHLINGEMANN R: 4161, 4224	VOSSMERBAEUMER U: 3144
MICHAEL R: 332, 2138	PILECKI W: 238	SCHMETTERER L: 4251	VOTRUBA M: 3314
MICHAUD JE: 472	PINELLO L: 379	SCHMIDT - ERFURTH U: 4165	WEFERS BETTINK - REMEIJER M: 2415
MIDENA E: 3136	PINILLA I: 208	SCHUMANN RG: 206	WEIGERT G: 3421
MIGLIOR S: 4153	PINNA A: 217	SCHWARTZ GF: 413, 2457	WELGE-LÜBEN U: 4244
MIGUEL L: 308	PITZ S: 2411	SCHWEITZER D: 3321	WILLERMAIN F: 410
MILANO G: 3122	PIZZAMIGLIO-MARTIN C: 369, 3453	SCORRANO L: 3312	WILLIAMS C: 2211
MILEA D: 4123	PLANT G: 3223, 3415, 4366	SCOTT A: 3142	WILLIAMS M: 246
MISSOTTEN GS: 477, 3326, 3437	PLEYER U: 331, 2137	SEIDOVA SFG: 240	WILLIAMS TA: 4454
MISSOTTEN T: 220, 2322	POCH O: 3161	SEN HN: 2324	WILMSMEYER S: 423, 4458
MODY V: 227, 2344	PODOLEANU A: 3325	SHAMSHINOA A: 411	WOOD TO: 3154
MOLNAR FE: 3263	PODKOCHY A: 354	SHEPPARD JPB: 377, 3217	WRIDE NK: 219
MONNIER V: 2141	POLAK M E: 4434	SHIMA DT: 3121	YEOM HY: 414
MONTEIRO-GRILLO M: 4341	POLSKA E: 3423	SIDDQUI S: 228, 2345	YGGE J: 3222
MONTERO-MORENO JA: 4243	POURJAVAN S: 466	SIEVING P: 257, 258, 1361	YU A: 3141
MONTES MICO R: 3257	POURNARAS JAC: 3334	SILVA BELTRÁN B: 2123	ZACK DJ: 2421, 3211
MOORE JE: 371	PRADA J: 218	SJÖSTRAND JB: 235	ZASEEVA MV: 2153
MORA A: 2161	PREISING MN: 2262	SKINNER KC: 386	ZAWINKA C: 4343
MORGAN IG: 2213	PROENCA H: 2122	SKORKOVSKA S: 4152	ZIAHOSSEINI K: 357
MOTULSKY E: 1351	PUEYO V: 432	SLETTEDAL JK: 351	ZRENNER E: 3162, 3444
MOURIAUX F: 4233	PUK O: 3213	SMITH AF: 316	ZUCCA I: 381
MOUTRAY TN: 245	PURVIN V: 4121	SOBIESZCZANSKA M: 407	
MRUGACZ M: 350	QUEIROS A: 363	SOBRADO CALVO P: 255	
MULDREW KA: 318	RADHAKRISHNAN H: 3254	SÖDERBERG PG: 2144, 2441	
MÜLLER LJ: 4313	RAHI JS: 2111	SODI A: 380, 2412	
MULLINS RF: 3114	RAJA V: 315, 378	SOMANATHAN S: 329	
MUNIER F: 2433	RAMIREZ AI: 207	SORO MARTÍNEZ MI: 249	
MUÑOZ MA: 433	RAMOS P: 473	SPILEERS W: 4261	
MUQIT MMK: 4232	RAO N: 2423	SRINIVASAN VJ: 3323	
MUSKENS RPHM: 431, 2453, 4157	RASUL N: 359	STACHS O: 4311	
MYCHASKIW MA: 443	RAUSCHER FG: 4365	STALMANS I: 2253, 2355, 4164, 4253, 4257	
NEIRA W: 348	RECHICHI MR: 436	STEFANSSON E: 4252, 4443	
NEPP J: 3125	REMKY A: 2252	STEWART JA: 442	
NEUWIRTH A: 226	RENIER C: 2255	STEWART WC: 444	
NGUYEN KHOA JL: 3253	RESCH H: 3332	SUMMANEN PA: 3365	
NIETO A: 365	REYNIER P: 3412	SYNEK S: 303, 3267	
NIITYKOSKI M: 415	RIGAL SASTOURNE JC: 233	SZCZESNA DH: 343, 3454	
NILSSON M: 244	RIVA CE: 453, 4347	TEUS MA: 4456	
NTAMPOS K: 225	ROBERT PY: 337, 372, 3157	THURET G: 333, 475, 2139, 4214	
NUBILE M: 3352, 4314	ROBIN AL: 4351	TIGHE B: 361	
NUNES S: 3366	ROCHA DE SOUSA A: 470, 2413	TODOROVA MG: 241	

This programme book is organised chronologically



The sessions are colour-coded

Special Interest Symposium (SIS)	Keynote Lecture	Workshop
Free Papers	General Assembly & Business Meeting	Poster Session
Joint Meeting	Course	Social

FP = Free Paper session

SIS = Special Interest Symposium

rf = Rapid Fire presentation

Thank you Sponsors

MAIN



SIS



Exhibitors



**ENTRIES ACCEPTED FROM
15 FEBRUARY 2007 THROUGH 15 FEBRUARY 2008**



ANNOUNCING THE 2008

INNOVATIVE OPHTHALMOLOGY RESEARCH AWARD

*A global award from MSD
recognizing scientific excellence*

**For more information about eligibility and submission
guidelines, please visit the official IORA Web site at
www.ophthalmologyaward.com**

**Award recipients will be announced in 2008 at a
major ophthalmology congress.**

This biennial award (formerly known as the Chibret Award, or the MSD Award) was established to encourage young researchers to undertake investigative work in critical areas of ophthalmology that may one day lead to meaningful improvements in patients' lives.

The Innovative Ophthalmology Research Award (IORA) is sponsored by Merck Sharp & Dohme (MSD) (known as Merck & Co., Inc. in the USA). As a global, research-driven pharmaceutical company that discovers, develops, manufactures, and markets a broad range of human health products, MSD takes enormous pride in stimulating and sponsoring promising scientists to pioneer scientific advances that will surely lead to the better treatment and cure of diseases.

2 0 0 8



Copyright © 2006 Merck & Co., Inc., Whitehouse Station, NJ, USA. All rights reserved.
6-08 CST 2006-W-136301-J

EVER 2006		Gemini I	Gemini III	Vega	Pegasus	Fenix I	Fenix III	Fenix II	IT-room
Wednesday 4 October 2006		COURSE I	COURSE II	COURSE III	COURSE IV	COURSE V			
14:00 - 17:00	Statistics T KIVEÅ, B DAMATO	How to handle Emergencies in patients with ocular inflammation — B BOOGAIGH	Electrophysiology in acquired retinal disease and extended ERG — G HOLDER	Visual Fields in Optic Nerve diseases P AYDIN, V DAYANIK, L MARTIN, R OZDEN	FRO — Fund for Research in Ophthalmology L MISCOTEN	Web-Based resources P STEVING			
17:15 - 17:30	Welcome by the President EVER 2006 — Tero KIVEÅ						in Fenix III		
17:35 - 18:15	AERI lecture : Antivirals for viral eye infections — Erik DE CLERCQ						in Fenix III		
18:20 - 19:00	EVER Lecture : The Evolution of Electrical Responses from the Eye — Nicholas GALLOWAY						in Fenix III		
19:00 - 21:00	EVER Welcome Garden Party						in Marinotel		
Thursday 5 October 2006									
08:30 - 10:00	Myopia - Eye growth, development and Genetics — SM SAW, M VOTRUBA	FP Immunology/Microbiology: Experimental & clinical uveitis/microbiology — B BOOGAIGH, PH KESTEYN	FP Cornea: Cornea Grafting CH LIU, G THURET	Diabetes and Cataract SD VARMA, K HEGDE	Ocular Biomechanics K KOTLAR	FP Retina: Retinal Imaging CH RIVA, F VERBAAK			
10:15 - 10:55	Keynote Lecture : Cone and cone rod dystrophies, genotype, phenotype and disease mechanisms — Anthony MOORE						in Fenix III		
11:15 - 12:45	Myopia and refractive error: epidemiology SM SAW, C WILLIAMS	Current approaches in Endophthalmitis MD DE SMET, L KODIKIAN	Anatomy and Immune regulation at the Ocular Surface — E KNOP, N KNOPP, JJ GICQUEL	Use of micronutrients I ENGYEL, N OSBORNE	FP Glaucoma: Microbiology & Bloodflow & IOP — S ORGUL, I STALMANS	EPOS: Diagnostic & therapeutic advances in paediatric retinal diseases, Part1 — B LORENZ			
14:00 - 15:30	Mechanism of action of neuroprotective factors in retina — J TOMBRAN-TINK, C BARNSTABE	FP Immunology/Microbiology: Clinical uveitis U PLEYER, N RAO, PH KESTEYN	FP Anatomy: Ocular anatomy and cell biology E KNOP	FP Lens SD VARMA, P SODERBERG	Dynamic contour tonometry M PACHE, T ZEYEN	EPOS: Diagnostic & therapeutic advances in paediatric retinal diseases, Part2 — B LORENZ			
15:45 - 16:25	ACTA Lecture : The Interplay of Clinical and Basic Knowledge in X-linked Retinoschisis — Paul STEVING						in Fenix III		
16:30 - 17:20	Poster Session 1 : Anatomy / Cell Biology — Immunology / Microbiology — ARVO Session: Pearls of Research From US Institutions — N DELAMERE	Lens and Cataract —	Vision Sciences / Electrophysiol. / Physiol. Optics	New IOL technologies R BARRAQUER, P SODERBERG	FP Retina: Antiangiogenic treatments MD DESMET, F BANDELLO	in Neptune			
17:30 - 19:00	FP Molecular Biology/Genetics/Epidemiology: Phenotyping & Mutations - A MOORE, M VOTRUBA								
Friday 6 October 2006									
08:30 - 10:00	Retinal Pigment Epithelium H UUSITALO, K KAARNIRANTA	FP Neuro-ophthalmology G PLANT, A KAWASAKI	Ocular complications of radiotherapy B DAWATO, M JAGER	FP Anatomy: Cell biology of retina and optic nerve head — K LOEFFLER	FP Cornea: Ocular surface, inflammation and dry eye — HS DUA, C GARCHER CREUZOR	Genot - An integrated project funded by the EU: Functional Genomics of the retina in Health and Disease — SAHEL, J CUNHA-VAZ			
10:15 - 10:55	Keynote Lecture: Advance of Ophthalmology in China and the Way to International Ophthalmology — Jiliang ZHAO						in Fenix III		
11:15 - 12:45	FP Molecular Biology/Genetics/Epidemiology: Gene expression, Animal models & Eye development. D ZACK, J GRAY	Botulinum usage in ophthalmology practice P AYDIN	OOG Business Meeting E MIDENA	MAP Kinase Functions in the Ocular Lens and beyond — DWU	Wavefront Aberrometry JJ GICQUEL, PL DIGHEIRO	FP Retina: Vitreoretinal surgery: Experimental / Clinical — C POURNARAS, B KIRCHHOFF			
12:30 - 13:30	THEA Lunchtime session: A new approach in topical treatment of ocular infections						in Fenix III		
14:00 - 15:30	Mitochondria in Eye disease - pathophysiology and mechanisms of cell biology — M VOTRUBA, P AYDIN	Novel Ophthalmic Technologies IV: imaging E MIDENA, L DESARDINS	Capsular tension Rings — C LIU	FP Cornea: Corneal wound healing JJ GICQUEL, PH KESTEYN	FP Retina - Medical Retina J CUNHA-VAZ, P SUMMAREN	in Fenix III			
15:45 - 16:25	Ophthalmic Research Lecture: Photoreceptor Mitochondrial Oxidative Stress in Experimental Uveitis — Narcing RAO						in Neptune		
16:30 - 17:20	Poster Session 2 : Retina / Vitreous — Cornea / Ocular Surface — Molecular Biology / Genetics / Epidemiology						New Options in the treatment of diabetic macular edema — J CUNHA-VAZ, F BANDELLO		
17:30 - 19:00	Mitochondria in Eye disease - clinical studies and FP Physiology/Biochemistry/Pharmacology: steps towards therapy — M VOTRUBA, P AYDIN	Blood Flow — CH RIVA, C ZAWINKA	FP Pathology/Oncology 2 CH ALL-ERICKSSON, S HEEGAARD	FP Vision Sciences, Electrophysiology, Physiol. Optics — G HOLDER, W SPLEERS	FP Cornea: Contact lenses & Refractive surgery JJ GICQUEL, N LOPEZ-GIL				
19:00 - 19:30	Business meetings of the scientific sections								
Saturday 7 October 2006									
08:30 - 10:00	Keratoprosthesis and Corneal Bioengineering 1 CH LIU, JJ GICQUEL	Neuro-ophthalmology in the Emergency Room — A KAWASAKI	Eyelid tumours I FMOURAUX, M ROSNER	How to get your work published ? J PLEYER, P AYDIN, A DICK, J GRAW, S VARMA	FP Glaucoma: Psychophysics & Optic disc VEGF from Basic Pharmacology to Clinical Use — L SCHMETTERER, STALMANS				
10:15 - 10:55	Keynote Lecture: Light damage and retinal degenerations: a model that sometimes tells the truth — Charlotte REME						in Fenix III		
11:15 - 12:45	Keratoprosthesis and Cornea Bioengineering 2 JJ GICQUEL, CH LIU	Cellular and molecular mechanisms of angiogenesis and lymphangiogenesis — HT AGOSTINI, F FMOURAUX, M ROSNER	Eyelid tumours II FMOURAUX, M ROSNER	FP Physiology/Biochemistry/Pharmacology: Pharmacology — G GARHOFFER, K GUNGOR	Ocular Blood Flow in Glaucoma Practice ISTALMANS	The patient can't see but the doctor can't see why — G HOLDER			
14:00 - 15:30	Confocal Imaging of the Ocular Surface L MASTROPASQUA	Biochemical and Genetic Markers in Diabetic Retinopathy — P DE SOUZA RAMALHO, MP BICHO	FP Pathology/Oncology 3 J PEER, MA SATORI ALVAREZ	FP Physiology/Biochemistry/Pharmacology: Blood Flow II — L SCHMETTERER, G WEGERT	Compliance in the management of Glaucoma A ROBIN	Doctor I cannot see well, but can I still drive? J BARBUR, G HOLDER			
15:35 - 16:25	Poster Session 3: Neuro-ophthalmology/Strabismology —	Glaucoma —	Physiology/Biochemistry/Pharmacology —	Pathology/Oncology		in Neptune			
16:30 - 17:25	EVER General Assembly and Prize Giving						in Fenix III		
17:30 - 19:00	Ocular Surface and New developments in Dry Eye — M ROLANDO						ISeCV Session P LACHAPELLE		
20:00 - 23:00	EVER Farewell Dinner						in Marinotel		
									www.ever.be